0001493152-23-013379.txt : 20230424 0001493152-23-013379.hdr.sgml : 20230424 20230424170011 ACCESSION NUMBER: 0001493152-23-013379 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 45 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230424 DATE AS OF CHANGE: 20230424 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Genvor Inc CENTRAL INDEX KEY: 0001792941 STANDARD INDUSTRIAL CLASSIFICATION: AGRICULTURE PRODUCTION - CROPS [0100] IRS NUMBER: 832054746 STATE OF INCORPORATION: NV FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-234815 FILM NUMBER: 23840770 BUSINESS ADDRESS: STREET 1: 13155 NOEL ROAD, SUITE 900 CITY: DALLAS STATE: TX ZIP: 75240 BUSINESS PHONE: 214-427-1921 MAIL ADDRESS: STREET 1: 13155 NOEL ROAD, SUITE 900 CITY: DALLAS STATE: TX ZIP: 75240 FORMER COMPANY: FORMER CONFORMED NAME: Allure Worldwide, Inc. DATE OF NAME CHANGE: 20191031 10-Q 1 form10-q.htm
0001792941 false Q2 --09-30 0001792941 2022-10-01 2023-03-31 0001792941 2023-04-19 0001792941 2023-03-31 0001792941 2022-09-30 0001792941 us-gaap:SeriesAPreferredStockMember 2023-03-31 0001792941 us-gaap:SeriesAPreferredStockMember 2022-09-30 0001792941 us-gaap:SeriesBPreferredStockMember 2023-03-31 0001792941 us-gaap:SeriesBPreferredStockMember 2022-09-30 0001792941 2023-01-01 2023-03-31 0001792941 2022-01-01 2022-03-31 0001792941 2021-10-01 2022-03-31 0001792941 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0001792941 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2021-09-30 0001792941 us-gaap:CommonStockMember 2021-09-30 0001792941 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001792941 us-gaap:RetainedEarningsMember 2021-09-30 0001792941 2021-09-30 0001792941 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-12-31 0001792941 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2021-12-31 0001792941 us-gaap:CommonStockMember 2021-12-31 0001792941 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001792941 us-gaap:RetainedEarningsMember 2021-12-31 0001792941 2021-12-31 0001792941 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-09-30 0001792941 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2022-09-30 0001792941 us-gaap:CommonStockMember 2022-09-30 0001792941 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001792941 us-gaap:RetainedEarningsMember 2022-09-30 0001792941 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-12-31 0001792941 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2022-12-31 0001792941 us-gaap:CommonStockMember 2022-12-31 0001792941 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001792941 us-gaap:RetainedEarningsMember 2022-12-31 0001792941 2022-12-31 0001792941 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-10-01 2021-12-31 0001792941 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2021-10-01 2021-12-31 0001792941 us-gaap:CommonStockMember 2021-10-01 2021-12-31 0001792941 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2021-12-31 0001792941 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0001792941 2021-10-01 2021-12-31 0001792941 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-01-01 2022-03-31 0001792941 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2022-01-01 2022-03-31 0001792941 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001792941 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001792941 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001792941 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-10-01 2022-12-31 0001792941 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2022-10-01 2022-12-31 0001792941 us-gaap:CommonStockMember 2022-10-01 2022-12-31 0001792941 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2022-12-31 0001792941 us-gaap:RetainedEarningsMember 2022-10-01 2022-12-31 0001792941 2022-10-01 2022-12-31 0001792941 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-03-31 0001792941 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-01-01 2023-03-31 0001792941 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001792941 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001792941 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001792941 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-03-31 0001792941 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2022-03-31 0001792941 us-gaap:CommonStockMember 2022-03-31 0001792941 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001792941 us-gaap:RetainedEarningsMember 2022-03-31 0001792941 2022-03-31 0001792941 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-03-31 0001792941 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-03-31 0001792941 us-gaap:CommonStockMember 2023-03-31 0001792941 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001792941 us-gaap:RetainedEarningsMember 2023-03-31 0001792941 GNVR:PaycheckProtectionProgramMember 2020-04-09 0001792941 GNVR:NoteholderBMember 2022-10-01 2023-03-31 0001792941 GNVR:NoteholderAMember 2022-10-01 2023-03-31 0001792941 GNVR:NoteholderAMember 2023-03-31 0001792941 GNVR:NoteholderBMember 2023-03-31 0001792941 GNVR:NoteholderCMember 2022-10-01 2023-03-31 0001792941 GNVR:NoteholderCMember 2023-03-31 0001792941 GNVR:NoteholderDMember 2022-10-01 2023-03-31 0001792941 GNVR:NoteholderDMember 2023-03-31 0001792941 GNVR:NoteholderEMember 2022-10-01 2023-03-31 0001792941 GNVR:NoteholderEMember 2023-03-31 0001792941 GNVR:NoteholderFMember 2022-10-01 2023-03-31 0001792941 GNVR:NoteholderFMember 2023-03-31 0001792941 GNVR:NoteholderGMember 2022-10-01 2023-03-31 0001792941 GNVR:NoteholderGMember 2023-03-31 0001792941 GNVR:NoteholderHMember 2022-10-01 2023-03-31 0001792941 GNVR:NoteholderHMember 2023-03-31 0001792941 GNVR:NoteholderIMember 2022-10-01 2023-03-31 0001792941 GNVR:NoteholderIMember 2023-03-31 0001792941 GNVR:NoteholderFMember srt:MinimumMember 2022-10-01 2023-03-31 0001792941 GNVR:NoteholderFMember srt:MaximumMember 2022-10-01 2023-03-31 0001792941 us-gaap:SeriesAPreferredStockMember 2022-08-10 0001792941 us-gaap:SeriesAPreferredStockMember 2022-08-02 2022-08-10 0001792941 GNVR:BradleyWhiteMember 2022-08-16 0001792941 GNVR:ClaytonYatesMember 2022-08-16 0001792941 GNVR:JesseJaynesMember 2022-08-16 0001792941 us-gaap:SeriesBPreferredStockMember 2022-10-19 0001792941 us-gaap:SeriesBPreferredStockMember 2022-10-01 2022-10-19 0001792941 2022-04-21 2022-04-21 0001792941 2022-06-30 0001792941 GNVR:ShareholderMember GNVR:StockIssueForCashMember 2022-11-17 2022-11-17 0001792941 GNVR:JaynesInvestmentLLCMember us-gaap:SeriesBPreferredStockMember 2022-10-19 2022-10-19 0001792941 GNVR:ACTHoldingsLLCMember us-gaap:SeriesBPreferredStockMember 2022-10-19 2022-10-19 0001792941 GNVR:LASBFamilyTrustMember us-gaap:SeriesBPreferredStockMember 2022-10-19 2022-10-19 0001792941 GNVR:JesseMichaelJaynesMember us-gaap:SeriesBPreferredStockMember 2022-10-19 2022-10-19 0001792941 GNVR:BradleyWhiteMember us-gaap:SeriesBPreferredStockMember 2022-10-19 2022-10-19 0001792941 GNVR:PJAdvisoryGroupMember us-gaap:SeriesBPreferredStockMember 2022-10-19 2022-10-19 0001792941 us-gaap:SeriesBPreferredStockMember 2022-10-19 2022-10-19 0001792941 2022-01-01 2022-09-30 0001792941 2021-10-01 2022-09-30 0001792941 us-gaap:InvestorMember 2022-10-01 2023-03-31 0001792941 GNVR:ConsultingAgreementsMember srt:ChiefExecutiveOfficerMember 2022-10-01 2023-03-31 0001792941 GNVR:ConsultingAgreementsMember srt:ChiefExecutiveOfficerMember 2022-10-01 2023-03-31 0001792941 GNVR:ConsultingAgreementsMember srt:ChiefExecutiveOfficerMember 2023-03-31 0001792941 GNVR:ConsultingAgreementsMember srt:ChiefExecutiveOfficerMember 2022-09-30 0001792941 GNVR:ConsultingAgreementsMember GNVR:ConsultantMember 2020-07-24 2020-07-24 0001792941 2021-10-02 2021-10-02 0001792941 us-gaap:ResearchAndDevelopmentArrangementMember 2023-03-31 0001792941 us-gaap:ResearchAndDevelopmentArrangementMember 2022-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2023

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ____________ to ____________

 

Commission File Number: 333-234815

 

GENVOR INCORPORATED
(Exact name of registrant as specified in its charter)

 

Nevada   83-2054746
(State or other jurisdiction of incorporation)   (IRS Employer Identification Number)

 

13155 Noel Road, Suite 900

Dallas Texas, 75240

(Address of principal executive offices)

 

(214) 427-1921

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act: None.

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☐ Yes ☒ No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
  Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

 

As of April 19, 2023, the Company had 18,422,821 shares of common stock outstanding.

 

 

 

  

 

 

GENVOR INCORPORATED

INDEX

 

  Page
PART I. FINANCIAL INFORMATION  
   
Item 1. Financial Statements 3
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 4
Item 3. Quantitative and Qualitative Disclosures about Market Risks 7
Item 4. Controls and Procedures 7
     
PART II. OTHER INFORMATION  
     
Item 1. Legal Proceedings 8
Item 1A. Risk Factors 8
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 8
Item 3. Defaults Upon Senior Securities 8
Item 4. Mine Safety Disclosures 8
Item 5. Other Information 8
Item 6. Exhibits 9
     
SIGNATURES 10

 

2

 

 

PART I – FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

Genvor Incorporated

 

Index to Financial Statements

 

    Page
     
Condensed Consolidated Balance Sheets at March 31, 2023 and September 30, 2022 (unaudited)   F-1
     
Condensed Consolidated Statements of Operations for the three and six months ended March 31, 2023 and 2022 (unaudited)   F-2
     
Condensed Consolidated Statement of Changes in Stockholders’ Deficit for the six months ended March 31, 2023 and 2022 (unaudited)   F-3
     
Condensed Consolidated Statements of Cash Flows for the six months ended March 31, 2023 and 2022 (unaudited)   F-4
     
Notes to Condensed Consolidated Financial Statements (unaudited)   F-5

 

3

 

 

Genvor Incorporated

(f/k/a Allure Worldwide, Inc.)

Condensed Consolidated Balance Sheets

(unaudited)

 

   March 31,   September 30, 
   2023   2022 
ASSETS        
Current assets:          
Cash  $1,513   $296,386 
Other current assets   15,397    2,000 
Total current assets   16,910    298,386 
           
Fixed assets, net   16,650    17,565 
           
Total assets  $33,560   $315,951 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
Current liabilities:          
Convertible notes payable  $1,162,000   $1,052,000 
Accounts payable and accrued expenses   302,295    516,658 
Due to related party   3,846    3,846 
SBA loan   48,750    48,750 
USDA CRADA liability   246,400    246,400 
Total current liabilities   1,763,291    1,867,654 
Non-current liabilities:          
Convertible notes payable, net of discounts   149,444    89,221 
Total non-current liabilities   149,444    89,221 
Total liabilities   1,912,735    1,956,875 
           
Commitments and contingencies (Note 6)   -    - 
           
Stockholders’ deficit:          
Preferred stock, $0.001 par value, 20,000,000 shares authorized         
Preferred stock - series A, 10 shares authorized, 9 and 9 shares issued and outstanding as of March 31, 2023 and September 30, 2022, respectively   -    - 
Preferred stock - series B, 2,500,000 shares authorized, 2,060,536 and 0 shares issued and outstanding as of March 31, 2023 and September 30, 2022, respectively   2,061    - 
Common stock, $0.001 par value, 300,000,000 shares authorized, 18,422,821 and 38,678,155 shares issued and outstanding as of March 31, 2023 and September 30, 2022, respectively   18,423    38,678 
Additional paid-in capital   14,789,509    14,608,815 
Accumulated deficit   (16,689,168)   (16,288,417)
Total stockholders’ deficit   (1,879,175)   (1,640,924)
           
Total liabilities and stockholders’ deficit  $33,560   $315,951 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-1

 

 

Genvor Incorporated

(f/k/a Allure Worldwide, Inc.)

Condensed Consolidated Statements of Operations

(unaudited)

 

   2023   2022   2023   2022 
   For the Three Months Ended   For the Six Months Ended 
   March 31,   March 31, 
   2023   2022   2023   2022 
                 
Revenue   $-   $-   $-   $- 
                     
Operating expenses                     
Professional fees    58,858    79,505    65,662    87,758 
Payroll related expenses    37,500    45,725    75,000    143,225 
Research and development    -    102,800    -    109,248 
Stock-based compensation    -    

3,010,000

    -    3,210,000 
Depreciation expense    458    458    916    916 
Other general and administrative expenses    58,466    (36,173)   127,286    104,487 
Total operating expenses    155,282    3,202,315    268,864    3,655,634 
                     
Operating loss    (155,282)   (3,202,315)   (268,864)   (3,655,634)
                     
Other income (expense)                     
Interest expense    (5,819)   (33,230)   (11,665)   (61,002)
Penalties    (30,000)   (30,000)   (60,000)   (60,000)
Amortization of debt discount    (30,112)   -    (60,223)   - 
Total other income (expense)    (65,930)   (63,230)   (131,887)   (121,002)
                     
Net loss   $(221,212)  $(3,265,545)  $(400,751)  $(3,776,636)
                     
Basic and diluted net loss per common share   $(0.01)  $(0.16)  $(0.02)  $(0.19)
Basic and diluted weighted average common shares outstanding    18,381,710    20,000,000    20,449,202    20,000,000 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-2

 

 

Genvor Incorporated

(f/k/a Allure Worldwide, Inc.)

Consolidated Statements of Changes in Stockholders’ Deficit

For the Three and Six Months Ended March 31, 2023 and 2022

(unaudited)

 

   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   Total 
   Series A   Series B           Additional        
   Preferred Stock   Preferred Stock   Common Stock   Paid-in   Accumulated     
   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   Total 
Balance, September 30, 2021   -   $-    -   $-    20,000,000   $2,000   $-   $(64,540)   (62,540)
Recapilitalization / RTO impact   -    -    -    -    -    18,000    8,546,798    (10,947,544)   (2,382,746)
Adjusted balance, beginning of period   -    -    -    -    20,000,000    20,000    8,546,798    (11,012,084)   (2,445,286)
Common stock issued for services   -    -    -    -    2,650,000    2,650    197,350    -    200,000 
Exercise of options   -    -    -    -    1,400,000    1,400    -         1,400 
Common stock issued for cash   -    -    -    -    1,475,020    1,475    736,035         737,510 
Net loss for the period ended December 31, 2021   -    -    -    -    -    -    -    (511,091)   (511,091)
Balance, December 31, 2021   -   $-    -   $-    25,525,020   $25,525   $9,480,183   $(11,523,175)  $(2,017,467)
Common stock issued for services   -    -    -    -    6,020,000    6,020    3,003,980    -    3,010,000 
Issuance of common stock for services   -    -    -    -    -    -    -    -    - 
Common stock issued for cash   -    -    -    -    280,000    280    139,720    -    140,000 
Common stock issued for debt conversion   -    -    -    -    688,675    689    336,884    -    337,573 
Payment for reverse capitalization   -    -    -    -    -    -    (150,000)   -    (150,000)
419 fund raising services   -    -    -    -    170,000    170    (170)   -    - 
Net loss for the period ended March 31, 2022   -    -    -    -    -    -    -    (3,265,545)   (3,265,545)
Balance, March 31, 2022   -   $-    -   $-    32,683,695   $32,684   $12,810,597   $(14,788,720)  $(1,945,439)
                                              
Balance, September 30, 2022   -   $-    -   $-    38,678,155   $38,678   $14,608,815   $(16,288,417)  $(1,640,924)
Conversion of common stock into Series B preferred stock   -    -    2,060,536    2,061    (20,605,334)   (20,605)   18,544    -    - 
Sale of common stock   -    -    -    -    300,000    300    149,700    -    150,000 
Net loss for the period ended December 31, 2022   -    -    -    -    -    -    -    (179,539)   (179,539)
Balance, December 31, 2022   -   $-    2,060,536   $2,061    18,372,821   $18,373   $14,777,059   $(16,467,956)  $(1,670,463)
Sale of common stock   -    -    -    -    50,000    50    12,450    -    12,500 
Net loss for the period ended March 31, 2023   -    -    -    -    -    -    -    (221,212)   (221,212)
Balance, March 31, 2023   -   $-    2,060,536   $2,061    18,422,821   $18,423   $14,789,509   $(16,689,168)  $(1,879,175)

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-3

 

 

Genvor Incorporated

(f/k/a Allure Worldwide, Inc.)

Condensed Consolidated Statements of Cash Flow

For the Six Months Ended March 31,

(unaudited)

 

   2023   2022 
Cash flows from operating activities:          
Net loss  $(400,751)  $(3,776,636)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation expense   916    916 
Late fee capitalized into notes payable   

60,000

    

60,000

 
Stock-based compensation   -    3,210,000 
Amortization of debt discount   60,223    - 
Changes in assets and liabilities:          
Prepaid expenses   -    496 
Other current assets   (13,397)   55,665 
Accounts payable and accrued expenses   (214,364)   (248,543)
USDA CRADA liability   -    2,800 
Net cash used in operating activities   (507,373)   (695,302)
           
Cash flows from financing activities:          
Proceeds from notes payable   50,000    34,375 
Exercise of stock options   

-

    

1,400

 
Proceeds from sale of common stock   162,500    877,510 
Net cash provided by financing activities   212,500    913,285 
           
Net increase (decrease) in cash   (294,873)   217,983 
           
Cash at beginning of period   296,386    7,310 
           
Cash at end of period  $1,513   $225,293 
           
Cash paid for interest  $-   $- 
Cash paid for taxes  $-   $- 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-4

 

 

GENVOR INCORPORATED

Notes to Condensed Consolidated Financial Statements

March 31, 2023

(unaudited)

 

NOTE 1 – ORGANIZATION AND BASIS OF PRESENTATION

 

On May 27, 2022, Genvor Incorporated, formerly known as Allure Worldwide, Inc. (the “Company” or “Genvor” or “we”), a Nevada corporation, Genvor Acquisition, Corp., a Delaware corporation and a wholly owned subsidiary of the Company (“Merger Sub”), and Genvor Inc., a Delaware corporation (“Old Genvor”), completed their previously announced merger transaction pursuant to which the Company acquired Old Genvor (the “Acquisition”), and Old Genvor became a wholly-owned subsidiary of the Company. The Acquisition was completed pursuant to an Exchange Agreement, dated as of January 11, 2021 (the “Acquisition Agreement”), pursuant to which Old Genvor was to be acquired by the Company as its wholly owned subsidiary and each share of Old Genvor common stock would be exchanged for a share of the Company’s common stock, and a merger agreement, dated March 2, 2022 (the “Merger Agreement”), pursuant to which Merger Sub merged with and into Old Genvor, with Old Genvor continuing as a wholly owned subsidiary of the Company and the surviving corporation of the merger, and each share of Old Genvor being converted into the right to receive a share of the Company (the “Merger”). After closing of the Merger, the Company was renamed “Genvor Incorporated”. Genvor develops plant-based defense technology designed to help farmers achieve global food security.

 

During May 2019, Old Genvor acquired Nexion Biosciences LLC (“NBLLC”) from a founder for nominal consideration as a wholly owned subsidiary. NBLLC was formed in the state of Delaware on December 28, 2018 (“inception”). The consolidated financial statements of the Company include the accounts of Genvor Incorporated, Old Genvor, and its wholly owned subsidiary NBLLC. Intercompany accounts and transactions have been eliminated upon consolidation.

 

Nature of Operations

 

The Company’s business plan is developing plant-based defense technology designed to help farmers achieve global food security. The Company’s technology was developed by two university scientists, Dr. Clayton Yates and Dr. Jesse Jaynes, who shared a mission to develop crop protection technology designed to defend against crop diseases effecting both animals and humans alike.

 

Basis of Presentation

 

The accompanying unaudited financial information as of and for the six months ended March 31, 2023 and 2022 has been prepared in accordance with GAAP for interim financial information and with the instructions to Quarterly Report on Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, such financial information includes all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial position at such date and the operating results and cash flows for such periods. Operating results for the six months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the entire year or for any other subsequent interim period.

 

Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been omitted pursuant to the rules of the U.S. Securities and Exchange Commission, or the SEC. These unaudited financial statements and related notes should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended September 30, 2022, as filed with the SEC.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All significant intercompany balances and transactions have been eliminated in the consolidation. The consolidated financial statements included herein, presented in accordance with United States generally accepted accounting principles (“GAAP”) and stated in United States dollars, have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission.

 

F-5

 

 

Liquidity and Going Concern

 

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. At March 31, 2023, the Company had an accumulated deficit of $16,689,168. For the six months ended March 31, 2023, the Company recognized a net loss of $400,751 and had net cash used in operating activities of $507,373, with no revenues earned, and a lack of operational history. These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern.

 

While the Company is attempting to generate revenues, the Company’s cash position may not be significant enough to support the Company’s daily operations. Management intends to raise additional funds by way of additional public and/or private offerings of its stock. Management believes that the actions presently being taken to further implement its business plan and generate revenues provide the opportunity for the Company to continue as a going concern. While the Company believes in the viability of its strategy to generate revenues and in its ability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate revenues. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Cash Flow Reporting

 

The Company follows Accounting Standards Codification (“ASC 230”), Statement of Cash Flows, for cash flow reporting, classifies cash receipts and payments according to whether they stem from operating, investing, or financing activities and provides definitions of each category, and uses the indirect or reconciliation method (“indirect method”) as defined by ASC 230, Statement of Cash Flows, to report net cash flow from operating activities by adjusting net income to reconcile it to net cash flow from operating activities by removing the effects of (a) all deferrals of past operating cash receipts and payments and all accruals of expected future operating cash receipts and payments and (b) all items that are included in net income that do not affect operating cash receipts and payments.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid debt instruments and other short-term investments with maturity of three months or less, when purchased, to be cash equivalents. There were no cash equivalents as of March 31, 2023, and September 30, 2022.

 

The Company maintains its cash balances at one financial institution that is insured by the Federal Deposit Insurance Corporation. At March 31, 2023, and September 30, 2022, $0 and $46,386, respectively, of the Company’s cash balances were in excess of federally insured limits.

 

Fixed Assets

 

Furniture and equipment are stated at cost. Depreciation is provided by the straight-line method over the useful lives of the related assets, approximately seven years. Expenditures for minor enhancements and maintenance are expensed as incurred.

 

F-6

 

 

Stock-Based Compensation

 

The Company accounts for stock-based instruments issued to employees in accordance with ASC Topic 718, Compensation – Stock Compensation, and Certain Redeemable Financial Instruments. ASC Topic 718 requires companies to recognize in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees. The value of the portion of an award that is ultimately expected to vest is recognized as an expense over the requisite service periods using the straight-line attribution method.

 

Fair Value of Financial Instruments

 

The book values of cash, accounts receivable, and accounts payable approximate their respective fair values due to the short-term nature of these instruments. The fair value hierarchy under GAAP distinguishes between assumptions based on market data (observable inputs) and an entity’s own assumptions (unobservable inputs).

 

The hierarchy consists of three levels

 

  ● Level one — Quoted market prices in active markets for identical assets or liabilities;
  ● Level two — Inputs other than level one inputs that are either directly or indirectly observable; and
  ● Level three — Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.

 

Determining which category an asset or liability falls within the hierarchy requires significant judgment. We evaluate our hierarchy disclosures each quarter.

 

Financial Instruments

 

The Company’s financial instruments include cash and cash equivalents, payables, and accrued interest and short-term and long-term notes payable and are accounted for under the provisions of ASC 825, Financial Instruments. The carrying amount of these financial instruments, as reflected in the accompanying consolidated balance sheet, approximates fair value.

 

Long-lived Assets

 

The Company’s long-lived assets and other assets (consisting of furniture, equipment and a patent) are reviewed for impairment in accordance with the guidance of the ASC 360, Property, Plant, and Equipment, and ASC 205, Presentation of Financial Statements. The Company tests for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Impairment evaluations involve management’s estimates on asset useful lives and future cash flows. Actual useful lives and cash flows could be different from those estimated by management which could have a material effect on our reporting results and financial positions. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. During the six months ended March 31, 2023, and 2022, the Company had not experienced impairment losses on its long-lived assets.

 

Research and Development

 

The Company expenses the cost of research and development as incurred. Research and development expenses consist primarily of professional service costs associated with the development of the plant-based defense technology products. For the six months ended March 31, 2023 and 2022, the Company had $0 and $109,248 in research and development expenses, respectively.

 

F-7

 

 

Patents

 

Any patent costs for internally developed patents will be expensed as incurred. Costs to maintain and defend patents are recorded as administrative expenses in the statement of operations.

 

Purchased patents are recorded at cost and reviewed for impairment in accordance with the guidance of the ASC 360, Property, Plant, and Equipment, and ASC 205, Presentation of Financial Statements.

 

Income Taxes

 

The Company accounts for income taxes in accordance with FASB ASC 740, Income Taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of existing assets and liabilities and loss carryforwards and their respective tax bases.

 

Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income (loss) in the years in which those temporary differences are expected to be recovered or settled.

 

The effect of a change in tax rules on deferred tax assets and liabilities is recognized in operations in the year of change. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized.

 

Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for uncertain tax positions as of March 31, 2023. Interest and penalties in any, related to unrecognized tax benefits would be recognized as interest expense. The Company does not have any accrued interest or penalties associated with unrecognized tax benefits, nor was any significant interest expense recognized during the six months ended March 31, 2023.

 

Loss Per Share of Common Stock

 

Basic net loss per common share is computed using the weighted average number of common shares outstanding. Diluted earnings per share (“EPS”) include additional dilution from common stock equivalents, such as stock issuable pursuant to the exercise of stock options, warrants and convertible notes. Common stock equivalents are not included in the computation of diluted earnings per share when the Company reports a loss because to do so would be anti-dilutive for periods presented. The Company had total potential additional dilutive securities outstanding at March 31, 2023, and September 30, 2022, of 22,065,343 and 1,460,009, respectively.

 

Recent Accounting Pronouncements

 

In August 2020, the FASB issued ASU 2020-06, Debt with Conversion and Other Options, which simplifies accounting for convertible instruments. The new guidance eliminates two of the three models in ASC 470-20 that require separating embedded conversion features from convertible instruments. The guidance also addresses how convertible instruments are accounted for in the diluted earnings per share calculation. The guidance is effective for fiscal years beginning after December 15, 2021. The Company is currently evaluating the impact of ASU 2020-06 on its consolidated financial statements.

 

Recently Issued Accounting Standards: Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.

 

NOTE 3 – BORROWINGS

 

Commercial Loan

 

On April 9, 2020, the Company received a loan from the Small Business Administration pursuant to the Paycheck Protection Program (PPP) in the principal amount of $48,750. The note bears interest at a variable rate of approximately 1% and matured in April 2022; and it is currently in default. Forgiveness for the loan was applied for and is pending. The principal amount of the loan was based on the consulting agreement salary between Nexion Biosciences, Inc., organized in the state of Florida (NBFL) (a related party) and the CEO.

 

F-8

 

 

Notes Payable

 

From time to time, the Company’s subsidiary, Genvor Inc., enters into unsecured notes payable with individual investors. Only Noteholder E (below) has security in the form of a personal guarantee by the CEO and prior consultant (Note 6). The terms of these notes are listed below. Several of the notes are convertible into shares of the Company’s common stock as detailed in the following schedule.

 

                 Balance 
                 Convertible 
         Interest   Loan   into 
Noteholder  Origination  Maturity  Rate   Balance   Shares (c) 
Noteholder A (a)  2019  12/31/2021   0%  $217,000    N/A 
Noteholder B (a)  3/19/2019  4/29/2019   0%   510,000    N/A 
Noteholder C (a)  3/1/2019  2/29/2020   18%   32,500    N/A 
Noteholder D (d)  4/29/2019  unspecified   0%   300,000    30,000 
Noteholder E (a)  8/1/2019  8/31/2019   0%   37,500     N/A  
Noteholder F (a)(b)  2/27/2020  4/30/2020   0%   2,500    5,000 
Noteholder G  8/3/2021  8/3/2023   10%   12,500    25,000 
Noteholder H  6/27/2022  6/27/2024   5%   300,000    1,000,000 
Noteholder I (c)  10/26/2022  12/31/2023   3%   50,000    400,000 
               1,462,000    1,460,000 
(d) Debt discount              (150,556)     
              $1,311,444      

 

(a)Past due at December 31, 2022
(b)Note is payable in a combination of $2,500 to $6,000 in cash and 5,000 to 15,000 share of common stock
(c)Convertible into common stock of the subsidiary, Genvor Inc.

 

The notes do not have default provisions except Noteholder B receives a default penalty of $10,000 each month the note goes unpaid.

 

Interest expense totaled $71,665 and $121,002, respectively, for the six months ended March 31, 2023, and 2022, including default penalties. Late fees totaled $60,000 and $60,000, respectively, for the six months ended March 31, 2023, and 2022.

 

NOTE 4 – STOCKHOLDERS’ DEFICIT

 

Preferred Stock

 

The authorized preferred stock of the Company consists of 20,000,000 shares with a $0.001 par value.

 

F-9

 

 

Series A Preferred Stock

 

On August 10, 2022, the Company designated 10 shares of its preferred stock as Series A Preferred Stock (“Series A”). Each share of Series A entitles the holder to ten million (10,000,000) votes on all matters submitted to a vote of the stockholders of the Corporation. When and as any dividend or distribution is declared or paid by the Company on the common stock, the Series A holders are entitled to participate in such dividend or distribution. Each Series A share is convertible, at the option of the holder, into one share of fully paid and non-assessable common stock. Upon any liquidation, dissolution, or winding-up of the Company, the Series A holders are entitled to receive out the assets of the Company, for each share of Series A, an amount equal to par value before any distribution or payment shall be made to the holder of any junior securities (including common stock and all other equity or equity equivalent securities of the Company).

 

As of March 31, 2023, and September 30, 2022, there were 9 and 9 shares of Series A preferred stock issued and outstanding, respectively. The preferred stock was issued on August 16, 2022, as follows: Bradley White (Chief Executive Officer), 3 shares; Dr. Clayton Yates (Chief Scientific Officer and Chairman), 3 shares; and Dr. Jesse Jaynes (Chief Research Officer and Director), 3 shares. See Note 7.

 

Series B Preferred Stock

 

On October 19, 2022, the Company filed a Certificate of Designation with the State of Nevada to designate its Series B Preferred Stock (“Series B”). The designation authorized 2,500,000 shares of Series B. Each share of Series B shall have 10 votes on all matters submitted to a vote of the stockholders of the Company. Each share of Series B is convertible into 10 shares of common stock of the Company.

 

On October 19, 2022, the following shareholders converted shares of common stock of the Company into shares of Series B to modify the common shares outstanding to reduce the outstanding common stock issued by the Company, as follows:

 

Name 

Common Shares

Exchanged

  

Series B

Issued

 
Jaynes Investment LLC   2,000,000    200,000 
ACT Holdings LLC   7,312,612    731,262 
LASB Family Trust   3,800,112    380,012 
Jesse Michael Jaynes   4,767,611    476,762 
Bradley White (a)   1,225,000    122,500 
PJ Advisory Group   1,500,000    150,000 
Total   20,605,334    2,060,536 

 

(a)Related party

 

The conversion of the common stock into the Series B was valued at par, respectively, offset to additional paid-in capital. The Series B is convertible into common stock into the original amount of common stock converted therefore there is no change in the amount of common stock outstanding on a fully diluted basis.

 

As of March 31, 2023, and September 30, 2022, there were 2,060,536 and 0 shares of Series B preferred stock issued and outstanding, respectively.

 

Common Stock

 

The authorized common stock of the Company consists of 300,000,000 shares with a $0.001 par value. All common stock shares are non-assessable and have one vote per share.

 

In connection with the Merger (see Note 1), the founding shareholders of the Company cancelled 18,144,112 shares of common stock, retaining 5%, or 1,855,888 shares of common stock, as of June 30, 2022. The cancellation is presented in the accompanying statements of changes in stockholders’ deficit within the line item “Retroactive application of recapitalization.”

 

F-10

 

 

Stock Issued for Cash

 

On November 17, 2022, the Company issued 300,000 shares of common stock to a shareholder for $150,000.

 

NOTE 5 – FEDERAL INCOME TAX

 

As of March 31, 2023, and September 30, 2022, the Company has net operating loss carry forwards of $2,667,462 and $2,572,885, respectively, which may be available to reduce future years’ taxable income through 2043. The Company’s net operating loss carry forwards may be subject to annual limitations, which could reduce or defer the utilization of the losses as a result of an ownership change as defined in Section 382 of the Internal Revenue Code.

 

The Company’s tax expense differs from the “expected” tax expense for Federal income tax purposes (computed by applying the United States Federal tax rate of 21% to loss before taxes for fiscal year 2023 and 2022), as follows:

 

   March 31,   September 30, 
   2023   2022 
Tax benefit at the statutory rate  $(84,158)  $(204,559)
State income taxes, net of federal income tax benefit   (10,420)   (25,326)
Change in valuation allowance   94,577    229,885 
Total  $-   $- 

 

The tax effects of the temporary differences between reportable financial statement income and taxable income are recognized as deferred tax assets and liabilities.

 

The tax years 2023 and 2022 remains open for examination by federal agencies and other jurisdictions in which it operates.

 

The tax effect of significant components of the Company’s deferred tax assets and liabilities at March 31, 2023, and September 30, 2022, are as follows:

 

   March 31,   September 30, 
   2023   2022 
Net operating loss carryforward  $2,667,462   $2,572,885 
Total gross deferred tax assets   2,667,462    2,572,885 
Less: Deferred tax asset valuation allowance   (2,667,462)   (2,572,885)
Total net deferred taxes  $-   $- 

 

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment.

 

Because of the historical earnings history of the Company, the net deferred tax assets for 2022 and 2021 were fully offset by a 100% valuation allowance. The valuation allowance for the remaining net deferred tax assets was $2,667,462 and $2,572,885 as of March 31, 2023, and September 30, 2022, respectively.

 

F-11

 

 

NOTE 6 – COMMITMENTS AND CONTINGENCIES

 

From time to time, the Company may be involved in litigation in the ordinary course of business. The Company is not currently involved in any litigation that we believe could have a material adverse effect on its financial condition or results of operations.

 

Subscription Agreement and Cash Held in Escrow

 

On February 20, 2019, the Company entered into a subscription escrow agreement (the “Trust Agreement”) with Branch Banking and Trust Company (“BB&T”). This Trust Agreement was established for the subscription agreement proceeds raised and escrowed pursuant to the Company’s prior Rule 419 S-1 offering. The balance held in trust at March 31, 2023 and September 30, 2022, totaled $19,705.

 

Upon completion of the Merger (see Notes 1 and 8), the Company issued 975,000 common stock shares to the investors in that prior S-1 offering during July 2022 and were released to the Company.

 

Consulting Agreements

 

During the six months ended March 31, 2023, the Company paid the CEO $3,000 pursuant to a consulting agreement carried over from related party NBFL. The agreement provides for an annual salary of $150,000 which increases based on certain capital raise thresholds. At March 31, 2023 and September 30, 2022, accrued payroll owed to the CEO totaled $192,638 and $188,484, respectively, as presented in the accompanying consolidated balance sheets.

 

On July 24, 2020, the Company entered into a consulting agreement for business development activities, networking, negotiations, and strategic planning. The compensation pursuant to the agreement was $20,000 monthly.

 

Office Lease

 

The Company entered into a sublease agreement with the above consultant (providing business development assistance from 2019-2020) effective August 1, 2019, subject to the terms and conditions of the office lease held by the consultant at 15540 Quorum Drive #2624, Addison, Texas. On January 1, 2019, the Company adopted ASC 842 requiring this lease to be recorded as an asset and corresponding liability on its balance sheet. The Company records rent expense associated with this lease on the straight-line basis in conjunction with the terms of the underlying lease. A discount rate was not used in the determination of the right of use asset and liability since its effect would not be significant. The lease moved to a month-to-month basis beginning in September 2021 at $2,810 per month in addition to common area maintenance charges. During the six months ended March 31, 2023, and 2022, we incurred $6,590 and $20,607, respectively, in office rental expense.

 

Research and Development Agreement

 

During September 2020, the Company assumed a Cooperative Research And Development Agreement (CRADA) with the United States Department of Agriculture (USDA), Agricultural Research Service (ARS). Under this agreement, the Company committed to funding the remaining amount due. As of March 31, 2023, and September 30, 2022, $246,400 and $246,400, respectively, remained outstanding and is presented in the accompanying consolidated balance sheets as USDA CRADA liability.

 

NOTE 7 – RELATED PARTY TRANSACTIONS

 

Share Issuances to the Board of Directors

 

The Company issued Series A preferred stock on August 16, 2022, as follows: Bradley White (Chief Executive Officer), 3 shares; Dr. Clayton Yates (Chief Scientific Officer and Chairman), 3 shares; and Dr. Jesse Jaynes (Chief Research Officer and Director), 3 shares. See Note 4.

 

NOTE 8 – SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events from the balance sheet through the date of this filing and determined there were no events to disclose except the following.

 

F-12

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Rule 175 of the Securities Act of 1933, as amended, and Rule 3b-6 of the Securities Act of 1934, as amended, that involve substantial risks and uncertainties. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our industry, our beliefs and our assumptions. Words such as “anticipate,” “expects,” “intends,” “plans,” “believes,” “seeks” and “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this Form 10-Q. Investors should carefully consider all of such risks before making an investment decision with respect to the Company’s stock. The following discussion and analysis should be read in conjunction with our financial statements and summary of selected financial data for Genvor Incorporated. Such discussion represents only the best present assessment from our Management.

 

Company Overview

 

Genvor Incorporated (the “Company”) was incorporated in Florida on September 26, 2018, as Allure Worldwide, Inc., and as of November 18, 2019, redomiciled to Nevada. On June 24, 2022, the Company changed its name to from Allure Worldwide, Inc. to Genvor Incorporated.

 

The Company was originally formed with the intention of seeking to acquire the assets or shares of an entity actively engaged in business which generates revenues, in exchange for its securities. On January 11, 2021, the Company entered into an Exchange Agreement (the “Purchase Agreement”) with Genvor Inc., a Delaware corporation (“Genvor”) to acquire (the “Acquisition”) Genvor. On March 2, 2022, the Company and Genvor entered into a merger agreement (the “Merger Agreement”) to consummate the Acquisition, and pursuant to which a wholly-owned subsidiary of the Company, Genvor Acquisition Corp., a Delaware corporation, would merge (the “Merger”) with and into Genvor, with each share of Genvor common stock issued immediately prior to the time of the merger automatically converted into the right to receive one share of common stock of the Company.

 

On May 27, 2022, the Acquisition closed, Merger Subsidiary merged with and into Genvor, each share of Genvor was exchanged for the right to receive one share of Company common stock, 35,261,871 shares of Company common stock were issued to Genvor’s pre-merger shareholders (the “Merger Shares”), constituting a change of control of the Company, and Genvor became a wholly owned subsidiary of the Company. As a result of these transactions, the Company had 55,261,871 issued and outstanding common shares upon the closing of the share exchange with Genvor, and subsequently the Company’s original founding shareholders cancelled 18,144,112 shares of Company common stock in connection with the Acquisition.

 

As a result of the Acquisition, the Company’s business plan is that of Genvor, and the Company is developing plant-based defense technology designed to help farmers achieve global food security.

 

The Company’s technology was developed by two university scientists, Dr. Clayton Yates and Dr. Jesse Jaynes, who shared a mission to develop crop protection technology designed to defend against crop diseases effecting both animals and humans alike. The Company’s technology is currently being advanced by the USDA in corn seed varieties and with U.S. Sugar in citrus trees.

 

The Company’s headquarters is located at 13155 Noel Road, Suite 900, Dallas, Texas, 75240.

 

The following Management Discussion and Analysis should be read in conjunction with the financial statements and accompanying notes included in this Form 10-Q.

 

Plan of Operation

 

The United States Food and Agriculture Organization reports that annual global crop losses due to plant pathogens and viruses are now estimated to exceed $100 billion. Alarming to the FDA are the fungi “Aspergillus Flavus,” which produce Aflatoxins, a toxic and carcinogenic compound known to cause liver cancer in humans and animals. Aspergillus Flavus is also the second leading cause of “aspergillosis” in humans. Patients infected with Aspergillus flavus often have reduced or compromised immune systems.

 

4

 

 

The U.S. Food and Drug Administration estimates the annual cost of Aflatoxin contamination in the United States at approximately $500 million through two categories of loss: market rejection and animal health impacts. As a result, the United States Department of Agriculture (USDA) has imposed strict guidelines for crop inspection and discovery of diseased crops caused by Aflatoxins. Both planted fields and harvested crops that are found to be contaminated beyond permitted testing levels must be destroyed. As a result, farmers and growers can be exposed to catastrophic economic losses. This Aflatoxin problem has created a significant opportunity for agricultural companies who can develop the technology needed to defend against Aflatoxins.

 

The Company’s Solution

 

The Company’s technology is the only known solution that it is aware of, which it believes provides broad spectrum effectiveness against Aspergillus Flavus and Aflatoxins. This technology is deliverable by both bioengineered seed trait, as well as through biopesticide application.

 

Dr. Jaynes, one of Genvor’s founders, has been on a 30+ year quest to find a global crop solution for defense against Aflatoxins. As a result of successful testing and collaboration between Dr. Jaynes and the United States Department of Agriculture, Agriculture Research Service (USDA-ARS), the USDA-ARS awarded Genvor with a Cooperative Research & Development Agreement in August of 2018. The stated goal of this agreement is to develop and commercialize disease resistant and nutritionally enhanced corn seed varieties using Genvor’s seed trait technology.

 

Seed Traits

 

In the United States, the adoption of crop seeds with enhanced traits has been staggering. Currently, over 90 percent of U.S. corn, cotton and soybeans are produced using seeds with enhanced traits. Trait fees for these three crops alone represent over $2 billion annually based on an average trait fee of $13 per acre on approximately 170 million acres. U.S. corn crops alone account for roughly $1.2 billion of the estimated $2 billion.

 

Biopesticides

 

Biopesticides are one of the fastest-growing crop protection market sectors, increasing at twice the compound annual growth rate of the crop protection market as a whole. Primary drivers of this growth include a rising global demand for organic foods, the trend in the reduction of chemical residues, stricter import and supermarket standards, shorter pre-harvest intervals, a push for sustainability, and the demand for additional modes of action for managing resistance. The biopesticide market in north America alone is currently estimated to be over $4.8 billion annually.

 

Genvor’s technology is effective with corn seed and is believed by Genvor to be effective with many known crop types, and the technology may be delivered as a topical spray in the form of a biopesticide.

 

Reports to Security Holders

 

The Company is required to file reports pursuant to Section 15(d) of the Securities Exchange Act of 1934 and is required to furnish its stockholders with annual reports containing consolidated financial statements audited by its independent registered public accounting firm and to make available quarterly reports containing unaudited consolidated financial statements for each of the first three quarters of each fiscal year ending September 30th. The Company files Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K and Current Reports on Form 8-K with the Securities and Exchange Commission. The Company may also file additional documents with the Commission if those documents become necessary in the course of its operations.

 

Available Information

 

All reports of the Company filed with the SEC are available free of charge through the SEC’s website at www.sec.gov. In addition, the public may read and copy materials filed by the Company at the SEC’s Public Reference Room located at 100 F Street, N.E., Washington, D.C. 20549. The public may also obtain additional information on the operation of the Public Reference Room by calling the Commission at 1-800-SEC-0330.

 

5

 

 

Results of Operations

 

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the financial statements and notes thereto for the three and nine months ended March 31, 2023, and 2022, and related management discussion herein.

 

Our financial statements are stated in U.S. Dollars and are prepared in accordance with generally accepted accounting principles of the United States (“GAAP”).

 

Going Concern Qualification

 

Several conditions and events cast substantial doubt about the Company’s ability to continue as a going concern. The Company has incurred cumulative net losses of $16,689,168 from its inception to March 31, 2023, and requires capital for its contemplated operational and marketing activities to take place. The Company’s ability to raise additional capital through debt or future issuances of capital stock is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raises substantial doubt about the Company’s ability to continue as a going concern.

 

For the Three Months Ended March 31, 2023, and 2022

 

Revenues

 

We did not earn any revenues during the three months ending March 31, 2023, and 2022.

 

Operating Loss

 

During the three months ending March 31, 2023, and 2022, the Company had an operating loss of $155,282 and $3,202,315, respectively. For the three months March 31, 2022, the primary expenses were stock-based compensation of $3,010,000. The decrease in operating loss was primarily due to decreases in payroll, stock-based compensation, and other general administrative expenses during the three months ending March 31, 2023, as compared to the three months ending March 31, 2022.

 

Net Loss

 

The Company incurred a net loss of $221,212 and $3,265,545, respectively, during the three months ended March 31, 2023, and 2022, as a result of the decreasing operating loss described operating loss described previously.

 

For the Six Months Ended March 31, 2023, and 2022

 

Revenues

 

We did not earn any revenues during the six months ending March 31, 2023, and 2022.

 

Operating Loss

 

During the six months ending March 31, 2023, and 2022, the Company had an operating loss of $268,864 and $3,655,634, respectively. For the six months March 31, 2022, the primary expenses were stock-based compensation of $3,210,000. The decrease in operating loss was primarily due to decreases in payroll, stock-based compensation, and other general administrative expenses during the six months ended March 31, 2022.

 

Net Loss

 

The Company incurred a net loss of $400,751 and $3,776,636, respectively, during the six months ended March 31, 2023, and 2022, as a result of the decreasing operating loss described previously.

 

6

 

 

Liquidity and Capital Resources

 

Based upon our current financial condition, we do not have sufficient cash to operate our business at the current level for the next twelve months. We intend to fund operations through debt and/or equity financing arrangements, which may be insufficient to fund expenditures or other cash requirements. We plan to seek additional financing in a private equity offering to secure funding for operations. There can be no assurance that we will be successful in raising additional funding. If we are not able to secure additional funding, the implementation of our business plan will be impaired. There can be no assurance that such additional financing will be available to us on acceptable terms or at all.

 

Working Capital

 

Cash Flow

 

We fund our operations with cash received from advances from officers and related parties and issuances of equity or notes payable.

 

Cash Flows from Operating Activities

 

For the six months ended March 31, 2023, as compared to the six months ended March 31, 2022, cash used in operating expenses increased due to payments of contract payroll and accounts payable, as well as due to an increase in professional fees and research and development expenses.

 

Cash Flows from Investing Activities

 

For the six months ended March 31, 2023, no cashflows were provided by or used in investing activities.

 

Cash Flows from Financing Activities

 

For the six months ended March 31, 2023, cash was raised through the sale of common stock.

 

Off-Balance Sheet Arrangements

 

The Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

Not Applicable.

 

ITEM 4. CONTROLS AND PROCEDURES.

 

Disclosure Controls and Procedures

 

The Securities and Exchange Commission defines the term “disclosure controls and procedures” to mean the company’s controls and other procedures of an issuer that are designed to ensure that information required to be disclosed in the reports that it files or submits under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Securities Exchange Act of 1934 is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. The Company maintains such a simple system of controls and procedures in an effort to ensure that all information which it is required to disclose in the reports it files under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified under the SEC’s rules and forms and that information required to be disclosed is accumulated and communicated to principal executive and principal financial officers to allow timely decisions regarding disclosure.

 

7

 

 

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on this evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were not effective to provide reasonable assurance of achieving the objectives of timely alerting them to material information required to be included in our periodic SEC reports and of ensuring that such information is recorded, processed, summarized and reported with the time periods specified. Our chief executive officer and chief financial officer also concluded that our disclosure controls and procedures were not effective as of the end of the period covered by this report to provide reasonable assurance of the achievement of these objectives.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in the Company’s internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 or 15d-15 of the Exchange Act that occurred during the quarter ended March 31, 2023, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

PART II - OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS.

 

The Company is not a party to any significant pending legal proceedings other than as disclosed below, and no other such proceedings are known to be contemplated. No director, officer or affiliate of the Company, and no owner of record or beneficial owner of more than 5.0% of the securities of the Company, or any associate of any such director, officer or security holder is a party adverse to the Company or has a material interest adverse to the Company in reference to pending litigation.

 

ITEM 1A. RISK FACTORS.

 

Not applicable.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

On November 17, 2022, the Company issued 300,000 shares of common stock in exchange for $150,000. These shares were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506(b) promulgated thereunder, as there was no general solicitation and the transaction did not involve a public offering.

 

On March 15, 2023, the Company issued 50,000 shares of common stock in exchange for $12,500. These shares were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506(b) promulgated thereunder, as there was no general solicitation and the transaction did not involve a public offering.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES.

 

None.

 

ITEM 5. OTHER INFORMATION.

 

None.

 

8

 

 

ITEM 6. EXHIBITS.

 

Exhibit   Description
     
3.1   Florida Articles of Incorporation (incorporated by reference to Exhibit 3.A to our Registration Statement on Form S-1, filed on May 4, 2020)
     
3.2   Nevada Articles of Incorporation (incorporated by reference to Exhibit 3.2 to our Quarterly Report on Form 10-Q, filed on July 20, 2021)
     
3.3   Certificate of Correction to Nevada Articles of Incorporation (incorporated by reference to Exhibit 3.3 to our Quarterly Report on Form 10-Q, filed on July 20, 2021)
     
3.4   Bylaws (incorporated by reference to Exhibit 3.B to our Registration Statement on Form S-1, filed on May 4, 2020)
     
10.1*   Exchange Agreement, by and between the Company and Genvor Inc. (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on February 1, 2021)
     
10.2*   Agreement and Plan of Merger, by and between the Company, Genvor Inc., and Genvor Acquisition Corp. (incorporated by reference to Exhibit 10.2 to our Annual Report on Form 10-K filed on March 21, 2022)
     
31.1**   Certification of CEO required by Rule 13a-14(1) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
31.2**   Certification of CFO required by Rule 13a-14(1) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
32.1**   Certification of CEO pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and Section 1350 of 18 U.S.C. 63
     
32.2**   Certification of CFO pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and Section 1350 of 18 U.S.C. 63
     
101.INS***   Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).
     
101.SCH***   Inline XBRL Taxonomy Extension Schema Document.
     
101.CAL***   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
     
101.DEF***   Inline XBRL Taxonomy Extension Definition Linkbase Document.
     
101.LAB***   Inline XBRL Taxonomy Extension Labels Linkbase Document.
     
101.PRE***   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
     
104   Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).

 

 

* Certain schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule or exhibit will be furnished supplementally to the Securities and Exchange Commission upon request; provided, however that the Company may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedule or Exhibit so furnished.

** Filed herewith.

*** XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

 

9

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  GENVOR INCORPORATED
     
Date: April 24, 2023 By: /s/ Bradley White
    Bradley White
   

Chief Executive Officer,

Chief Financial Officer & Director

 

10

 

 EX-31.1 2 ex31-1.htm

 

EXHIBITS 31.1 & 31.2

 

CERTIFICATION

 

I, Bradley White, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Genvor Incorporated;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: April 24, 2023 By: /s/ Bradley White
    Bradley White
    Chief Executive Officer and Chief Financial Officer

 

   
 EX-32.1 3 ex32-1.htm

 

EXHIBITS 32.1 & 32.2

 

CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Bradley White, Chief Executive Officer and Chief Financial Officer of Genvor Incorporated (the “Company”), certify, pursuant to 18 U.S.C. Section 1350 adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

  (1) the Quarterly Report on Form 10-Q of the Company for the period ended March 31, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and

 

  (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: April 24, 2023 By: /s/ Bradley White
    Bradley White
    Chief Executive Officer and Chief Financial Officer

 

   

 

 EX-101.SCH 4 gnvr-20230331.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flow (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - BORROWINGS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - STOCKHOLDERS’ DEFICIT link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - FEDERAL INCOME TAX link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - BORROWINGS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - STOCKHOLDERS’ DEFICIT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - FEDERAL INCOME TAX (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - SCHEDULE OF CONVERTIBLE NOTES PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - SCHEDULE OF CONVERTIBLE NOTES PAYABLE (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - BORROWINGS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - SCHEDULE OF CONVERTED SHARES OF COMMON STOCK (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - STOCKHOLDERS’ DEFICIT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - SCHEDULE OF LOSS BEFORE TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - FEDERAL INCOME TAX (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 5 gnvr-20230331_cal.xml XBRL CALCULATION FILE EX-101.DEF 6 gnvr-20230331_def.xml XBRL DEFINITION FILE EX-101.LAB 7 gnvr-20230331_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series A Preferred Stock [Member] Series B Preferred Stock [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Debt Instrument [Axis] Paycheck Protection Program [Member] Noteholder B [Member] Note Holder A [Member] Noteholder C [Member] Noteholder D [Member] Noteholder E [Member] Noteholder F [Member] Noteholder G [Member] Noteholder H [Member] Noteholder I [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Title of Individual [Axis] Bradley White [Member] Dr. Clayton Yates [Member] Dr. Jesse Jaynes [Member] Shareholder [Member] Stock Issued for Cash [Member] Related Party, Type [Axis] Jaynes Investment LLC [Member] ACT Holdings LLC [Member] LASB Family Trust [Member] Jesse Michael Jaynes [Member] PJ Advisory Group [Member] Investor [Member] Plan Name [Axis] Consulting Agreements [Member] Chief Executive Officer [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Related Party Transaction [Axis] Consultant [Member] Category of Item Purchased [Axis] Research and Development Arrangement [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement [Table] Statement [Line Items] ASSETS Current assets: Cash Other current assets Total current assets Fixed assets, net Total assets LIABILITIES AND STOCKHOLDERS’ DEFICIT Current liabilities: Convertible notes payable Accounts payable and accrued expenses Due to related party SBA loan USDA CRADA liability Total current liabilities Non-current liabilities: Convertible notes payable, net of discounts Total non-current liabilities Total liabilities Commitments and contingencies (Note 6) Stockholders’ deficit: Preferred stock value Common stock, $0.001 par value, 300,000,000 shares authorized, 18,422,821 and 38,678,155 shares issued and outstanding as of March 31, 2023 and September 30, 2022, respectively Additional paid-in capital Accumulated deficit Total stockholders’ deficit Total liabilities and stockholders’ deficit Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenue Operating expenses Professional fees Payroll related expenses Research and development Stock-based compensation Depreciation expense Other general and administrative expenses Total operating expenses Operating loss Other income (expense) Interest expense Penalties Amortization of debt discount Total other income (expense) Net loss Basic and diluted net loss per common share Basic and diluted weighted average common shares outstanding Balance Balance, shares Recapilitalization / RTO impact Adjusted balance, beginning of period Adjusted balance beginning of period, shares Common stock issued for services Common stock issued for services, shares Exercise of options Exercise of options, shares Common stock issued for cash Common stock issued for cash, shares Net loss Issuance of common stock for services Common stock issued for debt conversion Common stock issued for debt conversion, shares Payment for reverse capitalization 419 fund raising services 419 fund raising services, shares Conversion of common stock into Series B preferred stock Conversion of common stock into Series B preferred stock, shares Sale of common stock Sale of common stock, shares Balance Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Late fee capitalized into notes payable Amortization of debt discount Changes in assets and liabilities: Prepaid expenses Other current assets Accounts payable and accrued expenses USDA CRADA liability Net cash used in operating activities Cash flows from financing activities: Proceeds from notes payable Exercise of stock options Proceeds from sale of common stock Net cash provided by financing activities Net increase (decrease) in cash Cash at beginning of period Cash at end of period Cash paid for interest Cash paid for taxes Accounting Policies [Abstract] ORGANIZATION AND BASIS OF PRESENTATION SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Broker-Dealer [Abstract] BORROWINGS Equity [Abstract] STOCKHOLDERS’ DEFICIT Income Tax Disclosure [Abstract] FEDERAL INCOME TAX Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Subsequent Events [Abstract] SUBSEQUENT EVENTS Use of Estimates Cash Flow Reporting Cash and Cash Equivalents Fixed Assets Stock-Based Compensation Fair Value of Financial Instruments Financial Instruments Long-lived Assets Research and Development Patents Income Taxes Loss Per Share of Common Stock Recent Accounting Pronouncements SCHEDULE OF CONVERTIBLE NOTES PAYABLE SCHEDULE OF CONVERTED SHARES OF COMMON STOCK SCHEDULE OF LOSS BEFORE TAXES SCHEDULE OF DEFERRED TAX ASSETS Accumulated deficit Net loss Net cash used in operating activities Cash equivalents Cash uninsured amount Fixed assets, estimated useful lives Research and development expenses Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Origination Maturity date Interest rate Loan Balance Number of shares the notesis convertible into shares Debt discount Total loan Notes payable converted Shares issued during conversion Principal amont Interest rate [custom:DebtDefaultPenaltyAmount] Interest expense Late fees Schedule of Stock by Class [Table] Class of Stock [Line Items] Common Shares Exchanged Series B Issued Preferred stock, shares par value Designation authorized shares Number of votes Conversion share description Common stock, shares par value Number of common stock cancel Number of common stock retaining Stock Issued During Period, Shares, New Issues Stock Issued During Period, Value, New Issues Tax benefit at the statutory rate State income taxes, net of federal income tax benefit Change in valuation allowance Total Net operating loss carryforward Total gross deferred tax assets Less: Deferred tax asset valuation allowance Total net deferred taxes Net operating loss carry forwards Federal tax statutory rate Valuation allowance for net deferred tax assets Long-Term Purchase Commitment [Table] Long-Term Purchase Commitment [Line Items] Assets held in trust Number of shares issued Related party payable Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold Accrued Payroll Taxes, Current Salary and Wage, Excluding Cost of Good and Service Sold Rent expense Fund Amount Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] Designation authorized shares. Penalties. Recapitalization rto impact. Founder shares issued amount. Payment for reverses capitalization. Issuance of common stock to prior S1 investors amount. Issuance of common stock for settlements amount. Fund raising services amount. Founder shares issued shares. Issuance of common stock to priors one investors shares. Issuance of common stock for settlements shares. Fund raising services shares. Patents [Policy Text Block] Related party payable Amount paid to consultant. Origination Noteholder B [Member] Noteholder C [Member] Noteholder D [Member] Noteholder E [Member] Noteholder F [Member] Noteholder G [Member] Noteholder H [Member] Noteholder I [Member] Fund amount. Future maturities of notes payable next twelve months. Future maturities of notes payable year two. Late fees. Issuance of common stock for services. Bradley White [Member] Dr. Clayton Yates [Member] Dr. Jesse Jaynes [Member] Jaynes Investment LLC [Member] ACT Holdings LLC [Member] LASB Family Trust [Member] Jesse Michael Jaynes [Member] PJ Advisory Group [Member] Nexion Contractor [Member] Share Issue for Services [Member] Stock Issued for Cash [Member] Consulting Agreements [Member] Consultant [Member] Note Holder A [Member] Issuance of common stock for settlements. Issuance of common stock for settlements, shares. Due to related party. Stockholders equity adjusted balance. Shares outstanding adjusted balance. Issuance of common stock, value. Issuance of common stock, shares. Sale of common stock. Sale of common stock, shares. Cash Flow Reporting [Policy Text Block] Paycheck Protection Program [Member] Debt default penalty amount. Number of common stock retaining. Transfer and Exchange Agreement [Member] Debt Holder [Member] Director One [Member] Director Two [Member] Director Three [Member] Three Directors [Member] Shareholder [Member] Daughter of CEO and Board Member [Member] Merger Disclosure [Text Block] Old Genvor [Member] Third-party [Member] Late fee capitalized into notes payable. Assets, Current Assets Liabilities, Current Liabilities, Noncurrent Liabilities Equity, Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Interest Expense Nonoperating Income (Expense) Shares, Outstanding Increase (Decrease) in Prepaid Expense Increase (Decrease) in Other Current Assets Increase (Decrease) in Accounts Payable Increase (Decrease) in Other Operating Liabilities Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Debt Instrument, Unamortized Discount Debt Instrument, Interest Rate, Stated Percentage Income Tax Expense (Benefit) Deferred Tax Assets, Net of Valuation Allowance EX-101.PRE 8 gnvr-20230331_pre.xml XBRL PRESENTATION FILE XML 9 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover - shares
 6 Months Ended
Mar. 31, 2023
Apr. 19, 2023
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Mar. 31, 2023  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2023  
Current Fiscal Year End Date --09-30  
Entity File Number 333-234815  
Entity Registrant Name GENVOR INCORPORATED  
Entity Central Index Key 0001792941  
Entity Tax Identification Number 83-2054746  
Entity Incorporation, State or Country Code NV  
Entity Address, Address Line One 13155 Noel Road  
Entity Address, Address Line Two Suite 900  
Entity Address, City or Town Dallas  
Entity Address, State or Province TX  
Entity Address, Postal Zip Code 75240  
City Area Code (214)  
Local Phone Number 427-1921  
Entity Current Reporting Status No  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Elected Not To Use the Extended Transition Period true  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   18,422,821
XML 10 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Mar. 31, 2023
Sep. 30, 2022
Current assets:    
Cash $ 1,513 $ 296,386
Other current assets 15,397 2,000
Total current assets 16,910 298,386
Fixed assets, net 16,650 17,565
Total assets 33,560 315,951
Current liabilities:    
Convertible notes payable 1,162,000 1,052,000
Accounts payable and accrued expenses 302,295 516,658
Due to related party 3,846 3,846
SBA loan 48,750 48,750
USDA CRADA liability 246,400 246,400
Total current liabilities 1,763,291 1,867,654
Non-current liabilities:    
Convertible notes payable, net of discounts 149,444 89,221
Total non-current liabilities 149,444 89,221
Total liabilities 1,912,735 1,956,875
Commitments and contingencies (Note 6)
Stockholders’ deficit:    
Common stock, $0.001 par value, 300,000,000 shares authorized, 18,422,821 and 38,678,155 shares issued and outstanding as of March 31, 2023 and September 30, 2022, respectively 18,423 38,678
Additional paid-in capital 14,789,509 14,608,815
Accumulated deficit (16,689,168) (16,288,417)
Total stockholders’ deficit (1,879,175) (1,640,924)
Total liabilities and stockholders’ deficit 33,560 315,951
Series A Preferred Stock [Member]    
Stockholders’ deficit:    
Preferred stock value
Series B Preferred Stock [Member]    
Stockholders’ deficit:    
Preferred stock value $ 2,061
XML 11 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Mar. 31, 2023
Sep. 30, 2022
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 20,000,000 20,000,000
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 300,000,000 300,000,000
Common stock, shares issued 18,422,821 38,678,155
Common stock, shares outstanding 18,422,821 38,678,155
Series A Preferred Stock [Member]    
Preferred stock, shares authorized 10 10
Preferred stock, shares issued 9 9
Preferred stock, shares outstanding 9 9
Series B Preferred Stock [Member]    
Preferred stock, shares authorized 2,500,000 2,500,000
Preferred stock, shares issued 2,060,536 0
Preferred stock, shares outstanding 2,060,536 0
XML 12 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]        
Revenue
Operating expenses        
Professional fees 58,858 79,505 65,662 87,758
Payroll related expenses 37,500 45,725 75,000 143,225
Research and development 102,800 109,248
Stock-based compensation 3,010,000 3,210,000
Depreciation expense 458 458 916 916
Other general and administrative expenses 58,466 (36,173) 127,286 104,487
Total operating expenses 155,282 3,202,315 268,864 3,655,634
Operating loss (155,282) (3,202,315) (268,864) (3,655,634)
Other income (expense)        
Interest expense (5,819) (33,230) (11,665) (61,002)
Penalties (30,000) (30,000) (60,000) (60,000)
Amortization of debt discount (30,112) (60,223)
Total other income (expense) (65,930) (63,230) (131,887) (121,002)
Net loss $ (221,212) $ (3,265,545) $ (400,751) $ (3,776,636)
Basic and diluted net loss per common share $ (0.01) $ (0.16) $ (0.02) $ (0.19)
Basic and diluted weighted average common shares outstanding 18,381,710 20,000,000 20,449,202 20,000,000
XML 13 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($)
Preferred Stock [Member]
Series A Preferred Stock [Member]
Preferred Stock [Member]
Series B Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance at Sep. 30, 2021 $ 2,000 $ (64,540) $ (62,540)
Balance, shares at Sep. 30, 2021 20,000,000      
Recapilitalization / RTO impact $ 18,000 8,546,798 (10,947,544) (2,382,746)
Adjusted balance, beginning of period $ 20,000 8,546,798 (11,012,084) (2,445,286)
Adjusted balance beginning of period, shares     20,000,000      
Common stock issued for services $ 2,650 197,350 200,000
Common stock issued for services, shares     2,650,000      
Exercise of options $ 1,400   1,400
Exercise of options, shares     1,400,000      
Common stock issued for cash $ 1,475 736,035   737,510
Common stock issued for cash, shares     1,475,020      
Net loss (511,091) (511,091)
Balance at Dec. 31, 2021 $ 25,525 9,480,183 (11,523,175) (2,017,467)
Balance, shares at Dec. 31, 2021 25,525,020      
Balance at Sep. 30, 2021 $ 2,000 (64,540) (62,540)
Balance, shares at Sep. 30, 2021 20,000,000      
Net loss           (3,776,636)
Balance at Mar. 31, 2022 $ 32,684 12,810,597 (14,788,720) (1,945,439)
Balance, shares at Mar. 31, 2022 32,683,695      
Balance at Dec. 31, 2021 $ 25,525 9,480,183 (11,523,175) (2,017,467)
Balance, shares at Dec. 31, 2021 25,525,020      
Common stock issued for services $ 6,020 3,003,980 3,010,000
Common stock issued for services, shares     6,020,000      
Common stock issued for cash $ 280 139,720 140,000
Common stock issued for cash, shares     280,000      
Net loss (3,265,545) (3,265,545)
Issuance of common stock for services
Common stock issued for debt conversion $ 689 336,884 337,573
Common stock issued for debt conversion, shares     688,675      
Payment for reverse capitalization (150,000) (150,000)
419 fund raising services $ 170 (170)
419 fund raising services, shares     170,000      
Balance at Mar. 31, 2022 $ 32,684 12,810,597 (14,788,720) (1,945,439)
Balance, shares at Mar. 31, 2022 32,683,695      
Balance at Sep. 30, 2022 $ 38,678 14,608,815 (16,288,417) (1,640,924)
Balance, shares at Sep. 30, 2022 38,678,155      
Net loss (179,539) (179,539)
Conversion of common stock into Series B preferred stock $ 2,061 $ (20,605) 18,544
Conversion of common stock into Series B preferred stock, shares   2,060,536 (20,605,334)      
Sale of common stock $ 300 149,700 150,000
Sale of common stock, shares     300,000      
Balance at Dec. 31, 2022 $ 2,061 $ 18,373 14,777,059 (16,467,956) (1,670,463)
Balance, shares at Dec. 31, 2022 2,060,536 18,372,821      
Balance at Sep. 30, 2022 $ 38,678 14,608,815 (16,288,417) (1,640,924)
Balance, shares at Sep. 30, 2022 38,678,155      
Net loss           (400,751)
Balance at Mar. 31, 2023 $ 2,061 $ 18,423 14,789,509 (16,689,168) (1,879,175)
Balance, shares at Mar. 31, 2023 2,060,536 18,422,821      
Balance at Dec. 31, 2022 $ 2,061 $ 18,373 14,777,059 (16,467,956) (1,670,463)
Balance, shares at Dec. 31, 2022 2,060,536 18,372,821      
Net loss (221,212) (221,212)
Sale of common stock $ 50 12,450 12,500
Sale of common stock, shares     50,000      
Balance at Mar. 31, 2023 $ 2,061 $ 18,423 $ 14,789,509 $ (16,689,168) $ (1,879,175)
Balance, shares at Mar. 31, 2023 2,060,536 18,422,821      
XML 14 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Cash Flow (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Cash flows from operating activities:        
Net loss $ (221,212) $ (3,265,545) $ (400,751) $ (3,776,636)
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation expense 458 458 916 916
Late fee capitalized into notes payable     60,000 60,000
Stock-based compensation 3,010,000 3,210,000
Amortization of debt discount 30,112 60,223
Changes in assets and liabilities:        
Prepaid expenses     496
Other current assets     (13,397) 55,665
Accounts payable and accrued expenses     (214,364) (248,543)
USDA CRADA liability     2,800
Net cash used in operating activities     (507,373) (695,302)
Cash flows from financing activities:        
Proceeds from notes payable     50,000 34,375
Exercise of stock options     1,400
Proceeds from sale of common stock     162,500 877,510
Net cash provided by financing activities     212,500 913,285
Net increase (decrease) in cash     (294,873) 217,983
Cash at beginning of period     296,386 7,310
Cash at end of period $ 1,513 $ 225,293 1,513 225,293
Cash paid for interest    
Cash paid for taxes    
XML 15 R7.htm IDEA: XBRL DOCUMENT v3.23.1
ORGANIZATION AND BASIS OF PRESENTATION
 6 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
ORGANIZATION AND BASIS OF PRESENTATION

NOTE 1 – ORGANIZATION AND BASIS OF PRESENTATION

 

On May 27, 2022, Genvor Incorporated, formerly known as Allure Worldwide, Inc. (the “Company” or “Genvor” or “we”), a Nevada corporation, Genvor Acquisition, Corp., a Delaware corporation and a wholly owned subsidiary of the Company (“Merger Sub”), and Genvor Inc., a Delaware corporation (“Old Genvor”), completed their previously announced merger transaction pursuant to which the Company acquired Old Genvor (the “Acquisition”), and Old Genvor became a wholly-owned subsidiary of the Company. The Acquisition was completed pursuant to an Exchange Agreement, dated as of January 11, 2021 (the “Acquisition Agreement”), pursuant to which Old Genvor was to be acquired by the Company as its wholly owned subsidiary and each share of Old Genvor common stock would be exchanged for a share of the Company’s common stock, and a merger agreement, dated March 2, 2022 (the “Merger Agreement”), pursuant to which Merger Sub merged with and into Old Genvor, with Old Genvor continuing as a wholly owned subsidiary of the Company and the surviving corporation of the merger, and each share of Old Genvor being converted into the right to receive a share of the Company (the “Merger”). After closing of the Merger, the Company was renamed “Genvor Incorporated”. Genvor develops plant-based defense technology designed to help farmers achieve global food security.

 

During May 2019, Old Genvor acquired Nexion Biosciences LLC (“NBLLC”) from a founder for nominal consideration as a wholly owned subsidiary. NBLLC was formed in the state of Delaware on December 28, 2018 (“inception”). The consolidated financial statements of the Company include the accounts of Genvor Incorporated, Old Genvor, and its wholly owned subsidiary NBLLC. Intercompany accounts and transactions have been eliminated upon consolidation.

 

Nature of Operations

 

The Company’s business plan is developing plant-based defense technology designed to help farmers achieve global food security. The Company’s technology was developed by two university scientists, Dr. Clayton Yates and Dr. Jesse Jaynes, who shared a mission to develop crop protection technology designed to defend against crop diseases effecting both animals and humans alike.

 

Basis of Presentation

 

The accompanying unaudited financial information as of and for the six months ended March 31, 2023 and 2022 has been prepared in accordance with GAAP for interim financial information and with the instructions to Quarterly Report on Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, such financial information includes all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial position at such date and the operating results and cash flows for such periods. Operating results for the six months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the entire year or for any other subsequent interim period.

 

Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been omitted pursuant to the rules of the U.S. Securities and Exchange Commission, or the SEC. These unaudited financial statements and related notes should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended September 30, 2022, as filed with the SEC.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All significant intercompany balances and transactions have been eliminated in the consolidation. The consolidated financial statements included herein, presented in accordance with United States generally accepted accounting principles (“GAAP”) and stated in United States dollars, have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission.

 

 

Liquidity and Going Concern

 

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. At March 31, 2023, the Company had an accumulated deficit of $16,689,168. For the six months ended March 31, 2023, the Company recognized a net loss of $400,751 and had net cash used in operating activities of $507,373, with no revenues earned, and a lack of operational history. These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern.

 

While the Company is attempting to generate revenues, the Company’s cash position may not be significant enough to support the Company’s daily operations. Management intends to raise additional funds by way of additional public and/or private offerings of its stock. Management believes that the actions presently being taken to further implement its business plan and generate revenues provide the opportunity for the Company to continue as a going concern. While the Company believes in the viability of its strategy to generate revenues and in its ability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate revenues. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

 
XML 16 R8.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 6 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Cash Flow Reporting

 

The Company follows Accounting Standards Codification (“ASC 230”), Statement of Cash Flows, for cash flow reporting, classifies cash receipts and payments according to whether they stem from operating, investing, or financing activities and provides definitions of each category, and uses the indirect or reconciliation method (“indirect method”) as defined by ASC 230, Statement of Cash Flows, to report net cash flow from operating activities by adjusting net income to reconcile it to net cash flow from operating activities by removing the effects of (a) all deferrals of past operating cash receipts and payments and all accruals of expected future operating cash receipts and payments and (b) all items that are included in net income that do not affect operating cash receipts and payments.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid debt instruments and other short-term investments with maturity of three months or less, when purchased, to be cash equivalents. There were no cash equivalents as of March 31, 2023, and September 30, 2022.

 

The Company maintains its cash balances at one financial institution that is insured by the Federal Deposit Insurance Corporation. At March 31, 2023, and September 30, 2022, $0 and $46,386, respectively, of the Company’s cash balances were in excess of federally insured limits.

 

Fixed Assets

 

Furniture and equipment are stated at cost. Depreciation is provided by the straight-line method over the useful lives of the related assets, approximately seven years. Expenditures for minor enhancements and maintenance are expensed as incurred.

 

 

Stock-Based Compensation

 

The Company accounts for stock-based instruments issued to employees in accordance with ASC Topic 718, Compensation – Stock Compensation, and Certain Redeemable Financial Instruments. ASC Topic 718 requires companies to recognize in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees. The value of the portion of an award that is ultimately expected to vest is recognized as an expense over the requisite service periods using the straight-line attribution method.

 

Fair Value of Financial Instruments

 

The book values of cash, accounts receivable, and accounts payable approximate their respective fair values due to the short-term nature of these instruments. The fair value hierarchy under GAAP distinguishes between assumptions based on market data (observable inputs) and an entity’s own assumptions (unobservable inputs).

 

The hierarchy consists of three levels

 

  ● Level one — Quoted market prices in active markets for identical assets or liabilities;
  ● Level two — Inputs other than level one inputs that are either directly or indirectly observable; and
  ● Level three — Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.

 

Determining which category an asset or liability falls within the hierarchy requires significant judgment. We evaluate our hierarchy disclosures each quarter.

 

Financial Instruments

 

The Company’s financial instruments include cash and cash equivalents, payables, and accrued interest and short-term and long-term notes payable and are accounted for under the provisions of ASC 825, Financial Instruments. The carrying amount of these financial instruments, as reflected in the accompanying consolidated balance sheet, approximates fair value.

 

Long-lived Assets

 

The Company’s long-lived assets and other assets (consisting of furniture, equipment and a patent) are reviewed for impairment in accordance with the guidance of the ASC 360, Property, Plant, and Equipment, and ASC 205, Presentation of Financial Statements. The Company tests for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Impairment evaluations involve management’s estimates on asset useful lives and future cash flows. Actual useful lives and cash flows could be different from those estimated by management which could have a material effect on our reporting results and financial positions. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. During the six months ended March 31, 2023, and 2022, the Company had not experienced impairment losses on its long-lived assets.

 

Research and Development

 

The Company expenses the cost of research and development as incurred. Research and development expenses consist primarily of professional service costs associated with the development of the plant-based defense technology products. For the six months ended March 31, 2023 and 2022, the Company had $0 and $109,248 in research and development expenses, respectively.

 

 

Patents

 

Any patent costs for internally developed patents will be expensed as incurred. Costs to maintain and defend patents are recorded as administrative expenses in the statement of operations.

 

Purchased patents are recorded at cost and reviewed for impairment in accordance with the guidance of the ASC 360, Property, Plant, and Equipment, and ASC 205, Presentation of Financial Statements.

 

Income Taxes

 

The Company accounts for income taxes in accordance with FASB ASC 740, Income Taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of existing assets and liabilities and loss carryforwards and their respective tax bases.

 

Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income (loss) in the years in which those temporary differences are expected to be recovered or settled.

 

The effect of a change in tax rules on deferred tax assets and liabilities is recognized in operations in the year of change. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized.

 

Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for uncertain tax positions as of March 31, 2023. Interest and penalties in any, related to unrecognized tax benefits would be recognized as interest expense. The Company does not have any accrued interest or penalties associated with unrecognized tax benefits, nor was any significant interest expense recognized during the six months ended March 31, 2023.

 

Loss Per Share of Common Stock

 

Basic net loss per common share is computed using the weighted average number of common shares outstanding. Diluted earnings per share (“EPS”) include additional dilution from common stock equivalents, such as stock issuable pursuant to the exercise of stock options, warrants and convertible notes. Common stock equivalents are not included in the computation of diluted earnings per share when the Company reports a loss because to do so would be anti-dilutive for periods presented. The Company had total potential additional dilutive securities outstanding at March 31, 2023, and September 30, 2022, of 22,065,343 and 1,460,009, respectively.

 

Recent Accounting Pronouncements

 

In August 2020, the FASB issued ASU 2020-06, Debt with Conversion and Other Options, which simplifies accounting for convertible instruments. The new guidance eliminates two of the three models in ASC 470-20 that require separating embedded conversion features from convertible instruments. The guidance also addresses how convertible instruments are accounted for in the diluted earnings per share calculation. The guidance is effective for fiscal years beginning after December 15, 2021. The Company is currently evaluating the impact of ASU 2020-06 on its consolidated financial statements.

 

Recently Issued Accounting Standards: Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.

 
XML 17 R9.htm IDEA: XBRL DOCUMENT v3.23.1
BORROWINGS
 6 Months Ended
Mar. 31, 2023
Broker-Dealer [Abstract]  
BORROWINGS

NOTE 3 – BORROWINGS

 

Commercial Loan

 

On April 9, 2020, the Company received a loan from the Small Business Administration pursuant to the Paycheck Protection Program (PPP) in the principal amount of $48,750. The note bears interest at a variable rate of approximately 1% and matured in April 2022; and it is currently in default. Forgiveness for the loan was applied for and is pending. The principal amount of the loan was based on the consulting agreement salary between Nexion Biosciences, Inc., organized in the state of Florida (NBFL) (a related party) and the CEO.

 

 

Notes Payable

 

From time to time, the Company’s subsidiary, Genvor Inc., enters into unsecured notes payable with individual investors. Only Noteholder E (below) has security in the form of a personal guarantee by the CEO and prior consultant (Note 6). The terms of these notes are listed below. Several of the notes are convertible into shares of the Company’s common stock as detailed in the following schedule.

 

                 Balance 
                 Convertible 
         Interest   Loan   into 
Noteholder  Origination  Maturity  Rate   Balance   Shares (c) 
Noteholder A (a)  2019  12/31/2021   0%  $217,000    N/A 
Noteholder B (a)  3/19/2019  4/29/2019   0%   510,000    N/A 
Noteholder C (a)  3/1/2019  2/29/2020   18%   32,500    N/A 
Noteholder D (d)  4/29/2019  unspecified   0%   300,000    30,000 
Noteholder E (a)  8/1/2019  8/31/2019   0%   37,500     N/A  
Noteholder F (a)(b)  2/27/2020  4/30/2020   0%   2,500    5,000 
Noteholder G  8/3/2021  8/3/2023   10%   12,500    25,000 
Noteholder H  6/27/2022  6/27/2024   5%   300,000    1,000,000 
Noteholder I (c)  10/26/2022  12/31/2023   3%   50,000    400,000 
               1,462,000    1,460,000 
(d) Debt discount              (150,556)     
              $1,311,444      

 

(a)Past due at December 31, 2022
(b)Note is payable in a combination of $2,500 to $6,000 in cash and 5,000 to 15,000 share of common stock
(c)Convertible into common stock of the subsidiary, Genvor Inc.

 

The notes do not have default provisions except Noteholder B receives a default penalty of $10,000 each month the note goes unpaid.

 

Interest expense totaled $71,665 and $121,002, respectively, for the six months ended March 31, 2023, and 2022, including default penalties. Late fees totaled $60,000 and $60,000, respectively, for the six months ended March 31, 2023, and 2022.

 
XML 18 R10.htm IDEA: XBRL DOCUMENT v3.23.1
STOCKHOLDERS’ DEFICIT
 6 Months Ended
Mar. 31, 2023
Equity [Abstract]  
STOCKHOLDERS’ DEFICIT

NOTE 4 – STOCKHOLDERS’ DEFICIT

 

Preferred Stock

 

The authorized preferred stock of the Company consists of 20,000,000 shares with a $0.001 par value.

 

 

Series A Preferred Stock

 

On August 10, 2022, the Company designated 10 shares of its preferred stock as Series A Preferred Stock (“Series A”). Each share of Series A entitles the holder to ten million (10,000,000) votes on all matters submitted to a vote of the stockholders of the Corporation. When and as any dividend or distribution is declared or paid by the Company on the common stock, the Series A holders are entitled to participate in such dividend or distribution. Each Series A share is convertible, at the option of the holder, into one share of fully paid and non-assessable common stock. Upon any liquidation, dissolution, or winding-up of the Company, the Series A holders are entitled to receive out the assets of the Company, for each share of Series A, an amount equal to par value before any distribution or payment shall be made to the holder of any junior securities (including common stock and all other equity or equity equivalent securities of the Company).

 

As of March 31, 2023, and September 30, 2022, there were 9 and 9 shares of Series A preferred stock issued and outstanding, respectively. The preferred stock was issued on August 16, 2022, as follows: Bradley White (Chief Executive Officer), 3 shares; Dr. Clayton Yates (Chief Scientific Officer and Chairman), 3 shares; and Dr. Jesse Jaynes (Chief Research Officer and Director), 3 shares. See Note 7.

 

Series B Preferred Stock

 

On October 19, 2022, the Company filed a Certificate of Designation with the State of Nevada to designate its Series B Preferred Stock (“Series B”). The designation authorized 2,500,000 shares of Series B. Each share of Series B shall have 10 votes on all matters submitted to a vote of the stockholders of the Company. Each share of Series B is convertible into 10 shares of common stock of the Company.

 

On October 19, 2022, the following shareholders converted shares of common stock of the Company into shares of Series B to modify the common shares outstanding to reduce the outstanding common stock issued by the Company, as follows:

 

Name 

Common Shares

Exchanged

  

Series B

Issued

 
Jaynes Investment LLC   2,000,000    200,000 
ACT Holdings LLC   7,312,612    731,262 
LASB Family Trust   3,800,112    380,012 
Jesse Michael Jaynes   4,767,611    476,762 
Bradley White (a)   1,225,000    122,500 
PJ Advisory Group   1,500,000    150,000 
Total   20,605,334    2,060,536 

 

(a)Related party

 

The conversion of the common stock into the Series B was valued at par, respectively, offset to additional paid-in capital. The Series B is convertible into common stock into the original amount of common stock converted therefore there is no change in the amount of common stock outstanding on a fully diluted basis.

 

As of March 31, 2023, and September 30, 2022, there were 2,060,536 and 0 shares of Series B preferred stock issued and outstanding, respectively.

 

Common Stock

 

The authorized common stock of the Company consists of 300,000,000 shares with a $0.001 par value. All common stock shares are non-assessable and have one vote per share.

 

In connection with the Merger (see Note 1), the founding shareholders of the Company cancelled 18,144,112 shares of common stock, retaining 5%, or 1,855,888 shares of common stock, as of June 30, 2022. The cancellation is presented in the accompanying statements of changes in stockholders’ deficit within the line item “Retroactive application of recapitalization.”

 

 

Stock Issued for Cash

 

On November 17, 2022, the Company issued 300,000 shares of common stock to a shareholder for $150,000.

 
XML 19 R11.htm IDEA: XBRL DOCUMENT v3.23.1
FEDERAL INCOME TAX
 6 Months Ended
Mar. 31, 2023
Income Tax Disclosure [Abstract]  
FEDERAL INCOME TAX

NOTE 5 – FEDERAL INCOME TAX

 

As of March 31, 2023, and September 30, 2022, the Company has net operating loss carry forwards of $2,667,462 and $2,572,885, respectively, which may be available to reduce future years’ taxable income through 2043. The Company’s net operating loss carry forwards may be subject to annual limitations, which could reduce or defer the utilization of the losses as a result of an ownership change as defined in Section 382 of the Internal Revenue Code.

 

The Company’s tax expense differs from the “expected” tax expense for Federal income tax purposes (computed by applying the United States Federal tax rate of 21% to loss before taxes for fiscal year 2023 and 2022), as follows:

 

   March 31,   September 30, 
   2023   2022 
Tax benefit at the statutory rate  $(84,158)  $(204,559)
State income taxes, net of federal income tax benefit   (10,420)   (25,326)
Change in valuation allowance   94,577    229,885 
Total  $-   $- 

 

The tax effects of the temporary differences between reportable financial statement income and taxable income are recognized as deferred tax assets and liabilities.

 

The tax years 2023 and 2022 remains open for examination by federal agencies and other jurisdictions in which it operates.

 

The tax effect of significant components of the Company’s deferred tax assets and liabilities at March 31, 2023, and September 30, 2022, are as follows:

 

   March 31,   September 30, 
   2023   2022 
Net operating loss carryforward  $2,667,462   $2,572,885 
Total gross deferred tax assets   2,667,462    2,572,885 
Less: Deferred tax asset valuation allowance   (2,667,462)   (2,572,885)
Total net deferred taxes  $-   $- 

 

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment.

 

Because of the historical earnings history of the Company, the net deferred tax assets for 2022 and 2021 were fully offset by a 100% valuation allowance. The valuation allowance for the remaining net deferred tax assets was $2,667,462 and $2,572,885 as of March 31, 2023, and September 30, 2022, respectively.

 

 
XML 20 R12.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES
 6 Months Ended
Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

NOTE 6 – COMMITMENTS AND CONTINGENCIES

 

From time to time, the Company may be involved in litigation in the ordinary course of business. The Company is not currently involved in any litigation that we believe could have a material adverse effect on its financial condition or results of operations.

 

Subscription Agreement and Cash Held in Escrow

 

On February 20, 2019, the Company entered into a subscription escrow agreement (the “Trust Agreement”) with Branch Banking and Trust Company (“BB&T”). This Trust Agreement was established for the subscription agreement proceeds raised and escrowed pursuant to the Company’s prior Rule 419 S-1 offering. The balance held in trust at March 31, 2023 and September 30, 2022, totaled $19,705.

 

Upon completion of the Merger (see Notes 1 and 8), the Company issued 975,000 common stock shares to the investors in that prior S-1 offering during July 2022 and were released to the Company.

 

Consulting Agreements

 

During the six months ended March 31, 2023, the Company paid the CEO $3,000 pursuant to a consulting agreement carried over from related party NBFL. The agreement provides for an annual salary of $150,000 which increases based on certain capital raise thresholds. At March 31, 2023 and September 30, 2022, accrued payroll owed to the CEO totaled $192,638 and $188,484, respectively, as presented in the accompanying consolidated balance sheets.

 

On July 24, 2020, the Company entered into a consulting agreement for business development activities, networking, negotiations, and strategic planning. The compensation pursuant to the agreement was $20,000 monthly.

 

Office Lease

 

The Company entered into a sublease agreement with the above consultant (providing business development assistance from 2019-2020) effective August 1, 2019, subject to the terms and conditions of the office lease held by the consultant at 15540 Quorum Drive #2624, Addison, Texas. On January 1, 2019, the Company adopted ASC 842 requiring this lease to be recorded as an asset and corresponding liability on its balance sheet. The Company records rent expense associated with this lease on the straight-line basis in conjunction with the terms of the underlying lease. A discount rate was not used in the determination of the right of use asset and liability since its effect would not be significant. The lease moved to a month-to-month basis beginning in September 2021 at $2,810 per month in addition to common area maintenance charges. During the six months ended March 31, 2023, and 2022, we incurred $6,590 and $20,607, respectively, in office rental expense.

 

Research and Development Agreement

 

During September 2020, the Company assumed a Cooperative Research And Development Agreement (CRADA) with the United States Department of Agriculture (USDA), Agricultural Research Service (ARS). Under this agreement, the Company committed to funding the remaining amount due. As of March 31, 2023, and September 30, 2022, $246,400 and $246,400, respectively, remained outstanding and is presented in the accompanying consolidated balance sheets as USDA CRADA liability.

 
XML 21 R13.htm IDEA: XBRL DOCUMENT v3.23.1
RELATED PARTY TRANSACTIONS
 6 Months Ended
Mar. 31, 2023
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

NOTE 7 – RELATED PARTY TRANSACTIONS

 

Share Issuances to the Board of Directors

 

The Company issued Series A preferred stock on August 16, 2022, as follows: Bradley White (Chief Executive Officer), 3 shares; Dr. Clayton Yates (Chief Scientific Officer and Chairman), 3 shares; and Dr. Jesse Jaynes (Chief Research Officer and Director), 3 shares. See Note 4.

 
XML 22 R14.htm IDEA: XBRL DOCUMENT v3.23.1
SUBSEQUENT EVENTS
 6 Months Ended
Mar. 31, 2023
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 8 – SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events from the balance sheet through the date of this filing and determined there were no events to disclose except the following.
XML 23 R15.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 6 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 
Cash Flow Reporting

Cash Flow Reporting

 

The Company follows Accounting Standards Codification (“ASC 230”), Statement of Cash Flows, for cash flow reporting, classifies cash receipts and payments according to whether they stem from operating, investing, or financing activities and provides definitions of each category, and uses the indirect or reconciliation method (“indirect method”) as defined by ASC 230, Statement of Cash Flows, to report net cash flow from operating activities by adjusting net income to reconcile it to net cash flow from operating activities by removing the effects of (a) all deferrals of past operating cash receipts and payments and all accruals of expected future operating cash receipts and payments and (b) all items that are included in net income that do not affect operating cash receipts and payments.

 
Cash and Cash Equivalents

Cash and Cash Equivalents

 

The Company considers all highly liquid debt instruments and other short-term investments with maturity of three months or less, when purchased, to be cash equivalents. There were no cash equivalents as of March 31, 2023, and September 30, 2022.

 

The Company maintains its cash balances at one financial institution that is insured by the Federal Deposit Insurance Corporation. At March 31, 2023, and September 30, 2022, $0 and $46,386, respectively, of the Company’s cash balances were in excess of federally insured limits.

 
Fixed Assets

Fixed Assets

 

Furniture and equipment are stated at cost. Depreciation is provided by the straight-line method over the useful lives of the related assets, approximately seven years. Expenditures for minor enhancements and maintenance are expensed as incurred.

 

 
Stock-Based Compensation

Stock-Based Compensation

 

The Company accounts for stock-based instruments issued to employees in accordance with ASC Topic 718, Compensation – Stock Compensation, and Certain Redeemable Financial Instruments. ASC Topic 718 requires companies to recognize in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees. The value of the portion of an award that is ultimately expected to vest is recognized as an expense over the requisite service periods using the straight-line attribution method.

 
Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

The book values of cash, accounts receivable, and accounts payable approximate their respective fair values due to the short-term nature of these instruments. The fair value hierarchy under GAAP distinguishes between assumptions based on market data (observable inputs) and an entity’s own assumptions (unobservable inputs).

 

The hierarchy consists of three levels

 

  ● Level one — Quoted market prices in active markets for identical assets or liabilities;
  ● Level two — Inputs other than level one inputs that are either directly or indirectly observable; and
  ● Level three — Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.

 

Determining which category an asset or liability falls within the hierarchy requires significant judgment. We evaluate our hierarchy disclosures each quarter.

 
Financial Instruments

Financial Instruments

 

The Company’s financial instruments include cash and cash equivalents, payables, and accrued interest and short-term and long-term notes payable and are accounted for under the provisions of ASC 825, Financial Instruments. The carrying amount of these financial instruments, as reflected in the accompanying consolidated balance sheet, approximates fair value.

 
Long-lived Assets

Long-lived Assets

 

The Company’s long-lived assets and other assets (consisting of furniture, equipment and a patent) are reviewed for impairment in accordance with the guidance of the ASC 360, Property, Plant, and Equipment, and ASC 205, Presentation of Financial Statements. The Company tests for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Impairment evaluations involve management’s estimates on asset useful lives and future cash flows. Actual useful lives and cash flows could be different from those estimated by management which could have a material effect on our reporting results and financial positions. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. During the six months ended March 31, 2023, and 2022, the Company had not experienced impairment losses on its long-lived assets.

 
Research and Development

Research and Development

 

The Company expenses the cost of research and development as incurred. Research and development expenses consist primarily of professional service costs associated with the development of the plant-based defense technology products. For the six months ended March 31, 2023 and 2022, the Company had $0 and $109,248 in research and development expenses, respectively.

 

 
Patents

Patents

 

Any patent costs for internally developed patents will be expensed as incurred. Costs to maintain and defend patents are recorded as administrative expenses in the statement of operations.

 

Purchased patents are recorded at cost and reviewed for impairment in accordance with the guidance of the ASC 360, Property, Plant, and Equipment, and ASC 205, Presentation of Financial Statements.

 
Income Taxes

Income Taxes

 

The Company accounts for income taxes in accordance with FASB ASC 740, Income Taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of existing assets and liabilities and loss carryforwards and their respective tax bases.

 

Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income (loss) in the years in which those temporary differences are expected to be recovered or settled.

 

The effect of a change in tax rules on deferred tax assets and liabilities is recognized in operations in the year of change. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized.

 

Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for uncertain tax positions as of March 31, 2023. Interest and penalties in any, related to unrecognized tax benefits would be recognized as interest expense. The Company does not have any accrued interest or penalties associated with unrecognized tax benefits, nor was any significant interest expense recognized during the six months ended March 31, 2023.

 
Loss Per Share of Common Stock

Loss Per Share of Common Stock

 

Basic net loss per common share is computed using the weighted average number of common shares outstanding. Diluted earnings per share (“EPS”) include additional dilution from common stock equivalents, such as stock issuable pursuant to the exercise of stock options, warrants and convertible notes. Common stock equivalents are not included in the computation of diluted earnings per share when the Company reports a loss because to do so would be anti-dilutive for periods presented. The Company had total potential additional dilutive securities outstanding at March 31, 2023, and September 30, 2022, of 22,065,343 and 1,460,009, respectively.

 
Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

In August 2020, the FASB issued ASU 2020-06, Debt with Conversion and Other Options, which simplifies accounting for convertible instruments. The new guidance eliminates two of the three models in ASC 470-20 that require separating embedded conversion features from convertible instruments. The guidance also addresses how convertible instruments are accounted for in the diluted earnings per share calculation. The guidance is effective for fiscal years beginning after December 15, 2021. The Company is currently evaluating the impact of ASU 2020-06 on its consolidated financial statements.

 

Recently Issued Accounting Standards: Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.
XML 24 R16.htm IDEA: XBRL DOCUMENT v3.23.1
BORROWINGS (Tables)
 6 Months Ended
Mar. 31, 2023
Broker-Dealer [Abstract]  
SCHEDULE OF CONVERTIBLE NOTES PAYABLE

                 Balance 
                 Convertible 
         Interest   Loan   into 
Noteholder  Origination  Maturity  Rate   Balance   Shares (c) 
Noteholder A (a)  2019  12/31/2021   0%  $217,000    N/A 
Noteholder B (a)  3/19/2019  4/29/2019   0%   510,000    N/A 
Noteholder C (a)  3/1/2019  2/29/2020   18%   32,500    N/A 
Noteholder D (d)  4/29/2019  unspecified   0%   300,000    30,000 
Noteholder E (a)  8/1/2019  8/31/2019   0%   37,500     N/A  
Noteholder F (a)(b)  2/27/2020  4/30/2020   0%   2,500    5,000 
Noteholder G  8/3/2021  8/3/2023   10%   12,500    25,000 
Noteholder H  6/27/2022  6/27/2024   5%   300,000    1,000,000 
Noteholder I (c)  10/26/2022  12/31/2023   3%   50,000    400,000 
               1,462,000    1,460,000 
(d) Debt discount              (150,556)     
              $1,311,444      

 

(a)Past due at December 31, 2022
(b)Note is payable in a combination of $2,500 to $6,000 in cash and 5,000 to 15,000 share of common stock
(c)Convertible into common stock of the subsidiary, Genvor Inc.
XML 25 R17.htm IDEA: XBRL DOCUMENT v3.23.1
STOCKHOLDERS’ DEFICIT (Tables)
 6 Months Ended
Mar. 31, 2023
Equity [Abstract]  
SCHEDULE OF CONVERTED SHARES OF COMMON STOCK

On October 19, 2022, the following shareholders converted shares of common stock of the Company into shares of Series B to modify the common shares outstanding to reduce the outstanding common stock issued by the Company, as follows:

 

Name 

Common Shares

Exchanged

  

Series B

Issued

 
Jaynes Investment LLC   2,000,000    200,000 
ACT Holdings LLC   7,312,612    731,262 
LASB Family Trust   3,800,112    380,012 
Jesse Michael Jaynes   4,767,611    476,762 
Bradley White (a)   1,225,000    122,500 
PJ Advisory Group   1,500,000    150,000 
Total   20,605,334    2,060,536 

 

(a)Related party
XML 26 R18.htm IDEA: XBRL DOCUMENT v3.23.1
FEDERAL INCOME TAX (Tables)
 6 Months Ended
Mar. 31, 2023
Income Tax Disclosure [Abstract]  
SCHEDULE OF LOSS BEFORE TAXES

   March 31,   September 30, 
   2023   2022 
Tax benefit at the statutory rate  $(84,158)  $(204,559)
State income taxes, net of federal income tax benefit   (10,420)   (25,326)
Change in valuation allowance   94,577    229,885 
Total  $-   $- 
SCHEDULE OF DEFERRED TAX ASSETS

The tax effect of significant components of the Company’s deferred tax assets and liabilities at March 31, 2023, and September 30, 2022, are as follows:

 

   March 31,   September 30, 
   2023   2022 
Net operating loss carryforward  $2,667,462   $2,572,885 
Total gross deferred tax assets   2,667,462    2,572,885 
Less: Deferred tax asset valuation allowance   (2,667,462)   (2,572,885)
Total net deferred taxes  $-   $- 
XML 27 R19.htm IDEA: XBRL DOCUMENT v3.23.1
ORGANIZATION AND BASIS OF PRESENTATION (Details Narrative) - USD ($)
 6 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Sep. 30, 2022
Accounting Policies [Abstract]      
Accumulated deficit $ 16,689,168   $ 16,288,417
Net loss 400,751    
Net cash used in operating activities $ 507,373 $ 695,302  
XML 28 R20.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Sep. 30, 2022
Accounting Policies [Abstract]          
Cash equivalents $ 0   $ 0   $ 0
Cash uninsured amount $ 0   $ 0   $ 46,386
Fixed assets, estimated useful lives 7 years   7 years    
Research and development expenses $ 102,800 $ 109,248  
XML 29 R21.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF CONVERTIBLE NOTES PAYABLE (Details)
 6 Months Ended
Mar. 31, 2023
USD ($)
shares
Short-Term Debt [Line Items]  
Loan Balance $ 1,462,000
Number of shares the notesis convertible into shares | shares 1,460,000
Debt discount $ (150,556)
Total loan $ 1,311,444
Note Holder A [Member]  
Short-Term Debt [Line Items]  
Origination 2019 [1]
Maturity date Dec. 31, 2021 [1]
Interest rate 0.00% [1]
Loan Balance $ 217,000 [1]
Noteholder B [Member]  
Short-Term Debt [Line Items]  
Origination 3/19/2019 [1]
Maturity date Apr. 29, 2019 [1]
Interest rate 0.00% [1]
Loan Balance $ 510,000 [1]
Noteholder C [Member]  
Short-Term Debt [Line Items]  
Origination 3/1/2019 [1]
Maturity date Feb. 29, 2020 [1]
Interest rate 18.00% [1]
Loan Balance $ 32,500 [1]
Noteholder D [Member]  
Short-Term Debt [Line Items]  
Origination 4/29/2019 [1]
Interest rate 0.00% [1]
Loan Balance $ 300,000 [1]
Number of shares the notesis convertible into shares | shares 30,000
Noteholder E [Member]  
Short-Term Debt [Line Items]  
Origination 8/1/2019 [1]
Maturity date Aug. 31, 2019 [1]
Interest rate 0.00% [1]
Loan Balance $ 37,500 [1]
Noteholder F [Member]  
Short-Term Debt [Line Items]  
Origination 2/27/2020 [1],[2]
Maturity date Apr. 30, 2020 [1],[2]
Interest rate 0.00% [1],[2]
Loan Balance $ 2,500 [1],[2]
Number of shares the notesis convertible into shares | shares 5,000 [1],[2]
Noteholder G [Member]  
Short-Term Debt [Line Items]  
Origination 8/3/2021
Maturity date Aug. 03, 2023
Interest rate 10.00%
Loan Balance $ 12,500
Number of shares the notesis convertible into shares | shares 25,000
Noteholder H [Member]  
Short-Term Debt [Line Items]  
Origination 6/27/2022
Maturity date Jun. 27, 2024
Interest rate 5.00%
Loan Balance $ 300,000
Number of shares the notesis convertible into shares | shares 1,000,000
Noteholder I [Member]  
Short-Term Debt [Line Items]  
Origination 10/26/2022 [1],[3]
Maturity date Dec. 31, 2023 [1],[3]
Interest rate 3.00% [1],[3]
Loan Balance $ 50,000 [1],[3]
Number of shares the notesis convertible into shares | shares 400,000 [1],[3]
[1] Past due at December 31, 2022
[2] Note is payable in a combination of $2,500 to $6,000 in cash and 5,000 to 15,000 share of common stock
[3] Convertible into common stock of the subsidiary, Genvor Inc.
XML 30 R22.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF CONVERTIBLE NOTES PAYABLE (Details) (Parenthetical)
 6 Months Ended
Mar. 31, 2023
USD ($)
shares
Short-Term Debt [Line Items]  
Shares issued during conversion 1,460,000
Noteholder F [Member]  
Short-Term Debt [Line Items]  
Shares issued during conversion 5,000 [1],[2]
Noteholder F [Member] | Minimum [Member]  
Short-Term Debt [Line Items]  
Notes payable converted | $ $ 2,500
Shares issued during conversion 5,000
Noteholder F [Member] | Maximum [Member]  
Short-Term Debt [Line Items]  
Notes payable converted | $ $ 6,000
Shares issued during conversion 15,000
[1] Note is payable in a combination of $2,500 to $6,000 in cash and 5,000 to 15,000 share of common stock
[2] Past due at December 31, 2022
XML 31 R23.htm IDEA: XBRL DOCUMENT v3.23.1
BORROWINGS (Details Narrative) - USD ($)
 6 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Apr. 09, 2020
Short-Term Debt [Line Items]      
Principal amont $ 1,462,000    
Interest expense 71,665 $ 121,002  
Late fees 60,000 $ 60,000  
Paycheck Protection Program [Member]      
Short-Term Debt [Line Items]      
Principal amont     $ 48,750
Interest rate     1.00%
Noteholder B [Member]      
Short-Term Debt [Line Items]      
Principal amont [1] 510,000    
[custom:DebtDefaultPenaltyAmount] $ 10,000    
[1] Past due at December 31, 2022
XML 32 R24.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF CONVERTED SHARES OF COMMON STOCK (Details) - Series B Preferred Stock [Member]
Oct. 19, 2022
shares
Class of Stock [Line Items]  
Common Shares Exchanged 20,605,334
Series B Issued 2,060,536
Jaynes Investment LLC [Member]  
Class of Stock [Line Items]  
Common Shares Exchanged 2,000,000
Series B Issued 200,000
ACT Holdings LLC [Member]  
Class of Stock [Line Items]  
Common Shares Exchanged 7,312,612
Series B Issued 731,262
LASB Family Trust [Member]  
Class of Stock [Line Items]  
Common Shares Exchanged 3,800,112
Series B Issued 380,012
Jesse Michael Jaynes [Member]  
Class of Stock [Line Items]  
Common Shares Exchanged 4,767,611
Series B Issued 476,762
Bradley White [Member]  
Class of Stock [Line Items]  
Common Shares Exchanged 1,225,000 [1]
Series B Issued 122,500 [1]
PJ Advisory Group [Member]  
Class of Stock [Line Items]  
Common Shares Exchanged 1,500,000
Series B Issued 150,000
[1] Related party
XML 33 R25.htm IDEA: XBRL DOCUMENT v3.23.1
STOCKHOLDERS’ DEFICIT (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended
Nov. 17, 2022
Aug. 10, 2022
Apr. 21, 2022
Oct. 19, 2022
Mar. 31, 2022
Dec. 31, 2021
Mar. 31, 2023
Sep. 30, 2022
Aug. 16, 2022
Jun. 30, 2022
Class of Stock [Line Items]                    
Preferred stock, shares authorized             20,000,000 20,000,000    
Preferred stock, shares par value             $ 0.001 $ 0.001    
Common stock, shares authorized             300,000,000 300,000,000    
Common stock, shares par value             $ 0.001 $ 0.001    
Number of common stock cancel     18,144,112              
Number of common stock retaining                   1,855,888
Stock Issued During Period, Value, New Issues         $ 140,000 $ 737,510        
Bradley White [Member]                    
Class of Stock [Line Items]                    
Preferred stock, shares issued                 3  
Dr. Clayton Yates [Member]                    
Class of Stock [Line Items]                    
Preferred stock, shares issued                 3  
Dr. Jesse Jaynes [Member]                    
Class of Stock [Line Items]                    
Preferred stock, shares issued                 3  
Series A Preferred Stock [Member]                    
Class of Stock [Line Items]                    
Preferred stock, shares authorized             10 10    
Designation authorized shares   10                
Number of votes   Each share of Series A entitles the holder to ten million (10,000,000) votes on all matters submitted to a vote of the stockholders of the Corporation                
Conversion share description   Each Series A share is convertible, at the option of the holder, into one share of fully paid and non-assessable common stock                
Preferred stock, shares issued             9 9    
Preferred stock, shares outstanding             9 9    
Series B Preferred Stock [Member]                    
Class of Stock [Line Items]                    
Preferred stock, shares authorized             2,500,000 2,500,000    
Designation authorized shares       2,500,000            
Number of votes       Each share of Series B shall have 10 votes on all matters submitted to a vote of the stockholders of the Company            
Conversion share description       Each share of Series B is convertible into 10 shares of common stock of the Company            
Preferred stock, shares issued             2,060,536 0    
Preferred stock, shares outstanding             2,060,536 0    
Stock Issued for Cash [Member] | Shareholder [Member]                    
Class of Stock [Line Items]                    
Stock Issued During Period, Shares, New Issues 300,000                  
Stock Issued During Period, Value, New Issues $ 150,000                  
XML 34 R26.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF LOSS BEFORE TAXES (Details) - USD ($)
 6 Months Ended 12 Months Ended
Mar. 31, 2023
Sep. 30, 2022
Income Tax Disclosure [Abstract]    
Tax benefit at the statutory rate $ (84,158) $ (204,559)
State income taxes, net of federal income tax benefit (10,420) (25,326)
Change in valuation allowance 94,577 229,885
Total
XML 35 R27.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF DEFERRED TAX ASSETS (Details) - USD ($)
Mar. 31, 2023
Sep. 30, 2022
Income Tax Disclosure [Abstract]    
Net operating loss carryforward $ 2,667,462 $ 2,572,885
Total gross deferred tax assets 2,667,462 2,572,885
Less: Deferred tax asset valuation allowance (2,667,462) (2,572,885)
Total net deferred taxes
XML 36 R28.htm IDEA: XBRL DOCUMENT v3.23.1
FEDERAL INCOME TAX (Details Narrative) - USD ($)
 6 Months Ended 9 Months Ended
Mar. 31, 2023
Sep. 30, 2022
Income Tax Disclosure [Abstract]    
Net operating loss carry forwards $ 2,667,462 $ 2,572,885
Federal tax statutory rate 21.00% 21.00%
Valuation allowance for net deferred tax assets $ 2,667,462 $ 2,572,885
XML 37 R29.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
 6 Months Ended
Oct. 02, 2021
Jul. 24, 2020
Mar. 31, 2023
Mar. 31, 2022
Sep. 30, 2022
Long-Term Purchase Commitment [Line Items]          
Assets held in trust     $ 19,705   $ 19,705
Rent expense $ 2,810   6,590 $ 20,607  
Research and Development Arrangement [Member]          
Long-Term Purchase Commitment [Line Items]          
Fund Amount     246,400   246,400
Chief Executive Officer [Member] | Consulting Agreements [Member]          
Long-Term Purchase Commitment [Line Items]          
Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold     150,000    
Accrued Payroll Taxes, Current     192,638   $ 188,484
Consulting Agreements [Member] | Consultant [Member]          
Long-Term Purchase Commitment [Line Items]          
Salary and Wage, Excluding Cost of Good and Service Sold   $ 20,000      
Consulting Agreements [Member] | Chief Executive Officer [Member]          
Long-Term Purchase Commitment [Line Items]          
Related party payable     $ 3,000    
Investor [Member]          
Long-Term Purchase Commitment [Line Items]          
Number of shares issued     975,000    
XML 38 R30.htm IDEA: XBRL DOCUMENT v3.23.1
RELATED PARTY TRANSACTIONS (Details Narrative)
Aug. 16, 2022
shares
Bradley White [Member]  
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]  
Preferred stock, shares issued 3
Dr. Clayton Yates [Member]  
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]  
Preferred stock, shares issued 3
Dr. Jesse Jaynes [Member]  
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]  
Preferred stock, shares issued 3
XML 39 form10-q_htm.xml IDEA: XBRL DOCUMENT 0001792941 2022-10-01 2023-03-31 0001792941 2023-04-19 0001792941 2023-03-31 0001792941 2022-09-30 0001792941 us-gaap:SeriesAPreferredStockMember 2023-03-31 0001792941 us-gaap:SeriesAPreferredStockMember 2022-09-30 0001792941 us-gaap:SeriesBPreferredStockMember 2023-03-31 0001792941 us-gaap:SeriesBPreferredStockMember 2022-09-30 0001792941 2023-01-01 2023-03-31 0001792941 2022-01-01 2022-03-31 0001792941 2021-10-01 2022-03-31 0001792941 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-09-30 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-09-30 0001792941 us-gaap:CommonStockMember 2021-09-30 0001792941 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001792941 us-gaap:RetainedEarningsMember 2021-09-30 0001792941 2021-09-30 0001792941 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001792941 us-gaap:CommonStockMember 2021-12-31 0001792941 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001792941 us-gaap:RetainedEarningsMember 2021-12-31 0001792941 2021-12-31 0001792941 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-09-30 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2022-09-30 0001792941 us-gaap:CommonStockMember 2022-09-30 0001792941 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001792941 us-gaap:RetainedEarningsMember 2022-09-30 0001792941 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001792941 us-gaap:CommonStockMember 2022-12-31 0001792941 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001792941 us-gaap:RetainedEarningsMember 2022-12-31 0001792941 2022-12-31 0001792941 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-10-01 2021-12-31 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-10-01 2021-12-31 0001792941 us-gaap:CommonStockMember 2021-10-01 2021-12-31 0001792941 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2021-12-31 0001792941 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0001792941 2021-10-01 2021-12-31 0001792941 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001792941 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001792941 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001792941 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001792941 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-10-01 2022-12-31 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2022-10-01 2022-12-31 0001792941 us-gaap:CommonStockMember 2022-10-01 2022-12-31 0001792941 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2022-12-31 0001792941 us-gaap:RetainedEarningsMember 2022-10-01 2022-12-31 0001792941 2022-10-01 2022-12-31 0001792941 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0001792941 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001792941 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001792941 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001792941 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0001792941 us-gaap:CommonStockMember 2022-03-31 0001792941 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001792941 us-gaap:RetainedEarningsMember 2022-03-31 0001792941 2022-03-31 0001792941 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0001792941 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0001792941 us-gaap:CommonStockMember 2023-03-31 0001792941 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001792941 us-gaap:RetainedEarningsMember 2023-03-31 0001792941 GNVR:PaycheckProtectionProgramMember 2020-04-09 0001792941 GNVR:NoteholderBMember 2022-10-01 2023-03-31 0001792941 GNVR:NoteholderAMember 2022-10-01 2023-03-31 0001792941 GNVR:NoteholderAMember 2023-03-31 0001792941 GNVR:NoteholderBMember 2023-03-31 0001792941 GNVR:NoteholderCMember 2022-10-01 2023-03-31 0001792941 GNVR:NoteholderCMember 2023-03-31 0001792941 GNVR:NoteholderDMember 2022-10-01 2023-03-31 0001792941 GNVR:NoteholderDMember 2023-03-31 0001792941 GNVR:NoteholderEMember 2022-10-01 2023-03-31 0001792941 GNVR:NoteholderEMember 2023-03-31 0001792941 GNVR:NoteholderFMember 2022-10-01 2023-03-31 0001792941 GNVR:NoteholderFMember 2023-03-31 0001792941 GNVR:NoteholderGMember 2022-10-01 2023-03-31 0001792941 GNVR:NoteholderGMember 2023-03-31 0001792941 GNVR:NoteholderHMember 2022-10-01 2023-03-31 0001792941 GNVR:NoteholderHMember 2023-03-31 0001792941 GNVR:NoteholderIMember 2022-10-01 2023-03-31 0001792941 GNVR:NoteholderIMember 2023-03-31 0001792941 srt:MinimumMember GNVR:NoteholderFMember 2022-10-01 2023-03-31 0001792941 srt:MaximumMember GNVR:NoteholderFMember 2022-10-01 2023-03-31 0001792941 us-gaap:SeriesAPreferredStockMember 2022-08-10 0001792941 us-gaap:SeriesAPreferredStockMember 2022-08-02 2022-08-10 0001792941 GNVR:BradleyWhiteMember 2022-08-16 0001792941 GNVR:ClaytonYatesMember 2022-08-16 0001792941 GNVR:JesseJaynesMember 2022-08-16 0001792941 us-gaap:SeriesBPreferredStockMember 2022-10-19 0001792941 us-gaap:SeriesBPreferredStockMember 2022-10-01 2022-10-19 0001792941 2022-04-21 2022-04-21 0001792941 2022-06-30 0001792941 GNVR:ShareholderMember GNVR:StockIssueForCashMember 2022-11-17 2022-11-17 0001792941 GNVR:JaynesInvestmentLLCMember us-gaap:SeriesBPreferredStockMember 2022-10-19 2022-10-19 0001792941 GNVR:ACTHoldingsLLCMember us-gaap:SeriesBPreferredStockMember 2022-10-19 2022-10-19 0001792941 GNVR:LASBFamilyTrustMember us-gaap:SeriesBPreferredStockMember 2022-10-19 2022-10-19 0001792941 GNVR:JesseMichaelJaynesMember us-gaap:SeriesBPreferredStockMember 2022-10-19 2022-10-19 0001792941 GNVR:BradleyWhiteMember us-gaap:SeriesBPreferredStockMember 2022-10-19 2022-10-19 0001792941 GNVR:PJAdvisoryGroupMember us-gaap:SeriesBPreferredStockMember 2022-10-19 2022-10-19 0001792941 us-gaap:SeriesBPreferredStockMember 2022-10-19 2022-10-19 0001792941 2022-01-01 2022-09-30 0001792941 2021-10-01 2022-09-30 0001792941 us-gaap:InvestorMember 2022-10-01 2023-03-31 0001792941 GNVR:ConsultingAgreementsMember srt:ChiefExecutiveOfficerMember 2022-10-01 2023-03-31 0001792941 srt:ChiefExecutiveOfficerMember GNVR:ConsultingAgreementsMember 2022-10-01 2023-03-31 0001792941 srt:ChiefExecutiveOfficerMember GNVR:ConsultingAgreementsMember 2023-03-31 0001792941 srt:ChiefExecutiveOfficerMember GNVR:ConsultingAgreementsMember 2022-09-30 0001792941 GNVR:ConsultingAgreementsMember GNVR:ConsultantMember 2020-07-24 2020-07-24 0001792941 2021-10-02 2021-10-02 0001792941 us-gaap:ResearchAndDevelopmentArrangementMember 2023-03-31 0001792941 us-gaap:ResearchAndDevelopmentArrangementMember 2022-09-30 iso4217:USD shares iso4217:USD shares pure 0001792941 false Q2 --09-30 10-Q true 2023-03-31 2023 false 333-234815 GENVOR INCORPORATED NV 83-2054746 13155 Noel Road Suite 900 Dallas TX 75240 (214) 427-1921 No Yes Non-accelerated Filer true true true false 18422821 1513 296386 15397 2000 16910 298386 16650 17565 33560 315951 1162000 1052000 302295 516658 3846 3846 48750 48750 246400 246400 1763291 1867654 149444 89221 149444 89221 1912735 1956875 0.001 0.001 20000000 20000000 10 10 9 9 9 9 2500000 2500000 2060536 2060536 0 0 2061 0.001 0.001 300000000 300000000 18422821 18422821 38678155 38678155 18423 38678 14789509 14608815 -16689168 -16288417 -1879175 -1640924 33560 315951 58858 79505 65662 87758 37500 45725 75000 143225 102800 109248 3010000 3210000 458 458 916 916 58466 -36173 127286 104487 155282 3202315 268864 3655634 -155282 -3202315 -268864 -3655634 5819 33230 11665 61002 -30000 -30000 -60000 -60000 30112 60223 -65930 -63230 -131887 -121002 -221212 -3265545 -400751 -3776636 -0.01 -0.16 -0.02 -0.19 18381710 20000000 20449202 20000000 20000000 2000 -64540 -62540 18000 8546798 -10947544 -2382746 20000000 20000 8546798 -11012084 -2445286 2650000 2650 197350 200000 1400000 1400 1400 1475020 1475 736035 737510 -511091 -511091 25525020 25525 9480183 -11523175 -2017467 6020000 6020 3003980 3010000 280000 280 139720 140000 688675 689 336884 337573 -150000 -150000 170000 170 -170 -3265545 -3265545 32683695 32684 12810597 -14788720 -1945439 38678155 38678 14608815 -16288417 -1640924 2060536 2061 -20605334 -20605 18544 300000 300 149700 150000 -179539 -179539 2060536 2061 18372821 18373 14777059 -16467956 -1670463 2060536 2061 18372821 18373 14777059 -16467956 -1670463 50000 50 12450 12500 -221212 -221212 2060536 2061 18422821 18423 14789509 -16689168 -1879175 2060536 2061 18422821 18423 14789509 -16689168 -1879175 -400751 -3776636 916 916 60000 60000 3210000 60223 -496 13397 -55665 -214364 -248543 2800 -507373 -695302 50000 34375 1400 162500 877510 212500 913285 -294873 217983 296386 7310 1513 225293 <p id="xdx_806_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zV9eBfsOTSJe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_826_zWZuAqmUicC7">ORGANIZATION AND BASIS OF PRESENTATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 27, 2022, Genvor Incorporated, formerly known as Allure Worldwide, Inc. (the “Company” or “Genvor” or “we”), a Nevada corporation, Genvor Acquisition, Corp., a Delaware corporation and a wholly owned subsidiary of the Company (“Merger Sub”), and Genvor Inc., a Delaware corporation (“Old Genvor”), completed their previously announced merger transaction pursuant to which the Company acquired Old Genvor (the “Acquisition”), and Old Genvor became a wholly-owned subsidiary of the Company. The Acquisition was completed pursuant to an Exchange Agreement, dated as of January 11, 2021 (the “Acquisition Agreement”), pursuant to which Old Genvor was to be acquired by the Company as its wholly owned subsidiary and each share of Old Genvor common stock would be exchanged for a share of the Company’s common stock, and a merger agreement, dated March 2, 2022 (the “Merger Agreement”), pursuant to which Merger Sub merged with and into Old Genvor, with Old Genvor continuing as a wholly owned subsidiary of the Company and the surviving corporation of the merger, and each share of Old Genvor being converted into the right to receive a share of the Company (the “Merger”). After closing of the Merger, the Company was renamed “Genvor Incorporated”. Genvor develops plant-based defense technology designed to help farmers achieve global food security.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During May 2019, Old Genvor acquired Nexion Biosciences LLC (“NBLLC”) from a founder for nominal consideration as a wholly owned subsidiary. NBLLC was formed in the state of Delaware on December 28, 2018 (“inception”). The consolidated financial statements of the Company include the accounts of Genvor Incorporated, Old Genvor, and its wholly owned subsidiary NBLLC. Intercompany accounts and transactions have been eliminated upon consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nature of Operations</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s business plan is developing plant-based defense technology designed to help farmers achieve global food security. The Company’s technology was developed by two university scientists, Dr. Clayton Yates and Dr. Jesse Jaynes, who shared a mission to develop crop protection technology designed to defend against crop diseases effecting both animals and humans alike.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis of Presentation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited financial information as of and for the six months ended March 31, 2023 and 2022 has been prepared in accordance with GAAP for interim financial information and with the instructions to Quarterly Report on Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, such financial information includes all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial position at such date and the operating results and cash flows for such periods. Operating results for the six months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the entire year or for any other subsequent interim period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been omitted pursuant to the rules of the U.S. Securities and Exchange Commission, or the SEC. These unaudited financial statements and related notes should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended September 30, 2022, as filed with the SEC.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principles of Consolidation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All significant intercompany balances and transactions have been eliminated in the consolidation. The consolidated financial statements included herein, presented in accordance with United States generally accepted accounting principles (“GAAP”) and stated in United States dollars, have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity and Going Concern</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. At March 31, 2023, the Company had an accumulated deficit of $<span id="xdx_907_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20230331_z4ilhDF3Gmek" title="Accumulated deficit">16,689,168</span>. For the six months ended March 31, 2023, the Company recognized a net loss of $<span id="xdx_902_eus-gaap--ProfitLoss_c20221001__20230331_z1J5QQiWA3W9" title="Net loss">400,751</span> and had net cash used in operating activities of $<span id="xdx_90C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20221001__20230331_zJKIjvxBDV1l" title="Net cash used in operating activities">507,373</span>, with no revenues earned, and a lack of operational history. These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While the Company is attempting to generate revenues, the Company’s cash position may not be significant enough to support the Company’s daily operations. Management intends to raise additional funds by way of additional public and/or private offerings of its stock. Management believes that the actions presently being taken to further implement its business plan and generate revenues provide the opportunity for the Company to continue as a going concern. While the Company believes in the viability of its strategy to generate revenues and in its ability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate revenues. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> -16689168 400751 -507373 <p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zPspXcx43Ut1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 – <span id="xdx_824_zRoBbMsX0fkd">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--UseOfEstimates_za3M9osmfypg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zqSHvqosAtCe">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_ecustom--CashFlowReportingPolicyTextBlock_zhq1NMIhucP8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span id="xdx_86A_zEnC1igwbAY">Cash Flow Reporting</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows Accounting Standards Codification (“ASC 230”), <i>Statement of Cash Flows</i>, for cash flow reporting, classifies cash receipts and payments according to whether they stem from operating, investing, or financing activities and provides definitions of each category, and uses the indirect or reconciliation method (“indirect method”) as defined by ASC 230, Statement of Cash Flows, to report net cash flow from operating activities by adjusting net income to reconcile it to net cash flow from operating activities by removing the effects of (a) all deferrals of past operating cash receipts and payments and all accruals of expected future operating cash receipts and payments and (b) all items that are included in net income that do not affect operating cash receipts and payments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zjgLaE86Z3yl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_z9bDSgW05gMj">Cash and Cash Equivalents</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all highly liquid debt instruments and other short-term investments with maturity of three months or less, when purchased, to be cash equivalents. There were <span id="xdx_906_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20230331_zeIJWse07xvh" title="Cash equivalents"><span id="xdx_904_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20220930_zjUJALqv5kma" title="Cash equivalents">no</span></span> cash equivalents as of March 31, 2023, and September 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains its cash balances at one financial institution that is insured by the Federal Deposit Insurance Corporation. At March 31, 2023, and September 30, 2022, $<span id="xdx_900_eus-gaap--CashFDICInsuredAmount_iI_c20230331_zfno6eb0GUzg" title="Cash uninsured amount">0</span> and $<span id="xdx_908_eus-gaap--CashFDICInsuredAmount_iI_c20220930_ze9vnTlPy6jd" title="Cash uninsured amount">46,386</span>, respectively, of the Company’s cash balances were in excess of federally insured limits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zyyztjxERnyh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span id="xdx_86B_z60BG7wnLoG1">Fixed Assets</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and equipment are stated at cost. Depreciation is provided by the straight-line method over the useful lives of the related assets, approximately <span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20230331_zS4zsmFd1tCe" title="Fixed assets, estimated useful lives">seven years</span>. Expenditures for minor enhancements and maintenance are expensed as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84C_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zkwHbcrmKlwe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zLOcEQ2uP352">Stock-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for stock-based instruments issued to employees in accordance with ASC Topic 718, <i>Compensation – Stock Compensation, and Certain Redeemable Financial Instruments</i>. ASC Topic 718 requires companies to recognize in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees. The value of the portion of an award that is ultimately expected to vest is recognized as an expense over the requisite service periods using the straight-line attribution method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z8eV0175Ldta" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zNjj18UlDiM">Fair Value of Financial Instruments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The book values of cash, accounts receivable, and accounts payable approximate their respective fair values due to the short-term nature of these instruments. The fair value hierarchy under GAAP distinguishes between assumptions based on market data (observable inputs) and an entity’s own assumptions (unobservable inputs).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The hierarchy consists of three levels</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level one — Quoted market prices in active markets for identical assets or liabilities;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level two — Inputs other than level one inputs that are either directly or indirectly observable; and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level three — Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determining which category an asset or liability falls within the hierarchy requires significant judgment. We evaluate our hierarchy disclosures each quarter.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zXUsgg4D8b8g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_z2tGXDkN5ebl">Financial Instruments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s financial instruments include cash and cash equivalents, payables, and accrued interest and short-term and long-term notes payable and are accounted for under the provisions of ASC 825, <i>Financial Instruments</i>. The carrying amount of these financial instruments, as reflected in the accompanying consolidated balance sheet, approximates fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zp2bKe9wUlZ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zjXWW6f6zxkf">Long-lived Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s long-lived assets and other assets (consisting of furniture, equipment and a patent) are reviewed for impairment in accordance with the guidance of the ASC 360, <i>Property, Plant, and Equipment</i>, and ASC 205, <i>Presentation of Financial Statements</i>. The Company tests for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Impairment evaluations involve management’s estimates on asset useful lives and future cash flows. Actual useful lives and cash flows could be different from those estimated by management which could have a material effect on our reporting results and financial positions. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. During the six months ended March 31, 2023, and 2022, the Company had not experienced impairment losses on its long-lived assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zMsnTL86L96h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zYOeqeqZtVvj">Research and Development</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company expenses the cost of research and development as incurred. Research and development expenses consist primarily of professional service costs associated with the development of the plant-based defense technology products. For the six months ended March 31, 2023 and 2022, the Company had $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_dxL_c20221001__20230331_zt1pov69pBqd" title="Research and development expenses::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0627">0</span></span> and $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20211001__20220331_zQe0cINz0DPh" title="Research and development expenses">109,248</span> in research and development expenses, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_ecustom--PatentsPolicyTextBlock_zPhm8eQrGY6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zd7wAzf3Ms67">Patents</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any patent costs for internally developed patents will be expensed as incurred. Costs to maintain and defend patents are recorded as administrative expenses in the statement of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchased patents are recorded at cost and reviewed for impairment in accordance with the guidance of the ASC 360, <i>Property, Plant, and Equipment</i>, and ASC 205, <i>Presentation of Financial Statements</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_841_eus-gaap--IncomeTaxPolicyTextBlock_z7BDrylCjbS3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zoFYhzVZ1pQ5">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes in accordance with FASB ASC 740, <i>Income Taxes</i>. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of existing assets and liabilities and loss carryforwards and their respective tax bases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income (loss) in the years in which those temporary differences are expected to be recovered or settled.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The effect of a change in tax rules on deferred tax assets and liabilities is recognized in operations in the year of change. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for uncertain tax positions as of March 31, 2023. Interest and penalties in any, related to unrecognized tax benefits would be recognized as interest expense. The Company does not have any accrued interest or penalties associated with unrecognized tax benefits, nor was any significant interest expense recognized during the six months ended March 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zhQ8AQOuw8ve" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_z9dfYZlB8tn1">Loss Per Share of Common Stock</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic net loss per common share is computed using the weighted average number of common shares outstanding. Diluted earnings per share (“EPS”) include additional dilution from common stock equivalents, such as stock issuable pursuant to the exercise of stock options, warrants and convertible notes. Common stock equivalents are not included in the computation of diluted earnings per share when the Company reports a loss because to do so would be anti-dilutive for periods presented. The Company had total potential additional dilutive securities outstanding at March 31, 2023, and September 30, 2022, of 22,065,343</span> and 1,460,009, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zBxpdtMxqi92" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_z4xuZr8p8wH8">Recent Accounting Pronouncements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the FASB issued ASU 2020-06, <i>Debt with Conversion and Other Options</i>, which simplifies accounting for convertible instruments. The new guidance eliminates two of the three models in ASC 470-20 that require separating embedded conversion features from convertible instruments. The guidance also addresses how convertible instruments are accounted for in the diluted earnings per share calculation. The guidance is effective for fiscal years beginning after December 15, 2021. The Company is currently evaluating the impact of ASU 2020-06 on its consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recently Issued Accounting Standards: Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.</span></p> <p id="xdx_854_zkrMdSR0NSeg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84C_eus-gaap--UseOfEstimates_za3M9osmfypg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zqSHvqosAtCe">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_ecustom--CashFlowReportingPolicyTextBlock_zhq1NMIhucP8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span id="xdx_86A_zEnC1igwbAY">Cash Flow Reporting</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows Accounting Standards Codification (“ASC 230”), <i>Statement of Cash Flows</i>, for cash flow reporting, classifies cash receipts and payments according to whether they stem from operating, investing, or financing activities and provides definitions of each category, and uses the indirect or reconciliation method (“indirect method”) as defined by ASC 230, Statement of Cash Flows, to report net cash flow from operating activities by adjusting net income to reconcile it to net cash flow from operating activities by removing the effects of (a) all deferrals of past operating cash receipts and payments and all accruals of expected future operating cash receipts and payments and (b) all items that are included in net income that do not affect operating cash receipts and payments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zjgLaE86Z3yl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_z9bDSgW05gMj">Cash and Cash Equivalents</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all highly liquid debt instruments and other short-term investments with maturity of three months or less, when purchased, to be cash equivalents. There were <span id="xdx_906_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20230331_zeIJWse07xvh" title="Cash equivalents"><span id="xdx_904_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20220930_zjUJALqv5kma" title="Cash equivalents">no</span></span> cash equivalents as of March 31, 2023, and September 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains its cash balances at one financial institution that is insured by the Federal Deposit Insurance Corporation. At March 31, 2023, and September 30, 2022, $<span id="xdx_900_eus-gaap--CashFDICInsuredAmount_iI_c20230331_zfno6eb0GUzg" title="Cash uninsured amount">0</span> and $<span id="xdx_908_eus-gaap--CashFDICInsuredAmount_iI_c20220930_ze9vnTlPy6jd" title="Cash uninsured amount">46,386</span>, respectively, of the Company’s cash balances were in excess of federally insured limits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 0 0 46386 <p id="xdx_845_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zyyztjxERnyh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span id="xdx_86B_z60BG7wnLoG1">Fixed Assets</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and equipment are stated at cost. Depreciation is provided by the straight-line method over the useful lives of the related assets, approximately <span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20230331_zS4zsmFd1tCe" title="Fixed assets, estimated useful lives">seven years</span>. Expenditures for minor enhancements and maintenance are expensed as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> P7Y <p id="xdx_84C_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zkwHbcrmKlwe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zLOcEQ2uP352">Stock-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for stock-based instruments issued to employees in accordance with ASC Topic 718, <i>Compensation – Stock Compensation, and Certain Redeemable Financial Instruments</i>. ASC Topic 718 requires companies to recognize in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees. The value of the portion of an award that is ultimately expected to vest is recognized as an expense over the requisite service periods using the straight-line attribution method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z8eV0175Ldta" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zNjj18UlDiM">Fair Value of Financial Instruments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The book values of cash, accounts receivable, and accounts payable approximate their respective fair values due to the short-term nature of these instruments. The fair value hierarchy under GAAP distinguishes between assumptions based on market data (observable inputs) and an entity’s own assumptions (unobservable inputs).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The hierarchy consists of three levels</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level one — Quoted market prices in active markets for identical assets or liabilities;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level two — Inputs other than level one inputs that are either directly or indirectly observable; and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level three — Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determining which category an asset or liability falls within the hierarchy requires significant judgment. We evaluate our hierarchy disclosures each quarter.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zXUsgg4D8b8g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_z2tGXDkN5ebl">Financial Instruments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s financial instruments include cash and cash equivalents, payables, and accrued interest and short-term and long-term notes payable and are accounted for under the provisions of ASC 825, <i>Financial Instruments</i>. The carrying amount of these financial instruments, as reflected in the accompanying consolidated balance sheet, approximates fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zp2bKe9wUlZ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zjXWW6f6zxkf">Long-lived Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s long-lived assets and other assets (consisting of furniture, equipment and a patent) are reviewed for impairment in accordance with the guidance of the ASC 360, <i>Property, Plant, and Equipment</i>, and ASC 205, <i>Presentation of Financial Statements</i>. The Company tests for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Impairment evaluations involve management’s estimates on asset useful lives and future cash flows. Actual useful lives and cash flows could be different from those estimated by management which could have a material effect on our reporting results and financial positions. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. During the six months ended March 31, 2023, and 2022, the Company had not experienced impairment losses on its long-lived assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_zMsnTL86L96h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zYOeqeqZtVvj">Research and Development</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company expenses the cost of research and development as incurred. Research and development expenses consist primarily of professional service costs associated with the development of the plant-based defense technology products. For the six months ended March 31, 2023 and 2022, the Company had $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_dxL_c20221001__20230331_zt1pov69pBqd" title="Research and development expenses::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0627">0</span></span> and $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20211001__20220331_zQe0cINz0DPh" title="Research and development expenses">109,248</span> in research and development expenses, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 109248 <p id="xdx_844_ecustom--PatentsPolicyTextBlock_zPhm8eQrGY6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zd7wAzf3Ms67">Patents</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any patent costs for internally developed patents will be expensed as incurred. Costs to maintain and defend patents are recorded as administrative expenses in the statement of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchased patents are recorded at cost and reviewed for impairment in accordance with the guidance of the ASC 360, <i>Property, Plant, and Equipment</i>, and ASC 205, <i>Presentation of Financial Statements</i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_841_eus-gaap--IncomeTaxPolicyTextBlock_z7BDrylCjbS3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zoFYhzVZ1pQ5">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes in accordance with FASB ASC 740, <i>Income Taxes</i>. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of existing assets and liabilities and loss carryforwards and their respective tax bases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income (loss) in the years in which those temporary differences are expected to be recovered or settled.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The effect of a change in tax rules on deferred tax assets and liabilities is recognized in operations in the year of change. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for uncertain tax positions as of March 31, 2023. Interest and penalties in any, related to unrecognized tax benefits would be recognized as interest expense. The Company does not have any accrued interest or penalties associated with unrecognized tax benefits, nor was any significant interest expense recognized during the six months ended March 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zhQ8AQOuw8ve" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_z9dfYZlB8tn1">Loss Per Share of Common Stock</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic net loss per common share is computed using the weighted average number of common shares outstanding. Diluted earnings per share (“EPS”) include additional dilution from common stock equivalents, such as stock issuable pursuant to the exercise of stock options, warrants and convertible notes. Common stock equivalents are not included in the computation of diluted earnings per share when the Company reports a loss because to do so would be anti-dilutive for periods presented. The Company had total potential additional dilutive securities outstanding at March 31, 2023, and September 30, 2022, of 22,065,343</span> and 1,460,009, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zBxpdtMxqi92" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_z4xuZr8p8wH8">Recent Accounting Pronouncements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the FASB issued ASU 2020-06, <i>Debt with Conversion and Other Options</i>, which simplifies accounting for convertible instruments. The new guidance eliminates two of the three models in ASC 470-20 that require separating embedded conversion features from convertible instruments. The guidance also addresses how convertible instruments are accounted for in the diluted earnings per share calculation. The guidance is effective for fiscal years beginning after December 15, 2021. The Company is currently evaluating the impact of ASU 2020-06 on its consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recently Issued Accounting Standards: Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.</span></p> <p id="xdx_80E_eus-gaap--SubordinatedBorrowingsDisclosureTextBlock_zEcnwiMPlQ4k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3 – <span id="xdx_82B_zHC1ysg8XYne">BORROWINGS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commercial Loan</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 9, 2020, the Company received a loan from the Small Business Administration pursuant to the Paycheck Protection Program (PPP) in the principal amount of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20200409__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramMember_zaEw37rHx4f2" title="Principal amont">48,750</span>. The note bears interest at a variable rate of approximately <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20200409__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramMember_z4MaFoZraeY6" title="Interest rate">1</span>% and matured in April 2022; and it is currently in default. Forgiveness for the loan was applied for and is pending. The principal amount of the loan was based on the consulting agreement salary between Nexion Biosciences, Inc., organized in the state of Florida (NBFL) (a related party) and the CEO.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes Payable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, the Company’s subsidiary, Genvor Inc., enters into unsecured notes payable with individual investors. Only Noteholder E (below) has security in the form of a personal guarantee by the CEO and prior consultant (Note 6). The terms of these notes are listed below. Several of the notes are convertible into shares of the Company’s common stock as detailed in the following schedule.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ConvertibleDebtTableTextBlock_z7jG155Q6hh1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zpPxKzZSWewf" style="display: none">SCHEDULE OF CONVERTIBLE NOTES PAYABLE</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-right: 0pt; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td> </td><td> </td> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Balance</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td> </td><td> </td> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Convertible</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td> </td><td> </td> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Loan</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">into</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Noteholder</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Origination</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Maturity</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Balance</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares (c)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left">Noteholder A (a)</td><td style="width: 2%"> </td> <td style="width: 11%; text-align: center"><span id="xdx_907_ecustom--Origination_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderAMember_fKGEp_zDron9kgn215" title="Origination">2019</span></td><td style="width: 2%"> </td> <td style="width: 11%; text-align: center"><span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderAMember_fKGEp_zgdTGHjWvjg8" title="Maturity date">12/31/2021</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_uPure_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderAMember_fKGEp_zYOHeab3451e" title="Interest rate">0</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtInstrumentFaceAmount_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderAMember_fKGEp_z8qKKTVO98ae" style="width: 9%; text-align: right" title="Loan Balance">217,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Noteholder B (a)</td><td> </td> <td style="text-align: center"><span id="xdx_90F_ecustom--Origination_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderBMember_fKGEp_zDCt809lGls1" title="Origination">3/19/2019</span></td><td> </td> <td style="text-align: center"><span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderBMember_fKGEp_zPtrpzQJBOu9" title="Maturity date">4/29/2019</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_uPure_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderBMember_fKGEp_zJKqnQ4Kjnle" title="Interest rate">0</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--DebtInstrumentFaceAmount_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderBMember_fKGEp_z3GOtBOZjqoe" style="text-align: right" title="Loan Balance">510,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Noteholder C (a)</td><td> </td> <td style="text-align: center"><span id="xdx_906_ecustom--Origination_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderCMember_fKGEp_zaQTf8BTj7Nk" title="Origination">3/1/2019</span></td><td> </td> <td style="text-align: center"><span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderCMember_fKGEp_zGGKEfYkURJ" title="Maturity date">2/29/2020</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_uPure_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderCMember_fKGEp_zInweYdYWFM7" title="Interest rate">18</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--DebtInstrumentFaceAmount_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderCMember_fKGEp_z1CqMd46O16i" style="text-align: right" title="Loan Balance">32,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Noteholder D (d)</td><td> </td> <td style="text-align: center"><span id="xdx_900_ecustom--Origination_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderDMember_fKGEp_zfuBZcG2zkL6" title="Origination">4/29/2019</span></td><td> </td> <td style="text-align: center">unspecified</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_uPure_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderDMember_fKGEp_zJP6DISG9je9" title="Interest rate">0</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--DebtInstrumentFaceAmount_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderDMember_fKGEp_znIjB8Qdxtjg" style="text-align: right" title="Loan Balance">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderDMember_zJp61mvSFM9a" style="text-align: right" title="Number of shares the notesis convertible into shares">30,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Noteholder E (a)</td><td> </td> <td style="text-align: center"><span id="xdx_906_ecustom--Origination_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderEMember_fKGEp_zadjZKkh7crf" title="Origination">8/1/2019</span></td><td> </td> <td style="text-align: center"><span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderEMember_fKGEp_zfl910Me89y4" title="Maturity date">8/31/2019</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_uPure_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderEMember_fKGEp_zqZiQZL2IBfi" title="Interest rate">0</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--DebtInstrumentFaceAmount_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderEMember_fKGEp_zCqDMIjhu7U" style="text-align: right" title="Loan Balance">37,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> N/A </span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Noteholder F (a)(b)</td><td> </td> <td style="text-align: center"><span id="xdx_904_ecustom--Origination_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderFMember_fKGEpKGIp_zkyY7gIW05Z" title="Origination">2/27/2020</span></td><td> </td> <td style="text-align: center"><span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderFMember_fKGEpKGIp_zzAH734GVn0l" title="Maturity date">4/30/2020</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_uPure_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderFMember_fKGEpKGIp_zSVjThog0Oo1" title="Interest rate">0</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--DebtInstrumentFaceAmount_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderFMember_fKGEpKGIp_z4OYychTsaw9" style="text-align: right" title="Loan Balance">2,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderFMember_fKGEpKGIp_zncYuwOesSB6" style="text-align: right" title="Number of shares the notesis convertible into shares">5,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Noteholder G</td><td> </td> <td style="text-align: center"><span id="xdx_90D_ecustom--Origination_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderGMember_zzc1AJWonyEc" title="Origination">8/3/2021</span></td><td> </td> <td style="text-align: center"><span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderGMember_zRrYaDDhmAkl" title="Maturity date">8/3/2023</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_uPure_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderGMember_zdrL6RSqtx3j" title="Interest rate">10</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--DebtInstrumentFaceAmount_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderGMember_zGBJErSdvug" style="text-align: right" title="Loan Balance">12,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderGMember_z539vpQIyPU2" style="text-align: right" title="Number of shares the notesis convertible into shares">25,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Noteholder H</td><td> </td> <td style="text-align: center"><span id="xdx_900_ecustom--Origination_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderHMember_zwfZTCy0PB1e" title="Origination">6/27/2022</span></td><td> </td> <td style="text-align: center"><span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderHMember_zOyUymzA8q77" title="Maturity date">6/27/2024</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_uPure_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderHMember_zyvguGZFoCb3" title="Interest rate">5</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--DebtInstrumentFaceAmount_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderHMember_ziqzzXmTOAF3" style="text-align: right" title="Loan Balance">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderHMember_zGUlW1dACc14" style="text-align: right" title="Number of shares the notesis convertible into shares">1,000,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Noteholder I (c)</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_90B_ecustom--Origination_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderIMember_fKGEpKGMp_zbfqlFdSKhOg" title="Origination">10/26/2022</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderIMember_fKGEpKGMp_zfIw24mrGaI1" title="Maturity date">12/31/2023</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_uPure_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderIMember_fKGEpKGMp_zLkFxWGmnema" title="Interest rate">3</span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--DebtInstrumentFaceAmount_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderIMember_fKGEpKGMp_zAkXXANtAAfj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Loan Balance">50,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderIMember_fKGEpKGMp_z7jNlEdj6ROk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares the notesis convertible into shares">400,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--DebtInstrumentFaceAmount_iI_c20230331_z6uW9x4qXp79" style="text-align: right" title="Loan Balance">1,462,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20221001__20230331_zsUNJqHt9CLg" style="text-align: right" title="Number of shares the notesis convertible into shares">1,460,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">(d) Debt discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_c20230331_zO6poq5dh956" style="border-bottom: Black 1.5pt solid; text-align: right" title="Debt discount">(150,556</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--LongTermDebt_iI_c20230331_z2oQCRAQ4ZPe" style="border-bottom: Black 2.5pt double; text-align: right" title="Total loan">1,311,444</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span id="xdx_F03_zlIsXQ4SZbCi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="text-align: justify"><span id="xdx_F13_zkUuXRYMHavg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Past due at December 31, 2022</span></td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span id="xdx_F0F_zUTXKNcn66kh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td id="xdx_F19_zn3j8rr2ZPsd" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note is payable in a combination of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtConversionOriginalDebtAmount1_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderFMember__srt--RangeAxis__srt--MinimumMember_zZQO3uOREn64" title="Notes payable converted">2,500</span> to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtConversionOriginalDebtAmount1_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderFMember__srt--RangeAxis__srt--MaximumMember_z34dUQOUui0i" title="Notes payable converted">6,000</span> in cash and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderFMember__srt--RangeAxis__srt--MinimumMember_zhoj0fWx07aa" title="Shares issued during conversion">5,000</span> to <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderFMember__srt--RangeAxis__srt--MaximumMember_zjl6bOvD7LP1" title="Shares issued during conversion">15,000</span> share of common stock</span></td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span id="xdx_F07_zuKy1JOYNBCb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td><td id="xdx_F19_zz6wMBSDBiLg" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible into common stock of the subsidiary, Genvor Inc.</span></td> </tr></table> <p id="xdx_8AD_znkoRW1zbzLj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The notes do not have default provisions except Noteholder B receives a default penalty of $<span id="xdx_900_ecustom--DebtDefaultPenaltyAmount_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderBMember_zg5ZbnXdU9i7">10,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each month the note goes unpaid.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expense totaled $<span id="xdx_900_eus-gaap--InterestExpenseDebt_c20221001__20230331_zvYVmrQh6vqi" title="Interest expense">71,665</span> and $<span id="xdx_90F_eus-gaap--InterestExpenseDebt_c20211001__20220331_ziR4ArqAiU58" title="Interest expense">121,002</span>, respectively, for the six months ended March 31, 2023, and 2022, including default penalties. Late fees totaled $<span id="xdx_90B_ecustom--LateFees_c20221001__20230331_zmfNnlK5a98g" title="Late fees">60,000</span> and $<span id="xdx_908_ecustom--LateFees_c20211001__20220331_ztuAhHB84bg5" title="Late fees">60,000</span>, respectively, for the six months ended March 31, 2023, and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 48750 0.01 <p id="xdx_89E_eus-gaap--ConvertibleDebtTableTextBlock_z7jG155Q6hh1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zpPxKzZSWewf" style="display: none">SCHEDULE OF CONVERTIBLE NOTES PAYABLE</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-right: 0pt; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td> </td><td> </td> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Balance</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td> </td><td> </td> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Convertible</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td> </td><td> </td> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Loan</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">into</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Noteholder</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Origination</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Maturity</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Balance</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares (c)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left">Noteholder A (a)</td><td style="width: 2%"> </td> <td style="width: 11%; text-align: center"><span id="xdx_907_ecustom--Origination_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderAMember_fKGEp_zDron9kgn215" title="Origination">2019</span></td><td style="width: 2%"> </td> <td style="width: 11%; text-align: center"><span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderAMember_fKGEp_zgdTGHjWvjg8" title="Maturity date">12/31/2021</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_uPure_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderAMember_fKGEp_zYOHeab3451e" title="Interest rate">0</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtInstrumentFaceAmount_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderAMember_fKGEp_z8qKKTVO98ae" style="width: 9%; text-align: right" title="Loan Balance">217,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Noteholder B (a)</td><td> </td> <td style="text-align: center"><span id="xdx_90F_ecustom--Origination_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderBMember_fKGEp_zDCt809lGls1" title="Origination">3/19/2019</span></td><td> </td> <td style="text-align: center"><span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderBMember_fKGEp_zPtrpzQJBOu9" title="Maturity date">4/29/2019</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_uPure_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderBMember_fKGEp_zJKqnQ4Kjnle" title="Interest rate">0</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--DebtInstrumentFaceAmount_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderBMember_fKGEp_z3GOtBOZjqoe" style="text-align: right" title="Loan Balance">510,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Noteholder C (a)</td><td> </td> <td style="text-align: center"><span id="xdx_906_ecustom--Origination_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderCMember_fKGEp_zaQTf8BTj7Nk" title="Origination">3/1/2019</span></td><td> </td> <td style="text-align: center"><span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderCMember_fKGEp_zGGKEfYkURJ" title="Maturity date">2/29/2020</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_uPure_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderCMember_fKGEp_zInweYdYWFM7" title="Interest rate">18</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--DebtInstrumentFaceAmount_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderCMember_fKGEp_z1CqMd46O16i" style="text-align: right" title="Loan Balance">32,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Noteholder D (d)</td><td> </td> <td style="text-align: center"><span id="xdx_900_ecustom--Origination_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderDMember_fKGEp_zfuBZcG2zkL6" title="Origination">4/29/2019</span></td><td> </td> <td style="text-align: center">unspecified</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_uPure_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderDMember_fKGEp_zJP6DISG9je9" title="Interest rate">0</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--DebtInstrumentFaceAmount_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderDMember_fKGEp_znIjB8Qdxtjg" style="text-align: right" title="Loan Balance">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderDMember_zJp61mvSFM9a" style="text-align: right" title="Number of shares the notesis convertible into shares">30,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Noteholder E (a)</td><td> </td> <td style="text-align: center"><span id="xdx_906_ecustom--Origination_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderEMember_fKGEp_zadjZKkh7crf" title="Origination">8/1/2019</span></td><td> </td> <td style="text-align: center"><span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderEMember_fKGEp_zfl910Me89y4" title="Maturity date">8/31/2019</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_uPure_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderEMember_fKGEp_zqZiQZL2IBfi" title="Interest rate">0</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--DebtInstrumentFaceAmount_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderEMember_fKGEp_zCqDMIjhu7U" style="text-align: right" title="Loan Balance">37,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> N/A </span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Noteholder F (a)(b)</td><td> </td> <td style="text-align: center"><span id="xdx_904_ecustom--Origination_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderFMember_fKGEpKGIp_zkyY7gIW05Z" title="Origination">2/27/2020</span></td><td> </td> <td style="text-align: center"><span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderFMember_fKGEpKGIp_zzAH734GVn0l" title="Maturity date">4/30/2020</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_uPure_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderFMember_fKGEpKGIp_zSVjThog0Oo1" title="Interest rate">0</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--DebtInstrumentFaceAmount_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderFMember_fKGEpKGIp_z4OYychTsaw9" style="text-align: right" title="Loan Balance">2,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderFMember_fKGEpKGIp_zncYuwOesSB6" style="text-align: right" title="Number of shares the notesis convertible into shares">5,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Noteholder G</td><td> </td> <td style="text-align: center"><span id="xdx_90D_ecustom--Origination_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderGMember_zzc1AJWonyEc" title="Origination">8/3/2021</span></td><td> </td> <td style="text-align: center"><span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderGMember_zRrYaDDhmAkl" title="Maturity date">8/3/2023</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_uPure_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderGMember_zdrL6RSqtx3j" title="Interest rate">10</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--DebtInstrumentFaceAmount_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderGMember_zGBJErSdvug" style="text-align: right" title="Loan Balance">12,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderGMember_z539vpQIyPU2" style="text-align: right" title="Number of shares the notesis convertible into shares">25,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Noteholder H</td><td> </td> <td style="text-align: center"><span id="xdx_900_ecustom--Origination_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderHMember_zwfZTCy0PB1e" title="Origination">6/27/2022</span></td><td> </td> <td style="text-align: center"><span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderHMember_zOyUymzA8q77" title="Maturity date">6/27/2024</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_uPure_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderHMember_zyvguGZFoCb3" title="Interest rate">5</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--DebtInstrumentFaceAmount_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderHMember_ziqzzXmTOAF3" style="text-align: right" title="Loan Balance">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderHMember_zGUlW1dACc14" style="text-align: right" title="Number of shares the notesis convertible into shares">1,000,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Noteholder I (c)</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_90B_ecustom--Origination_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderIMember_fKGEpKGMp_zbfqlFdSKhOg" title="Origination">10/26/2022</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderIMember_fKGEpKGMp_zfIw24mrGaI1" title="Maturity date">12/31/2023</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_uPure_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderIMember_fKGEpKGMp_zLkFxWGmnema" title="Interest rate">3</span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--DebtInstrumentFaceAmount_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderIMember_fKGEpKGMp_zAkXXANtAAfj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Loan Balance">50,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderIMember_fKGEpKGMp_z7jNlEdj6ROk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares the notesis convertible into shares">400,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--DebtInstrumentFaceAmount_iI_c20230331_z6uW9x4qXp79" style="text-align: right" title="Loan Balance">1,462,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20221001__20230331_zsUNJqHt9CLg" style="text-align: right" title="Number of shares the notesis convertible into shares">1,460,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">(d) Debt discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_c20230331_zO6poq5dh956" style="border-bottom: Black 1.5pt solid; text-align: right" title="Debt discount">(150,556</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--LongTermDebt_iI_c20230331_z2oQCRAQ4ZPe" style="border-bottom: Black 2.5pt double; text-align: right" title="Total loan">1,311,444</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span id="xdx_F03_zlIsXQ4SZbCi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="text-align: justify"><span id="xdx_F13_zkUuXRYMHavg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Past due at December 31, 2022</span></td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span id="xdx_F0F_zUTXKNcn66kh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td id="xdx_F19_zn3j8rr2ZPsd" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note is payable in a combination of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtConversionOriginalDebtAmount1_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderFMember__srt--RangeAxis__srt--MinimumMember_zZQO3uOREn64" title="Notes payable converted">2,500</span> to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtConversionOriginalDebtAmount1_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderFMember__srt--RangeAxis__srt--MaximumMember_z34dUQOUui0i" title="Notes payable converted">6,000</span> in cash and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderFMember__srt--RangeAxis__srt--MinimumMember_zhoj0fWx07aa" title="Shares issued during conversion">5,000</span> to <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIENPTlZFUlRJQkxFIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20221001__20230331__us-gaap--DebtInstrumentAxis__custom--NoteholderFMember__srt--RangeAxis__srt--MaximumMember_zjl6bOvD7LP1" title="Shares issued during conversion">15,000</span> share of common stock</span></td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span id="xdx_F07_zuKy1JOYNBCb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td><td id="xdx_F19_zz6wMBSDBiLg" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible into common stock of the subsidiary, Genvor Inc.</span></td> </tr></table> 2019 2021-12-31 0 217000 3/19/2019 2019-04-29 0 510000 3/1/2019 2020-02-29 0.18 32500 4/29/2019 0 300000 30000 8/1/2019 2019-08-31 0 37500 2/27/2020 2020-04-30 0 2500 5000 8/3/2021 2023-08-03 0.10 12500 25000 6/27/2022 2024-06-27 0.05 300000 1000000 10/26/2022 2023-12-31 0.03 50000 400000 1462000 1460000 150556 1311444 2500 6000 5000 15000 10000 71665 121002 60000 60000 <p id="xdx_80B_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zjAeVP54xyBb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4 – <span id="xdx_82A_zAoUtG5qhZWe">STOCKHOLDERS’ DEFICIT</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preferred Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The authorized preferred stock of the Company consists of <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_pp0d_c20230331_zMgRx7jxVML9" title="Preferred stock, shares authorized">20,000,000</span> shares with a $<span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230331_zOsWhJ6g5SH6" title="Preferred stock, shares par value">0.001</span> par value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series A Preferred Stock</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 10, 2022, the Company designated <span id="xdx_906_ecustom--DesignationAuthorizedShares_c20220810__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pp0d" title="Designation authorized shares">10</span> shares of its preferred stock as Series A Preferred Stock (“Series A”). <span id="xdx_901_eus-gaap--PreferredStockVotingRights_c20220802__20220810__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zQXFWNSDmYEl" title="Number of votes">Each share of Series A entitles the holder to ten million (10,000,000) votes on all matters submitted to a vote of the stockholders of the Corporation</span>. When and as any dividend or distribution is declared or paid by the Company on the common stock, the Series A holders are entitled to participate in such dividend or distribution. <span id="xdx_907_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20220802__20220810__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z40OC07jYgY" title="Conversion share description">Each Series A share is convertible, at the option of the holder, into one share of fully paid and non-assessable common stock</span>. Upon any liquidation, dissolution, or winding-up of the Company, the Series A holders are entitled to receive out the assets of the Company, for each share of Series A, an amount equal to par value before any distribution or payment shall be made to the holder of any junior securities (including common stock and all other equity or equity equivalent securities of the Company).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2023, and September 30, 2022, there were <span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zddOlqZWbP5c" title="Preferred stock, shares issued"><span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zV8r0JevsTpk" title="Preferred stock, shares outstanding">9</span></span> and <span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zdmZyHJPEG5d" title="Preferred stock, shares issued"><span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zXwTzHc7zYp7" title="Preferred stock, shares outstanding">9</span></span> shares of Series A preferred stock issued and outstanding, respectively. The preferred stock was issued on August 16, 2022, as follows: Bradley White (Chief Executive Officer), <span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_pp0d_c20220816__srt--TitleOfIndividualAxis__custom--BradleyWhiteMember_zcajVlErdqcc" title="Preferred stock, shares issued">3</span> shares; Dr. Clayton Yates (Chief Scientific Officer and Chairman), <span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_pp0d_c20220816__srt--TitleOfIndividualAxis__custom--ClaytonYatesMember_z4DdzN7NP5Y" title="Preferred stock, shares issued">3</span> shares; and Dr. Jesse Jaynes (Chief Research Officer and Director), <span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_pp0d_c20220816__srt--TitleOfIndividualAxis__custom--JesseJaynesMember_zbzuyLezt9Be" title="Preferred stock, shares issued">3</span> shares. See Note 7.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series B Preferred Stock</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 19, 2022, the Company filed a Certificate of Designation with the State of Nevada to designate its Series B Preferred Stock (“Series B”). The designation authorized <span id="xdx_908_ecustom--DesignationAuthorizedShares_c20221019__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pp0d" title="Designation authorized shares">2,500,000</span> shares of Series B. <span id="xdx_90A_eus-gaap--PreferredStockVotingRights_c20221001__20221019__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zeiydna6UfW5" title="Number of votes">Each share of Series B shall have 10 votes on all matters submitted to a vote of the stockholders of the Company</span>. <span id="xdx_908_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20221001__20221019__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_znJT2vb1a1se" title="Conversion share description">Each share of Series B is convertible into 10 shares of common stock of the Company</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfConversionsOfStockTextBlock_zG4csaVio3la" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 19, 2022, the following shareholders converted shares of common stock of the Company into shares of Series B to modify the common shares outstanding to reduce the outstanding common stock issued by the Company, as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_z4qyiFLE68N1" style="display: none">SCHEDULE OF CONVERTED SHARES OF COMMON STOCK</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Common Shares</p> <p style="margin-top: 0; margin-bottom: 0">Exchanged</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series B</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issued</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Jaynes Investment LLC</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ConversionOfStockSharesConverted1_pp0d_c20221019__20221019__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JaynesInvestmentLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_ztwQrd8gipo6" style="width: 16%; text-align: right" title="Common Shares Exchanged">2,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ConversionOfStockSharesIssued1_pp0d_c20221019__20221019__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JaynesInvestmentLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zemZfALZYhi4" style="width: 16%; text-align: right" title="Series B Issued">200,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">ACT Holdings LLC</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ConversionOfStockSharesConverted1_pp0d_c20221019__20221019__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ACTHoldingsLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zzgUC6eKCfX1" style="text-align: right" title="Common Shares Exchanged">7,312,612</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ConversionOfStockSharesIssued1_pp0d_c20221019__20221019__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ACTHoldingsLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zT0AaBg9E03l" style="text-align: right" title="Series B Issued">731,262</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">LASB Family Trust</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ConversionOfStockSharesConverted1_pp0d_c20221019__20221019__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LASBFamilyTrustMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z4yB3btm6Ssg" style="text-align: right" title="Common Shares Exchanged">3,800,112</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ConversionOfStockSharesIssued1_pp0d_c20221019__20221019__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LASBFamilyTrustMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z8Ljer7EXP4k" style="text-align: right" title="Series B Issued">380,012</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Jesse Michael Jaynes</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ConversionOfStockSharesConverted1_pp0d_c20221019__20221019__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JesseMichaelJaynesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zmHOAH2eO5oe" style="text-align: right" title="Common Shares Exchanged">4,767,611</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ConversionOfStockSharesIssued1_pp0d_c20221019__20221019__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JesseMichaelJaynesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z8IDepRDPmUb" style="text-align: right" title="Series B Issued">476,762</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Bradley White (a)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ConversionOfStockSharesConverted1_pp0d_c20221019__20221019__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BradleyWhiteMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_fKGEp_zSAKYfapLhEc" style="text-align: right" title="Common Shares Exchanged">1,225,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ConversionOfStockSharesIssued1_pp0d_c20221019__20221019__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BradleyWhiteMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_fKGEp_zTkjXlDJDTQ7" style="text-align: right" title="Series B Issued">122,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">PJ Advisory Group</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ConversionOfStockSharesConverted1_pp0d_c20221019__20221019__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PJAdvisoryGroupMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zPJfHg2Ibmbc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Common Shares Exchanged">1,500,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ConversionOfStockSharesIssued1_pp0d_c20221019__20221019__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PJAdvisoryGroupMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zYfTtufWv0wh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Series B Issued">150,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ConversionOfStockSharesConverted1_pp0d_c20221019__20221019__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zlTtQdBudW8k" style="border-bottom: Black 2.5pt double; text-align: right" title="Common Shares Exchanged">20,605,334</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ConversionOfStockSharesIssued1_pp0d_c20221019__20221019__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_ziMBJO8nPZP" style="border-bottom: Black 2.5pt double; text-align: right" title="Series B Issued">2,060,536</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span id="xdx_F04_zOZWoss2cUU3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="width: 5pt"/><td style="text-align: justify"><span id="xdx_F1E_zwrJV3sDTexk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related party</span></td> </tr></table> <p id="xdx_8AD_zpb9HzGXiA6j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The conversion of the common stock into the Series B was valued at par, respectively, offset to additional paid-in capital. The Series B is convertible into common stock into the original amount of common stock converted therefore there is no change in the amount of common stock outstanding on a fully diluted basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2023, and September 30, 2022, there were <span id="xdx_901_eus-gaap--PreferredStockSharesIssued_iI_pp0d_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z1jJKeUutuG4" title="Preferred stock, shares issued"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_pp0d_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zhakTvPNcgW8" title="Preferred stock, shares outstanding">2,060,536</span></span> and <span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_pp0d_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zlK4L1NYn33" title="Preferred stock, shares issued"><span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_pp0d_c20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zawh4sWLng21" title="Preferred stock, shares outstanding">0</span></span> shares of Series B preferred stock issued and outstanding, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Common Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The authorized common stock of the Company consists of <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_pp0d_c20230331_zDalmY7ThlE9" title="Common stock, shares authorized">300,000,000</span> shares with a $<span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230331_zJuxro1mtJr3" title="Common stock, shares par value">0.001</span> par value. All common stock shares are non-assessable and have one vote per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the Merger (see Note 1), the founding shareholders of the Company cancelled <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20220421__20220421_z2D4A4c7QE5e" title="Number of common stock cancel">18,144,112</span> shares of common stock, retaining 5%, or <span id="xdx_90A_ecustom--CommonStockRetainingShareValue_iI_pp0d_c20220630_zOGXDhEO0N4k" title="Number of common stock retaining">1,855,888</span> shares of common stock, as of June 30, 2022. The cancellation is presented in the accompanying statements of changes in stockholders’ deficit within the line item “Retroactive application of recapitalization.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Issued for Cash</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 17, 2022, the Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221117__20221117__srt--TitleOfIndividualAxis__custom--ShareholderMember__us-gaap--StatementClassOfStockAxis__custom--StockIssueForCashMember_zt991aYhyPkj">300,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock to a shareholder for $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221117__20221117__srt--TitleOfIndividualAxis__custom--ShareholderMember__us-gaap--StatementClassOfStockAxis__custom--StockIssueForCashMember_zHoPbsPWG0pf">150,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 20000000 0.001 10 Each share of Series A entitles the holder to ten million (10,000,000) votes on all matters submitted to a vote of the stockholders of the Corporation Each Series A share is convertible, at the option of the holder, into one share of fully paid and non-assessable common stock 9 9 9 9 3 3 3 2500000 Each share of Series B shall have 10 votes on all matters submitted to a vote of the stockholders of the Company Each share of Series B is convertible into 10 shares of common stock of the Company <p id="xdx_896_eus-gaap--ScheduleOfConversionsOfStockTextBlock_zG4csaVio3la" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 19, 2022, the following shareholders converted shares of common stock of the Company into shares of Series B to modify the common shares outstanding to reduce the outstanding common stock issued by the Company, as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_z4qyiFLE68N1" style="display: none">SCHEDULE OF CONVERTED SHARES OF COMMON STOCK</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Common Shares</p> <p style="margin-top: 0; margin-bottom: 0">Exchanged</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series B</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issued</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Jaynes Investment LLC</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ConversionOfStockSharesConverted1_pp0d_c20221019__20221019__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JaynesInvestmentLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_ztwQrd8gipo6" style="width: 16%; text-align: right" title="Common Shares Exchanged">2,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ConversionOfStockSharesIssued1_pp0d_c20221019__20221019__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JaynesInvestmentLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zemZfALZYhi4" style="width: 16%; text-align: right" title="Series B Issued">200,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">ACT Holdings LLC</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ConversionOfStockSharesConverted1_pp0d_c20221019__20221019__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ACTHoldingsLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zzgUC6eKCfX1" style="text-align: right" title="Common Shares Exchanged">7,312,612</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ConversionOfStockSharesIssued1_pp0d_c20221019__20221019__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ACTHoldingsLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zT0AaBg9E03l" style="text-align: right" title="Series B Issued">731,262</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">LASB Family Trust</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ConversionOfStockSharesConverted1_pp0d_c20221019__20221019__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LASBFamilyTrustMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z4yB3btm6Ssg" style="text-align: right" title="Common Shares Exchanged">3,800,112</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ConversionOfStockSharesIssued1_pp0d_c20221019__20221019__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LASBFamilyTrustMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z8Ljer7EXP4k" style="text-align: right" title="Series B Issued">380,012</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Jesse Michael Jaynes</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ConversionOfStockSharesConverted1_pp0d_c20221019__20221019__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JesseMichaelJaynesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zmHOAH2eO5oe" style="text-align: right" title="Common Shares Exchanged">4,767,611</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ConversionOfStockSharesIssued1_pp0d_c20221019__20221019__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JesseMichaelJaynesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z8IDepRDPmUb" style="text-align: right" title="Series B Issued">476,762</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Bradley White (a)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ConversionOfStockSharesConverted1_pp0d_c20221019__20221019__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BradleyWhiteMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_fKGEp_zSAKYfapLhEc" style="text-align: right" title="Common Shares Exchanged">1,225,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ConversionOfStockSharesIssued1_pp0d_c20221019__20221019__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BradleyWhiteMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_fKGEp_zTkjXlDJDTQ7" style="text-align: right" title="Series B Issued">122,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">PJ Advisory Group</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ConversionOfStockSharesConverted1_pp0d_c20221019__20221019__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PJAdvisoryGroupMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zPJfHg2Ibmbc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Common Shares Exchanged">1,500,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ConversionOfStockSharesIssued1_pp0d_c20221019__20221019__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PJAdvisoryGroupMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zYfTtufWv0wh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Series B Issued">150,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ConversionOfStockSharesConverted1_pp0d_c20221019__20221019__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zlTtQdBudW8k" style="border-bottom: Black 2.5pt double; text-align: right" title="Common Shares Exchanged">20,605,334</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ConversionOfStockSharesIssued1_pp0d_c20221019__20221019__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_ziMBJO8nPZP" style="border-bottom: Black 2.5pt double; text-align: right" title="Series B Issued">2,060,536</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span id="xdx_F04_zOZWoss2cUU3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="width: 5pt"/><td style="text-align: justify"><span id="xdx_F1E_zwrJV3sDTexk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related party</span></td> </tr></table> 2000000 200000 7312612 731262 3800112 380012 4767611 476762 1225000 122500 1500000 150000 20605334 2060536 2060536 2060536 0 0 300000000 0.001 18144112 1855888 300000 150000 <p id="xdx_800_eus-gaap--IncomeTaxDisclosureTextBlock_z1mv5r740r5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5 – <span id="xdx_827_zAnKKF5Gxcu3">FEDERAL INCOME TAX</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2023, and September 30, 2022, the Company has net operating loss carry forwards of $<span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20230331_zD2jf4D394Rg" title="Net operating loss carry forwards">2,667,462</span> and $<span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20220930_zB3AjTpqQsrd" title="Net operating loss carry forwards">2,572,885</span>, respectively, which may be available to reduce future years’ taxable income through 2043. The Company’s net operating loss carry forwards may be subject to annual limitations, which could reduce or defer the utilization of the losses as a result of an ownership change as defined in Section 382 of the Internal Revenue Code.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s tax expense differs from the “expected” tax expense for Federal income tax purposes (computed by applying the United States Federal tax rate of <span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c20221001__20230331_zqMIYDR16E51" title="Federal tax statutory rate"><span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c20220101__20220930_zAdFrRzrvGRe" title="Federal tax statutory rate">21%</span></span> to loss before taxes for fiscal year 2023 and 2022), as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zjVRgsOChgyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zRCmf15WJ2w9" style="display: none">SCHEDULE OF LOSS BEFORE TAXES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_494_20221001__20230331_zbxnnBYVTXt4" style="text-align: center">March 31,</td><td> </td><td> </td> <td colspan="2" id="xdx_49C_20211001__20220930_zCxrN0FVcTW2" style="text-align: center">September 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzKgE_z3Oy0fyqwdF2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-left: 0pt">Tax benefit at the statutory rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(84,158</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(204,559</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzKgE_zjGBa9O1lqq5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">State income taxes, net of federal income tax benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(10,420</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(25,326</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzKgE_z778mhArCws8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">94,577</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">229,885</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzKgE_zRhJWdJ5kBvi" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 0pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0857">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0858">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AC_zrbXmey9aVcc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The tax effects of the temporary differences between reportable financial statement income and taxable income are recognized as deferred tax assets and liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The tax years 2023 and 2022 remains open for examination by federal agencies and other jurisdictions in which it operates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z6gDVktiz2g1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The tax effect of significant components of the Company’s deferred tax assets and liabilities at March 31, 2023, and September 30, 2022, are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zX70pVNst7y3" style="display: none">SCHEDULE OF DEFERRED TAX ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_494_20230331_zEw1QPSDPNx2" style="text-align: center">March 31,</td><td> </td><td> </td> <td colspan="2" id="xdx_49C_20220930_zudgSewhp0Gg" style="text-align: center">September 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_zfkz45I0esHi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Net operating loss carryforward</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">2,667,462</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">2,572,885</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsGross_iI_maDTANzQs7_z9Ed9BQCv6ei" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">Total gross deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,667,462</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,572,885</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzQs7_zqwjv31jIWZj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Less: Deferred tax asset valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,667,462</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,572,885</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzQs7_zVrFVvyZBG04" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Total net deferred taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0871">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0872">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zLmY5iUwOOSd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because of the historical earnings history of the Company, the net deferred tax assets for 2022 and 2021 were fully offset by a 100% valuation allowance. The valuation allowance for the remaining net deferred tax assets was $<span id="xdx_906_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pp0p0_c20230331_zaGGyIaUnig2" title="Valuation allowance for net deferred tax assets">2,667,462</span> and $<span id="xdx_904_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pp0p0_c20220930_zAXncmsOaFT2" title="Valuation allowance for net deferred tax assets">2,572,885</span> as of March 31, 2023, and September 30, 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 2667462 2572885 0.21 0.21 <p id="xdx_899_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zjVRgsOChgyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zRCmf15WJ2w9" style="display: none">SCHEDULE OF LOSS BEFORE TAXES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_494_20221001__20230331_zbxnnBYVTXt4" style="text-align: center">March 31,</td><td> </td><td> </td> <td colspan="2" id="xdx_49C_20211001__20220930_zCxrN0FVcTW2" style="text-align: center">September 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzKgE_z3Oy0fyqwdF2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-left: 0pt">Tax benefit at the statutory rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(84,158</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(204,559</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzKgE_zjGBa9O1lqq5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">State income taxes, net of federal income tax benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(10,420</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(25,326</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzKgE_z778mhArCws8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">94,577</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">229,885</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzKgE_zRhJWdJ5kBvi" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 0pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0857">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0858">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> -84158 -204559 -10420 -25326 94577 229885 <p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z6gDVktiz2g1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The tax effect of significant components of the Company’s deferred tax assets and liabilities at March 31, 2023, and September 30, 2022, are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zX70pVNst7y3" style="display: none">SCHEDULE OF DEFERRED TAX ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_494_20230331_zEw1QPSDPNx2" style="text-align: center">March 31,</td><td> </td><td> </td> <td colspan="2" id="xdx_49C_20220930_zudgSewhp0Gg" style="text-align: center">September 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_zfkz45I0esHi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Net operating loss carryforward</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">2,667,462</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">2,572,885</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsGross_iI_maDTANzQs7_z9Ed9BQCv6ei" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0pt">Total gross deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,667,462</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,572,885</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzQs7_zqwjv31jIWZj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Less: Deferred tax asset valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,667,462</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,572,885</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzQs7_zVrFVvyZBG04" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Total net deferred taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0871">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0872">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 2667462 2572885 2667462 2572885 2667462 2572885 2667462 2572885 <p id="xdx_804_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z2tOLEDJq5ka" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 6 – <span id="xdx_82A_z0Z9VboHkgr2">COMMITMENTS AND CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, the Company may be involved in litigation in the ordinary course of business. The Company is not currently involved in any litigation that we believe could have a material adverse effect on its financial condition or results of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subscription Agreement and Cash Held in Escrow</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 20, 2019, the Company entered into a subscription escrow agreement (the “Trust Agreement”) with Branch Banking and Trust Company (“BB&amp;T”). This Trust Agreement was established for the subscription agreement proceeds raised and escrowed pursuant to the Company’s prior Rule 419 S-1 offering. The balance held in trust at March 31, 2023 and September 30, 2022, totaled $<span id="xdx_903_eus-gaap--AssetsHeldInTrust_iI_pp0p0_c20230331_zTVzd2FO8H7l" title="Assets held in trust"><span id="xdx_909_eus-gaap--AssetsHeldInTrust_iI_pp0p0_c20220930_zCTytDGzk0t7" title="Assets held in trust">19,705</span></span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon completion of the Merger (see Notes 1 and 8), the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0d_c20221001__20230331__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zt9e6eUZwGpl" title="Number of shares issued">975,000</span> common stock shares to the investors in that prior S-1 offering during July 2022 and were released to the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consulting Agreements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the six months ended March 31, 2023, the Company paid the CEO $<span id="xdx_90C_ecustom--RelatedPartyPayable_c20221001__20230331__us-gaap--PlanNameAxis__custom--ConsultingAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zbnS3xRyXe1i" title="Related party payable">3,000</span> pursuant to a consulting agreement carried over from related party NBFL. The agreement provides for an annual salary of $<span id="xdx_90E_eus-gaap--SalariesAndWages_pp0p0_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_z2RYHVIZiFFd">150,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">which increases based on certain capital raise thresholds. At March 31, 2023 and September 30, 2022, accrued payroll owed to the CEO totaled $<span id="xdx_90A_eus-gaap--AccruedPayrollTaxesCurrent_iI_pp0p0_c20230331__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_z0KWESjtdiC3">192,638 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90F_eus-gaap--AccruedPayrollTaxesCurrent_iI_pp0p0_c20220930__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zWf4fxmuOH5a">188,484</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, respectively, as presented in the accompanying consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 24, 2020, the Company entered into a consulting agreement for business development activities, networking, negotiations, and strategic planning. The compensation pursuant to the agreement was $<span id="xdx_90F_eus-gaap--SalariesWagesAndOfficersCompensation_pp0p0_c20200724__20200724__us-gaap--PlanNameAxis__custom--ConsultingAgreementsMember__us-gaap--RelatedPartyTransactionAxis__custom--ConsultantMember_zuVo7RoEZYOl">20,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">monthly.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Office Lease</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company entered into a sublease agreement with the above consultant (providing business development assistance from 2019-2020) effective August 1, 2019, subject to the terms and conditions of the office lease held by the consultant at 15540 Quorum Drive #2624, Addison, Texas. On January 1, 2019, the Company adopted ASC 842 requiring this lease to be recorded as an asset and corresponding liability on its balance sheet. The Company records rent expense associated with this lease on the straight-line basis in conjunction with the terms of the underlying lease. A discount rate was not used in the determination of the right of use asset and liability since its effect would not be significant. The lease moved to a month-to-month basis beginning in September 2021 at $<span id="xdx_905_eus-gaap--PaymentsForRent_pp0p0_c20211002__20211002_zJv0qWKl7Edk" title="Rent expense">2,810</span> per month in addition to common area maintenance charges. During the six months ended March 31, 2023, and 2022, we incurred $<span id="xdx_902_eus-gaap--PaymentsForRent_pp0p0_c20221001__20230331_zufTlTREclE9" title="Rent expense">6,590</span> and $<span id="xdx_901_eus-gaap--PaymentsForRent_pp0p0_c20211001__20220331_zQHXH3XGt5z1" title="Rent expense">20,607</span>, respectively, in office rental expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research and Development Agreement</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During September 2020, the Company assumed a Cooperative Research And Development Agreement (CRADA) with the United States Department of Agriculture (USDA), Agricultural Research Service (ARS). Under this agreement, the Company committed to funding the remaining amount due. As of March 31, 2023, and September 30, 2022, $<span id="xdx_90B_ecustom--FundAmount_iI_pp0p0_c20230331__us-gaap--LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis__us-gaap--ResearchAndDevelopmentArrangementMember_zwWg8nv97z6l" title="Fund Amount">246,400</span> and $<span id="xdx_906_ecustom--FundAmount_iI_pp0p0_c20220930__us-gaap--LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis__us-gaap--ResearchAndDevelopmentArrangementMember_zmQr4l6IUQH7" title="Fund Amount">246,400</span>, respectively, remained outstanding and is presented in the accompanying consolidated balance sheets as USDA CRADA liability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> 19705 19705 975000 3000 150000 192638 188484 20000 2810 6590 20607 246400 246400 <p id="xdx_807_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zeiqKN2qJ1Sa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7 – <span id="xdx_82B_z9nVfSybs9Dd">RELATED PARTY TRANSACTIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share Issuances to the Board of Directors</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company issued Series A preferred stock on August 16, 2022, as follows: Bradley White (Chief Executive Officer), <span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_pp0d_c20220816__srt--TitleOfIndividualAxis__custom--BradleyWhiteMember_zTIJU57zt9O6" title="Preferred stock, shares issued">3</span> shares; Dr. Clayton Yates (Chief Scientific Officer and Chairman), <span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_pp0d_c20220816__srt--TitleOfIndividualAxis__custom--ClaytonYatesMember_zXc80GBNzu0a" title="Preferred stock, shares issued">3</span> shares; and Dr. Jesse Jaynes (Chief Research Officer and Director), <span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_pp0d_c20220816__srt--TitleOfIndividualAxis__custom--JesseJaynesMember_zCmMTgnCjku9" title="Preferred stock, shares issued">3</span> shares. See Note 4.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 3 3 3 <p id="xdx_80A_eus-gaap--SubsequentEventsTextBlock_zLNhnfo8tFZe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 8 – <span id="xdx_82F_zq4bMAYLV708">SUBSEQUENT EVENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has evaluated subsequent events from the balance sheet through the date of this filing and determined there were no events to disclose except the following.</span></p> Past due at December 31, 2022 Note is payable in a combination of $2,500 to $6,000 in cash and 5,000 to 15,000 share of common stock Convertible into common stock of the subsidiary, Genvor Inc. Related party EXCEL 40 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 41 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 42 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 43 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 116 172 1 true 35 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://genvor.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://genvor.com/role/BalanceSheets Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://genvor.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://genvor.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) Sheet http://genvor.com/role/StatementsOfChangesInStockholdersDeficit Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flow (Unaudited) Sheet http://genvor.com/role/StatementsOfCashFlow Condensed Consolidated Statements of Cash Flow (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION Sheet http://genvor.com/role/OrganizationAndBasisOfPresentation ORGANIZATION AND BASIS OF PRESENTATION Notes 7 false false R8.htm 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://genvor.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - BORROWINGS Sheet http://genvor.com/role/Borrowings BORROWINGS Notes 9 false false R10.htm 00000010 - Disclosure - STOCKHOLDERS??? DEFICIT Sheet http://genvor.com/role/StockholdersDeficit STOCKHOLDERS??? DEFICIT Notes 10 false false R11.htm 00000011 - Disclosure - FEDERAL INCOME TAX Sheet http://genvor.com/role/FederalIncomeTax FEDERAL INCOME TAX Notes 11 false false R12.htm 00000012 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://genvor.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 12 false false R13.htm 00000013 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://genvor.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 13 false false R14.htm 00000014 - Disclosure - SUBSEQUENT EVENTS Sheet http://genvor.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 14 false false R15.htm 00000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://genvor.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 15 false false R16.htm 00000016 - Disclosure - BORROWINGS (Tables) Sheet http://genvor.com/role/BorrowingsTables BORROWINGS (Tables) Tables http://genvor.com/role/Borrowings 16 false false R17.htm 00000017 - Disclosure - STOCKHOLDERS??? DEFICIT (Tables) Sheet http://genvor.com/role/StockholdersDeficitTables STOCKHOLDERS??? DEFICIT (Tables) Tables http://genvor.com/role/StockholdersDeficit 17 false false R18.htm 00000018 - Disclosure - FEDERAL INCOME TAX (Tables) Sheet http://genvor.com/role/FederalIncomeTaxTables FEDERAL INCOME TAX (Tables) Tables http://genvor.com/role/FederalIncomeTax 18 false false R19.htm 00000019 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION (Details Narrative) Sheet http://genvor.com/role/OrganizationAndBasisOfPresentationDetailsNarrative ORGANIZATION AND BASIS OF PRESENTATION (Details Narrative) Details http://genvor.com/role/OrganizationAndBasisOfPresentation 19 false false R20.htm 00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://genvor.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://genvor.com/role/SummaryOfSignificantAccountingPoliciesPolicies 20 false false R21.htm 00000021 - Disclosure - SCHEDULE OF CONVERTIBLE NOTES PAYABLE (Details) Notes http://genvor.com/role/ScheduleOfConvertibleNotesPayableDetails SCHEDULE OF CONVERTIBLE NOTES PAYABLE (Details) Details 21 false false R22.htm 00000022 - Disclosure - SCHEDULE OF CONVERTIBLE NOTES PAYABLE (Details) (Parenthetical) Notes http://genvor.com/role/ScheduleOfConvertibleNotesPayableDetailsParenthetical SCHEDULE OF CONVERTIBLE NOTES PAYABLE (Details) (Parenthetical) Details 22 false false R23.htm 00000023 - Disclosure - BORROWINGS (Details Narrative) Sheet http://genvor.com/role/BorrowingsDetailsNarrative BORROWINGS (Details Narrative) Details http://genvor.com/role/BorrowingsTables 23 false false R24.htm 00000024 - Disclosure - SCHEDULE OF CONVERTED SHARES OF COMMON STOCK (Details) Sheet http://genvor.com/role/ScheduleOfConvertedSharesOfCommonStockDetails SCHEDULE OF CONVERTED SHARES OF COMMON STOCK (Details) Details 24 false false R25.htm 00000025 - Disclosure - STOCKHOLDERS??? DEFICIT (Details Narrative) Sheet http://genvor.com/role/StockholdersDeficitDetailsNarrative STOCKHOLDERS??? DEFICIT (Details Narrative) Details http://genvor.com/role/StockholdersDeficitTables 25 false false R26.htm 00000026 - Disclosure - SCHEDULE OF LOSS BEFORE TAXES (Details) Sheet http://genvor.com/role/ScheduleOfLossBeforeTaxesDetails SCHEDULE OF LOSS BEFORE TAXES (Details) Details 26 false false R27.htm 00000027 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details) Sheet http://genvor.com/role/ScheduleOfDeferredTaxAssetsDetails SCHEDULE OF DEFERRED TAX ASSETS (Details) Details 27 false false R28.htm 00000028 - Disclosure - FEDERAL INCOME TAX (Details Narrative) Sheet http://genvor.com/role/FederalIncomeTaxDetailsNarrative FEDERAL INCOME TAX (Details Narrative) Details http://genvor.com/role/FederalIncomeTaxTables 28 false false R29.htm 00000029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://genvor.com/role/CommitmentsAndContingencies 29 false false R30.htm 00000030 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://genvor.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://genvor.com/role/RelatedPartyTransactions 30 false false All Reports Book All Reports form10-q.htm ex31-1.htm ex32-1.htm gnvr-20230331.xsd gnvr-20230331_cal.xml gnvr-20230331_def.xml gnvr-20230331_lab.xml gnvr-20230331_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 45 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-q.htm": { "axisCustom": 0, "axisStandard": 10, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 449, "http://xbrl.sec.gov/dei/2023": 28 }, "contextCount": 116, "dts": { "calculationLink": { "local": [ "gnvr-20230331_cal.xml" ] }, "definitionLink": { "local": [ "gnvr-20230331_def.xml" ] }, "inline": { "local": [ "form10-q.htm" ] }, "labelLink": { "local": [ "gnvr-20230331_lab.xml" ] }, "presentationLink": { "local": [ "gnvr-20230331_pre.xml" ] }, "schema": { "local": [ "gnvr-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 289, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2023": 90, "http://genvor.com/20230331": 24, "http://xbrl.sec.gov/dei/2023": 4, "total": 118 }, "keyCustom": 22, "keyStandard": 150, "memberCustom": 22, "memberStandard": 11, "nsprefix": "GNVR", "nsuri": "http://genvor.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://genvor.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - STOCKHOLDERS\u2019 DEFICIT", "menuCat": "Notes", "order": "10", "role": "http://genvor.com/role/StockholdersDeficit", "shortName": "STOCKHOLDERS\u2019 DEFICIT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - FEDERAL INCOME TAX", "menuCat": "Notes", "order": "11", "role": "http://genvor.com/role/FederalIncomeTax", "shortName": "FEDERAL INCOME TAX", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - COMMITMENTS AND CONTINGENCIES", "menuCat": "Notes", "order": "12", "role": "http://genvor.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - RELATED PARTY TRANSACTIONS", "menuCat": "Notes", "order": "13", "role": "http://genvor.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - SUBSEQUENT EVENTS", "menuCat": "Notes", "order": "14", "role": "http://genvor.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "menuCat": "Policies", "order": "15", "role": "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:SubordinatedBorrowingsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - BORROWINGS (Tables)", "menuCat": "Tables", "order": "16", "role": "http://genvor.com/role/BorrowingsTables", "shortName": "BORROWINGS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SubordinatedBorrowingsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfConversionsOfStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - STOCKHOLDERS\u2019 DEFICIT (Tables)", "menuCat": "Tables", "order": "17", "role": "http://genvor.com/role/StockholdersDeficitTables", "shortName": "STOCKHOLDERS\u2019 DEFICIT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfConversionsOfStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - FEDERAL INCOME TAX (Tables)", "menuCat": "Tables", "order": "18", "role": "http://genvor.com/role/FederalIncomeTaxTables", "shortName": "FEDERAL INCOME TAX (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION (Details Narrative)", "menuCat": "Details", "order": "19", "role": "http://genvor.com/role/OrganizationAndBasisOfPresentationDetailsNarrative", "shortName": "ORGANIZATION AND BASIS OF PRESENTATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": "0", "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "menuCat": "Statements", "order": "2", "role": "http://genvor.com/role/BalanceSheets", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "menuCat": "Details", "order": "20", "role": "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:CashEquivalentsAtCarryingValue", "span", "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "us-gaap:SubordinatedBorrowingsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - SCHEDULE OF CONVERTIBLE NOTES PAYABLE (Details)", "menuCat": "Details", "order": "21", "role": "http://genvor.com/role/ScheduleOfConvertibleNotesPayableDetails", "shortName": "SCHEDULE OF CONVERTIBLE NOTES PAYABLE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "us-gaap:SubordinatedBorrowingsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "us-gaap:SubordinatedBorrowingsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - SCHEDULE OF CONVERTIBLE NOTES PAYABLE (Details) (Parenthetical)", "menuCat": "Details", "order": "22", "role": "http://genvor.com/role/ScheduleOfConvertibleNotesPayableDetailsParenthetical", "shortName": "SCHEDULE OF CONVERTIBLE NOTES PAYABLE (Details) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "link:footnote", "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "us-gaap:SubordinatedBorrowingsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-012023-03-31_custom_NoteholderFMember_srt_MinimumMember", "decimals": "0", "lang": null, "name": "us-gaap:DebtConversionOriginalDebtAmount1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "us-gaap:SubordinatedBorrowingsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - BORROWINGS (Details Narrative)", "menuCat": "Details", "order": "23", "role": "http://genvor.com/role/BorrowingsDetailsNarrative", "shortName": "BORROWINGS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubordinatedBorrowingsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": "0", "lang": null, "name": "us-gaap:InterestExpenseDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfConversionsOfStockTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-192022-10-19_us-gaap_SeriesBPreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ConversionOfStockSharesConverted1", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - SCHEDULE OF CONVERTED SHARES OF COMMON STOCK (Details)", "menuCat": "Details", "order": "24", "role": "http://genvor.com/role/ScheduleOfConvertedSharesOfCommonStockDetails", "shortName": "SCHEDULE OF CONVERTED SHARES OF COMMON STOCK (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfConversionsOfStockTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-192022-10-19_us-gaap_SeriesBPreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ConversionOfStockSharesConverted1", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - STOCKHOLDERS\u2019 DEFICIT (Details Narrative)", "menuCat": "Details", "order": "25", "role": "http://genvor.com/role/StockholdersDeficitDetailsNarrative", "shortName": "STOCKHOLDERS\u2019 DEFICIT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-04-212022-04-21", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - SCHEDULE OF LOSS BEFORE TAXES (Details)", "menuCat": "Details", "order": "26", "role": "http://genvor.com/role/ScheduleOfLossBeforeTaxesDetails", "shortName": "SCHEDULE OF LOSS BEFORE TAXES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)", "menuCat": "Details", "order": "27", "role": "http://genvor.com/role/ScheduleOfDeferredTaxAssetsDetails", "shortName": "SCHEDULE OF DEFERRED TAX ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - FEDERAL INCOME TAX (Details Narrative)", "menuCat": "Details", "order": "28", "role": "http://genvor.com/role/FederalIncomeTaxDetailsNarrative", "shortName": "FEDERAL INCOME TAX (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AssetsHeldInTrust", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "menuCat": "Details", "order": "29", "role": "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AssetsHeldInTrust", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://genvor.com/role/BalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-08-16_custom_BradleyWhiteMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesIssued", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "menuCat": "Details", "order": "30", "role": "http://genvor.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-012023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfessionalFees", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://genvor.com/role/StatementsOfOperations", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-012023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfessionalFees", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Consolidated Statements of Changes in Stockholders' Deficit (Unaudited)", "menuCat": "Statements", "order": "5", "role": "http://genvor.com/role/StatementsOfChangesInStockholdersDeficit", "shortName": "Consolidated Statements of Changes in Stockholders' Deficit (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-10-012021-12-31_us-gaap_CommonStockMember", "decimals": "0", "lang": null, "name": "GNVR:RecapitalizationRtoImpact", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-012023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flow (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://genvor.com/role/StatementsOfCashFlow", "shortName": "Condensed Consolidated Statements of Cash Flow (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": "0", "lang": null, "name": "GNVR:LateFeeCapitalizedIntoNotesPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION", "menuCat": "Notes", "order": "7", "role": "http://genvor.com/role/OrganizationAndBasisOfPresentation", "shortName": "ORGANIZATION AND BASIS OF PRESENTATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "menuCat": "Notes", "order": "8", "role": "http://genvor.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubordinatedBorrowingsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - BORROWINGS", "menuCat": "Notes", "order": "9", "role": "http://genvor.com/role/Borrowings", "shortName": "BORROWINGS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubordinatedBorrowingsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 35, "tag": { "GNVR_ACTHoldingsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ACT Holdings LLC [Member]", "label": "ACT Holdings LLC [Member]" } } }, "localname": "ACTHoldingsLLCMember", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/ScheduleOfConvertedSharesOfCommonStockDetails" ], "xbrltype": "domainItemType" }, "GNVR_BradleyWhiteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bradley White [Member]", "label": "Bradley White [Member]" } } }, "localname": "BradleyWhiteMember", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/RelatedPartyTransactionsDetailsNarrative", "http://genvor.com/role/ScheduleOfConvertedSharesOfCommonStockDetails", "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "GNVR_CashFlowReportingPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash Flow Reporting [Policy Text Block]", "label": "Cash Flow Reporting" } } }, "localname": "CashFlowReportingPolicyTextBlock", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "GNVR_ClaytonYatesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dr. Clayton Yates [Member]", "label": "Dr. Clayton Yates [Member]" } } }, "localname": "ClaytonYatesMember", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/RelatedPartyTransactionsDetailsNarrative", "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "GNVR_CommonStockRetainingShareValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of common stock retaining.", "label": "Number of common stock retaining" } } }, "localname": "CommonStockRetainingShareValue", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "GNVR_ConsultantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consultant [Member]", "label": "Consultant [Member]" } } }, "localname": "ConsultantMember", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "GNVR_ConsultingAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consulting Agreements [Member]", "label": "Consulting Agreements [Member]" } } }, "localname": "ConsultingAgreementsMember", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "GNVR_DebtDefaultPenaltyAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt default penalty amount.", "label": "[custom:DebtDefaultPenaltyAmount]" } } }, "localname": "DebtDefaultPenaltyAmount", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/BorrowingsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "GNVR_DesignationAuthorizedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designation authorized shares.", "label": "Designation authorized shares" } } }, "localname": "DesignationAuthorizedShares", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "GNVR_DueToRelatedPartyCurrent": { "auth_ref": [], "calculation": { "http://genvor.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Due to related party.", "label": "Due to related party" } } }, "localname": "DueToRelatedPartyCurrent", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "GNVR_FundAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fund amount.", "label": "Fund Amount" } } }, "localname": "FundAmount", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "GNVR_FundRaisingServicesAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fund raising services amount.", "label": "419 fund raising services" } } }, "localname": "FundRaisingServicesAmount", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "GNVR_FundRaisingServicesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fund raising services shares.", "label": "419 fund raising services, shares" } } }, "localname": "FundRaisingServicesShares", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "GNVR_IssuanceOfCommonStockForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock for services.", "label": "Issuance of common stock for services" } } }, "localname": "IssuanceOfCommonStockForServices", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "GNVR_JaynesInvestmentLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Jaynes Investment LLC [Member]", "label": "Jaynes Investment LLC [Member]" } } }, "localname": "JaynesInvestmentLLCMember", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/ScheduleOfConvertedSharesOfCommonStockDetails" ], "xbrltype": "domainItemType" }, "GNVR_JesseJaynesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dr. Jesse Jaynes [Member]", "label": "Dr. Jesse Jaynes [Member]" } } }, "localname": "JesseJaynesMember", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/RelatedPartyTransactionsDetailsNarrative", "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "GNVR_JesseMichaelJaynesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Jesse Michael Jaynes [Member]", "label": "Jesse Michael Jaynes [Member]" } } }, "localname": "JesseMichaelJaynesMember", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/ScheduleOfConvertedSharesOfCommonStockDetails" ], "xbrltype": "domainItemType" }, "GNVR_LASBFamilyTrustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "LASB Family Trust [Member]", "label": "LASB Family Trust [Member]" } } }, "localname": "LASBFamilyTrustMember", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/ScheduleOfConvertedSharesOfCommonStockDetails" ], "xbrltype": "domainItemType" }, "GNVR_LateFeeCapitalizedIntoNotesPayable": { "auth_ref": [], "calculation": { "http://genvor.com/role/StatementsOfCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Late fee capitalized into notes payable.", "label": "Late fee capitalized into notes payable" } } }, "localname": "LateFeeCapitalizedIntoNotesPayable", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "GNVR_LateFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Late fees.", "label": "Late fees" } } }, "localname": "LateFees", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/BorrowingsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "GNVR_NoteholderAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Holder A [Member]", "label": "Note Holder A [Member]" } } }, "localname": "NoteholderAMember", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/ScheduleOfConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "GNVR_NoteholderBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Noteholder B [Member]", "label": "Noteholder B [Member]" } } }, "localname": "NoteholderBMember", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/BorrowingsDetailsNarrative", "http://genvor.com/role/ScheduleOfConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "GNVR_NoteholderCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Noteholder C [Member]", "label": "Noteholder C [Member]" } } }, "localname": "NoteholderCMember", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/ScheduleOfConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "GNVR_NoteholderDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Noteholder D [Member]", "label": "Noteholder D [Member]" } } }, "localname": "NoteholderDMember", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/ScheduleOfConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "GNVR_NoteholderEMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Noteholder E [Member]", "label": "Noteholder E [Member]" } } }, "localname": "NoteholderEMember", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/ScheduleOfConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "GNVR_NoteholderFMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Noteholder F [Member]", "label": "Noteholder F [Member]" } } }, "localname": "NoteholderFMember", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/ScheduleOfConvertibleNotesPayableDetails", "http://genvor.com/role/ScheduleOfConvertibleNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "GNVR_NoteholderGMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Noteholder G [Member]", "label": "Noteholder G [Member]" } } }, "localname": "NoteholderGMember", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/ScheduleOfConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "GNVR_NoteholderHMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Noteholder H [Member]", "label": "Noteholder H [Member]" } } }, "localname": "NoteholderHMember", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/ScheduleOfConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "GNVR_NoteholderIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Noteholder I [Member]", "label": "Noteholder I [Member]" } } }, "localname": "NoteholderIMember", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/ScheduleOfConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "GNVR_Origination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Origination", "label": "Origination" } } }, "localname": "Origination", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/ScheduleOfConvertibleNotesPayableDetails" ], "xbrltype": "stringItemType" }, "GNVR_OtherGeneralAndAdministrativeExpenses": { "auth_ref": [], "calculation": { "http://genvor.com/role/StatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Other general and administrative expenses" } } }, "localname": "OtherGeneralAndAdministrativeExpenses", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "GNVR_PJAdvisoryGroupMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PJ Advisory Group [Member]", "label": "PJ Advisory Group [Member]" } } }, "localname": "PJAdvisoryGroupMember", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/ScheduleOfConvertedSharesOfCommonStockDetails" ], "xbrltype": "domainItemType" }, "GNVR_PatentsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Patents [Policy Text Block]", "label": "Patents" } } }, "localname": "PatentsPolicyTextBlock", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "GNVR_PaycheckProtectionProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Paycheck Protection Program [Member]", "label": "Paycheck Protection Program [Member]" } } }, "localname": "PaycheckProtectionProgramMember", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/BorrowingsDetailsNarrative" ], "xbrltype": "domainItemType" }, "GNVR_PaymentForReversesCapitalization": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment for reverses capitalization.", "label": "Payment for reverse capitalization" } } }, "localname": "PaymentForReversesCapitalization", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "GNVR_Penalties": { "auth_ref": [], "calculation": { "http://genvor.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Penalties.", "label": "Penalties" } } }, "localname": "Penalties", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "GNVR_RecapitalizationRtoImpact": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Recapitalization rto impact.", "label": "Recapilitalization / RTO impact" } } }, "localname": "RecapitalizationRtoImpact", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "GNVR_RelatedPartyPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Related party payable", "label": "Related party payable" } } }, "localname": "RelatedPartyPayable", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "GNVR_ShareholderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shareholder [Member]", "label": "Shareholder [Member]" } } }, "localname": "ShareholderMember", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "GNVR_SharesOutstandingAdjustedBalance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares outstanding adjusted balance.", "label": "Adjusted balance beginning of period, shares" } } }, "localname": "SharesOutstandingAdjustedBalance", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "GNVR_StockIssueForCashMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued for Cash [Member]", "label": "Stock Issued for Cash [Member]" } } }, "localname": "StockIssueForCashMember", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "GNVR_StockIssuedDuringPeriodSharesSaleOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of common stock, shares.", "label": "Sale of common stock, shares" } } }, "localname": "StockIssuedDuringPeriodSharesSaleOfCommonStock", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "GNVR_StockIssuedDuringPeriodValueSaleOfCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sale of common stock.", "label": "Sale of common stock" } } }, "localname": "StockIssuedDuringPeriodValueSaleOfCommonStock", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "GNVR_StockholdersEquityAdjustedBalance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stockholders equity adjusted balance.", "label": "Adjusted balance, beginning of period" } } }, "localname": "StockholdersEquityAdjustedBalance", "nsuri": "http://genvor.com/20230331", "presentation": [ "http://genvor.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r474" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r472", "r474", "r475" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r473" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r474" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r474" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r476" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r480" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r474" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r469" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r462" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r470" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://genvor.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_BrokersAndDealersAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Broker-Dealer [Abstract]" } } }, "localname": "BrokersAndDealersAbstract", "nsuri": "http://fasb.org/srt/2023", "xbrltype": "stringItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r498" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r176", "r177", "r178", "r179", "r226", "r294", "r328", "r359", "r360", "r420", "r421", "r422", "r423", "r424", "r432", "r433", "r438", "r444", "r445", "r449", "r504", "r545", "r546", "r547", "r548", "r549", "r550" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://genvor.com/role/ScheduleOfConvertibleNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r176", "r177", "r178", "r179", "r226", "r294", "r328", "r359", "r360", "r420", "r421", "r422", "r423", "r424", "r432", "r433", "r438", "r444", "r445", "r449", "r504", "r545", "r546", "r547", "r548", "r549", "r550" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://genvor.com/role/ScheduleOfConvertibleNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r176", "r177", "r178", "r179", "r224", "r226", "r228", "r229", "r230", "r293", "r294", "r328", "r359", "r360", "r420", "r421", "r422", "r423", "r424", "r432", "r433", "r438", "r444", "r445", "r449", "r452", "r500", "r504", "r546", "r547", "r548", "r549", "r550" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://genvor.com/role/ScheduleOfConvertibleNotesPayableDetailsParenthetical" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r176", "r177", "r178", "r179", "r224", "r226", "r228", "r229", "r230", "r293", "r294", "r328", "r359", "r360", "r420", "r421", "r422", "r423", "r424", "r432", "r433", "r438", "r444", "r445", "r449", "r452", "r500", "r504", "r546", "r547", "r548", "r549", "r550" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://genvor.com/role/ScheduleOfConvertibleNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r498", "r541" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://genvor.com/role/RelatedPartyTransactionsDetailsNarrative", "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://genvor.com/role/RelatedPartyTransactionsDetailsNarrative", "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r13" ], "calculation": { "http://genvor.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedPayrollTaxesCurrent": { "auth_ref": [ "r15" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Payroll Taxes, Current" } } }, "localname": "AccruedPayrollTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r64", "r448", "r555" ], "calculation": { "http://genvor.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r231", "r232", "r233", "r346", "r494", "r495", "r496", "r536", "r559" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r4", "r36" ], "calculation": { "http://genvor.com/role/StatementsOfCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://genvor.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Amortization of debt discount", "negatedLabel": "Amortization of debt discount" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfCashFlow", "http://genvor.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r86", "r108", "r128", "r155", "r162", "r166", "r171", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r259", "r263", "r275", "r315", "r382", "r448", "r460", "r502", "r503", "r543" ], "calculation": { "http://genvor.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r106", "r113", "r128", "r171", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r259", "r263", "r275", "r448", "r502", "r503", "r543" ], "calculation": { "http://genvor.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsHeldInTrust": { "auth_ref": [ "r490" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations.", "label": "Assets held in trust" } } }, "localname": "AssetsHeldInTrust", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r55", "r75", "r76" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "ORGANIZATION AND BASIS OF PRESENTATION" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/OrganizationAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r94", "r317", "r357", "r377", "r448", "r460", "r482" ], "calculation": { "http://genvor.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r24", "r72", "r125" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash at end of period", "periodStartLabel": "Cash at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r0", "r72" ], "calculation": { "http://genvor.com/role/StatementsOfCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r482", "r553" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Cash uninsured amount" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r103", "r109", "r110", "r111", "r128", "r145", "r146", "r148", "r150", "r153", "r154", "r171", "r180", "r182", "r183", "r184", "r187", "r188", "r208", "r209", "r212", "r215", "r222", "r275", "r336", "r337", "r338", "r339", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r358", "r369", "r391", "r412", "r425", "r426", "r427", "r428", "r429", "r481", "r491", "r497" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheets", "http://genvor.com/role/BalanceSheetsParenthetical", "http://genvor.com/role/ScheduleOfConvertedSharesOfCommonStockDetails", "http://genvor.com/role/StatementsOfChangesInStockholdersDeficit", "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [ "r109", "r110", "r111", "r153", "r208", "r209", "r210", "r212", "r215", "r220", "r222", "r336", "r337", "r338", "r339", "r444", "r481", "r491" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/ScheduleOfConvertedSharesOfCommonStockDetails", "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r19", "r53", "r316", "r368" ], "calculation": { "http://genvor.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies (Note 6)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r78", "r174", "r175", "r431", "r501" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r450", "r451", "r452", "r454", "r455", "r456", "r457", "r494", "r495", "r536", "r554", "r559" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value", "verboseLabel": "Common stock, shares par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheetsParenthetical", "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r63", "r369" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheetsParenthetical", "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r7", "r63", "r369", "r388", "r559", "r560" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r63", "r319", "r448" ], "calculation": { "http://genvor.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.001 par value, 300,000,000 shares authorized, 18,422,821 and 38,678,155 shares issued and outstanding as of March 31, 2023 and September 30, 2022, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.", "label": "Stock-Based Compensation" } } }, "localname": "CompensationRelatedCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r27", "r28", "r29" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Common Shares Exchanged" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/ScheduleOfConvertedSharesOfCommonStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r27", "r28", "r29" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Series B Issued" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/ScheduleOfConvertedSharesOfCommonStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.", "label": "SCHEDULE OF CONVERTIBLE NOTES PAYABLE" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BorrowingsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleLongTermNotesPayable": { "auth_ref": [ "r18" ], "calculation": { "http://genvor.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible notes payable, net of discounts" } } }, "localname": "ConvertibleLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableCurrent": { "auth_ref": [ "r15" ], "calculation": { "http://genvor.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible notes payable" } } }, "localname": "ConvertibleNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertiblePreferredStockTermsOfConversion": { "auth_ref": [ "r11", "r41", "r44", "r62", "r80", "r81" ], "lang": { "en-us": { "role": { "documentation": "Description of conversion terms for preferred stock.", "label": "Conversion share description" } } }, "localname": "ConvertiblePreferredStockTermsOfConversion", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r27", "r29" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Number of shares the notesis convertible into shares", "verboseLabel": "Shares issued during conversion" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/ScheduleOfConvertibleNotesPayableDetails", "http://genvor.com/role/ScheduleOfConvertibleNotesPayableDetailsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionOriginalDebtAmount1": { "auth_ref": [ "r27", "r29" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Notes payable converted" } } }, "localname": "DebtConversionOriginalDebtAmount1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/ScheduleOfConvertibleNotesPayableDetailsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r10", "r59", "r60", "r87", "r88", "r130", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r283", "r439", "r440", "r441", "r442", "r443", "r492" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BorrowingsDetailsNarrative", "http://genvor.com/role/ScheduleOfConvertibleNotesPayableDetails", "http://genvor.com/role/ScheduleOfConvertibleNotesPayableDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r50", "r52", "r189", "r283", "r440", "r441" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Loan Balance", "verboseLabel": "Principal amont" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BorrowingsDetailsNarrative", "http://genvor.com/role/ScheduleOfConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r17", "r50", "r201" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/ScheduleOfConvertibleNotesPayableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r17", "r190" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "verboseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BorrowingsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r102", "r439", "r537" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/ScheduleOfConvertibleNotesPayableDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r18", "r130", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r283", "r439", "r440", "r441", "r442", "r443", "r492" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BorrowingsDetailsNarrative", "http://genvor.com/role/ScheduleOfConvertibleNotesPayableDetails", "http://genvor.com/role/ScheduleOfConvertibleNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r49", "r52", "r505" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "negatedLabel": "Debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/ScheduleOfConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r244" ], "calculation": { "http://genvor.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Total gross deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r534" ], "calculation": { "http://genvor.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Total net deferred taxes" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r48", "r535" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net operating loss carryforward" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r245" ], "calculation": { "http://genvor.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Valuation allowance for net deferred tax assets", "negatedLabel": "Less: Deferred tax asset valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/FederalIncomeTaxDetailsNarrative", "http://genvor.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r4", "r37" ], "calculation": { "http://genvor.com/role/StatementsOfCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://genvor.com/role/StatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfCashFlow", "http://genvor.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r122", "r136", "r137", "r138", "r139", "r140", "r144", "r145", "r148", "r149", "r150", "r151", "r273", "r274", "r312", "r326", "r435" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic and diluted net loss per common share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r30", "r31" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Loss Per Share of Common Stock" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r129", "r240", "r253" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Federal tax statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/FederalIncomeTaxDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r7", "r104", "r117", "r118", "r119", "r131", "r132", "r133", "r135", "r141", "r143", "r152", "r172", "r173", "r223", "r231", "r232", "r233", "r249", "r250", "r265", "r266", "r267", "r268", "r269", "r270", "r272", "r276", "r277", "r278", "r279", "r280", "r281", "r284", "r329", "r330", "r331", "r346", "r412" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Financial Instruments" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r6", "r9" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r129", "r236", "r241", "r242", "r247", "r251", "r254", "r255", "r256", "r341" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "FEDERAL INCOME TAX" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/FederalIncomeTax" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r93", "r101", "r142", "r143", "r159", "r239", "r252", "r327" ], "calculation": { "http://genvor.com/role/ScheduleOfLossBeforeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "totalLabel": "Total" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/ScheduleOfLossBeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r116", "r237", "r238", "r242", "r243", "r246", "r248", "r335" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r533" ], "calculation": { "http://genvor.com/role/ScheduleOfLossBeforeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Change in valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/ScheduleOfLossBeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r240" ], "calculation": { "http://genvor.com/role/ScheduleOfLossBeforeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Tax benefit at the statutory rate" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/ScheduleOfLossBeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r533" ], "calculation": { "http://genvor.com/role/ScheduleOfLossBeforeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "State income taxes, net of federal income tax benefit" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/ScheduleOfLossBeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r23", "r26" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Cash paid for taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r3" ], "calculation": { "http://genvor.com/role/StatementsOfCashFlow": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "verboseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r488" ], "calculation": { "http://genvor.com/role/StatementsOfCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r3" ], "calculation": { "http://genvor.com/role/StatementsOfCashFlow": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "verboseLabel": "USDA CRADA liability" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r3" ], "calculation": { "http://genvor.com/role/StatementsOfCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r35", "r295", "r296", "r297", "r299", "r434" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "Long-lived Assets" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r51", "r91", "r120", "r158", "r282", "r397", "r458", "r556" ], "calculation": { "http://genvor.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r71", "r202", "r206", "r442", "r443" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest expense" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BorrowingsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r489" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.", "label": "Cash paid for interest" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestorMember": { "auth_ref": [ "r539", "r540" ], "lang": { "en-us": { "role": { "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.", "label": "Investor [Member]" } } }, "localname": "InvestorMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LaborAndRelatedExpense": { "auth_ref": [ "r487" ], "calculation": { "http://genvor.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.", "label": "Payroll related expenses" } } }, "localname": "LaborAndRelatedExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r14", "r128", "r171", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r260", "r263", "r264", "r275", "r367", "r436", "r460", "r502", "r543", "r544" ], "calculation": { "http://genvor.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r68", "r89", "r321", "r448", "r493", "r499", "r538" ], "calculation": { "http://genvor.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r16", "r107", "r128", "r171", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r260", "r263", "r264", "r275", "r448", "r502", "r543", "r544" ], "calculation": { "http://genvor.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r10", "r56", "r57", "r58", "r61", "r128", "r171", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r260", "r263", "r264", "r275", "r502", "r543", "r544" ], "calculation": { "http://genvor.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total non-current liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LoansPayableCurrent": { "auth_ref": [ "r15" ], "calculation": { "http://genvor.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.", "label": "SBA loan" } } }, "localname": "LoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r10", "r88", "r196", "r205", "r440", "r441", "r552" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Total loan" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/ScheduleOfConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by category of items purchased under a long-term purchase commitment.", "label": "Category of Item Purchased [Axis]" } } }, "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment." } } }, "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermPurchaseCommitmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Long-Term Purchase Commitment [Line Items]" } } }, "localname": "LongTermPurchaseCommitmentLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.", "label": "Long-Term Purchase Commitment [Table]" } } }, "localname": "LongTermPurchaseCommitmentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r124" ], "calculation": { "http://genvor.com/role/StatementsOfCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r72", "r73", "r74" ], "calculation": { "http://genvor.com/role/StatementsOfCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "negatedLabel": "Net cash used in operating activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/OrganizationAndBasisOfPresentationDetailsNarrative", "http://genvor.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r69", "r74", "r90", "r105", "r114", "r115", "r119", "r128", "r134", "r136", "r137", "r138", "r139", "r142", "r143", "r147", "r155", "r161", "r165", "r167", "r171", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r274", "r275", "r325", "r390", "r410", "r411", "r437", "r458", "r502" ], "calculation": { "http://genvor.com/role/StatementsOfCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://genvor.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfCashFlow", "http://genvor.com/role/StatementsOfChangesInStockholdersDeficit", "http://genvor.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r70" ], "calculation": { "http://genvor.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expense)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://genvor.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r155", "r161", "r165", "r167", "r437" ], "calculation": { "http://genvor.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r47" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Net operating loss carry forwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/FederalIncomeTaxDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r112", "r448" ], "calculation": { "http://genvor.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r15", "r448" ], "calculation": { "http://genvor.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "USDA CRADA liability" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRent": { "auth_ref": [ "r2" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash payments to lessor's for use of assets under operating leases.", "label": "Rent expense" } } }, "localname": "PaymentsForRent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [ "r450", "r451", "r454", "r455", "r456", "r457", "r554", "r559" ], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r62", "r208" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value", "verboseLabel": "Preferred stock, shares par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheetsParenthetical", "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r62", "r369" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheetsParenthetical", "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r62", "r208" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheetsParenthetical", "http://genvor.com/role/RelatedPartyTransactionsDetailsNarrative", "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r62", "r369", "r388", "r559", "r560" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheetsParenthetical", "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r62", "r318", "r448" ], "calculation": { "http://genvor.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock value" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockVotingRights": { "auth_ref": [ "r41", "r62" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Number of votes" } } }, "localname": "PreferredStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r1" ], "calculation": { "http://genvor.com/role/StatementsOfCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from sale of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r22" ], "calculation": { "http://genvor.com/role/StatementsOfCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from notes payable" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r1", "r8" ], "calculation": { "http://genvor.com/role/StatementsOfCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r458", "r557", "r558" ], "calculation": { "http://genvor.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional fees" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r105", "r114", "r115", "r123", "r128", "r134", "r142", "r143", "r155", "r161", "r165", "r167", "r171", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r258", "r261", "r262", "r274", "r275", "r313", "r324", "r345", "r390", "r410", "r411", "r437", "r446", "r447", "r459", "r485", "r502" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "verboseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r5", "r314", "r323", "r448" ], "calculation": { "http://genvor.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Fixed assets, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r5", "r97", "r100", "r322" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Fixed Assets" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Fixed assets, estimated useful lives" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r225", "r288", "r289", "r362", "r363", "r364", "r365", "r366", "r387", "r389", "r419" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://genvor.com/role/ScheduleOfConvertedSharesOfCommonStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r288", "r289", "r542" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r225", "r288", "r289", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r362", "r363", "r364", "r365", "r366", "r387", "r389", "r419", "r542" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party, Type [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://genvor.com/role/ScheduleOfConvertedSharesOfCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r285", "r286", "r287", "r289", "r290", "r342", "r343", "r344", "r394", "r395", "r396", "r416", "r418" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentArrangementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer.", "label": "Research and Development Arrangement [Member]" } } }, "localname": "ResearchAndDevelopmentArrangementMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r54", "r235", "r551" ], "calculation": { "http://genvor.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development", "verboseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfOperations", "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r65", "r82", "r320", "r332", "r333", "r340", "r370", "r448" ], "calculation": { "http://genvor.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Accumulated deficit", "negatedLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheets", "http://genvor.com/role/OrganizationAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r104", "r131", "r132", "r133", "r135", "r141", "r143", "r172", "r173", "r231", "r232", "r233", "r249", "r250", "r265", "r267", "r268", "r270", "r272", "r329", "r331", "r346", "r559" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r121", "r128", "r156", "r157", "r160", "r163", "r164", "r168", "r169", "r170", "r171", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r275", "r313", "r502" ], "calculation": { "http://genvor.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalariesAndWages": { "auth_ref": [ "r486" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold" } } }, "localname": "SalariesAndWages", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalariesWagesAndOfficersCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Salary and Wage, Excluding Cost of Good and Service Sold" } } }, "localname": "SalariesWagesAndOfficersCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfConversionsOfStockTextBlock": { "auth_ref": [ "r27", "r28", "r29" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to converting stock into another financial instrument(s) in a noncash (or part noncash) transaction.", "label": "SCHEDULE OF CONVERTED SHARES OF COMMON STOCK" } } }, "localname": "ScheduleOfConversionsOfStockTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StockholdersDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "auth_ref": [ "r45", "r83" ], "lang": { "en-us": { "role": { "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.", "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]" } } }, "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r85" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "SCHEDULE OF DEFERRED TAX ASSETS" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/FederalIncomeTaxTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "SCHEDULE OF LOSS BEFORE TAXES" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/FederalIncomeTaxTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-Term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BorrowingsDetailsNarrative", "http://genvor.com/role/ScheduleOfConvertibleNotesPayableDetails", "http://genvor.com/role/ScheduleOfConvertibleNotesPayableDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r38", "r39", "r40", "r41", "r42", "r43", "r44", "r80", "r81", "r82", "r109", "r110", "r111", "r153", "r208", "r209", "r210", "r212", "r215", "r220", "r222", "r336", "r337", "r338", "r339", "r444", "r481", "r491" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/ScheduleOfConvertedSharesOfCommonStockDetails", "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r483", "r484", "r506" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheets", "http://genvor.com/role/BalanceSheetsParenthetical", "http://genvor.com/role/StatementsOfChangesInStockholdersDeficit", "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [ "r483", "r484", "r506" ], "lang": { "en-us": { "role": { "documentation": "Series B preferred stock.", "label": "Series B Preferred Stock [Member]" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheets", "http://genvor.com/role/BalanceSheetsParenthetical", "http://genvor.com/role/ScheduleOfConvertedSharesOfCommonStockDetails", "http://genvor.com/role/StatementsOfChangesInStockholdersDeficit", "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r3" ], "calculation": { "http://genvor.com/role/StatementsOfCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://genvor.com/role/StatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfCashFlow", "http://genvor.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-Term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BorrowingsDetailsNarrative", "http://genvor.com/role/ScheduleOfConvertibleNotesPayableDetails", "http://genvor.com/role/ScheduleOfConvertibleNotesPayableDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r75", "r126" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r103", "r109", "r110", "r111", "r128", "r145", "r146", "r148", "r150", "r153", "r154", "r171", "r180", "r182", "r183", "r184", "r187", "r188", "r208", "r209", "r212", "r215", "r222", "r275", "r336", "r337", "r338", "r339", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r358", "r369", "r391", "r412", "r425", "r426", "r427", "r428", "r429", "r481", "r491", "r497" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheets", "http://genvor.com/role/BalanceSheetsParenthetical", "http://genvor.com/role/ScheduleOfConvertedSharesOfCommonStockDetails", "http://genvor.com/role/StatementsOfChangesInStockholdersDeficit", "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r7", "r21", "r104", "r117", "r118", "r119", "r131", "r132", "r133", "r135", "r141", "r143", "r152", "r172", "r173", "r223", "r231", "r232", "r233", "r249", "r250", "r265", "r266", "r267", "r268", "r269", "r270", "r272", "r276", "r277", "r278", "r279", "r280", "r281", "r284", "r329", "r330", "r331", "r346", "r412" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r131", "r132", "r133", "r152", "r298", "r334", "r358", "r361", "r362", "r363", "r364", "r365", "r366", "r369", "r372", "r373", "r374", "r375", "r376", "r378", "r379", "r380", "r381", "r383", "r384", "r385", "r386", "r387", "r389", "r392", "r393", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r412", "r453" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheets", "http://genvor.com/role/BalanceSheetsParenthetical", "http://genvor.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r131", "r132", "r133", "r152", "r298", "r334", "r358", "r361", "r362", "r363", "r364", "r365", "r366", "r369", "r372", "r373", "r374", "r375", "r376", "r378", "r379", "r380", "r381", "r383", "r384", "r385", "r386", "r387", "r389", "r392", "r393", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r412", "r453" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheets", "http://genvor.com/role/BalanceSheetsParenthetical", "http://genvor.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r7", "r20", "r41", "r82", "r199" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Common stock issued for debt conversion, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "auth_ref": [ "r7", "r41", "r62", "r63", "r82" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Conversion of common stock into Series B preferred stock, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Common stock issued for services, shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r7", "r62", "r63", "r82", "r336", "r412", "r426" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Common stock issued for cash, shares", "terseLabel": "Number of shares issued", "verboseLabel": "Stock Issued During Period, Shares, New Issues" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://genvor.com/role/StatementsOfChangesInStockholdersDeficit", "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares (or other type of equity) forfeited during the period.", "label": "Number of common stock cancel" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r7", "r62", "r63", "r82", "r227" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Exercise of options, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r7", "r21", "r82" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Common stock issued for debt conversion" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": { "auth_ref": [ "r7", "r21", "r82" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Conversion of common stock into Series B preferred stock" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Common stock issued for services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r7", "r62", "r63", "r82", "r346", "r412", "r426", "r459" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Common stock issued for cash", "verboseLabel": "Stock Issued During Period, Value, New Issues" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfChangesInStockholdersDeficit", "http://genvor.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r7", "r21", "r82" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Exercise of options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r63", "r66", "r67", "r77", "r371", "r388", "r413", "r414", "r448", "r460", "r493", "r499", "r538", "r559" ], "calculation": { "http://genvor.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheets", "http://genvor.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 deficit:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r79", "r127", "r207", "r209", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r221", "r223", "r271", "r415", "r417", "r430" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StockholdersDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubordinatedBorrowingsDisclosureTextBlock": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for borrowings under subordinated debt agreements that qualify as available in computing net capital under SEC's uniform net capital rule, including restrictive covenants, collateral, interest rates and due dates, amounts due by date and amount owed in total.", "label": "BORROWINGS" } } }, "localname": "SubordinatedBorrowingsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/Borrowings" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r291", "r292" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r32", "r33", "r34", "r95", "r96", "r98", "r99" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r144", "r150" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Basic and diluted weighted average common shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://genvor.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org//740/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "808", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org//850/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(b)", "Topic": "920", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(21))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(16))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(h)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(g)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(h)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(15))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f(1))", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r461": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r462": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r463": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r464": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r465": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r466": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r467": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r468": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r469": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r471": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r472": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r473": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r474": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r475": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r476": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r477": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r478": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r479": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(4))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(b))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r501": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r55": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(i)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org//275/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480876/942-470-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 46 0001493152-23-013379-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-013379-xbrl.zip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

  •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end